<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Genome Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">Genome Med</journal-id>
    <journal-title-group>
      <journal-title>Genome Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1756-994X</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10765705</article-id>
    <article-id pub-id-type="publisher-id">1276</article-id>
    <article-id pub-id-type="doi">10.1186/s13073-023-01276-2</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Using multi-scale genomics to associate poorly annotated genes with rare diseases</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Canavati</surname>
          <given-names>Christina</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Sherill-Rofe</surname>
          <given-names>Dana</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Kamal</surname>
          <given-names>Lara</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bloch</surname>
          <given-names>Idit</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zahdeh</surname>
          <given-names>Fouad</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sharon</surname>
          <given-names>Elad</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Terespolsky</surname>
          <given-names>Batel</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Allan</surname>
          <given-names>Islam Abu</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rabie</surname>
          <given-names>Grace</given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kawas</surname>
          <given-names>Mariana</given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kassem</surname>
          <given-names>Hanin</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Avraham</surname>
          <given-names>Karen B.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Renbaum</surname>
          <given-names>Paul</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Levy-Lahad</surname>
          <given-names>Ephrat</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Kanaan</surname>
          <given-names>Moien</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9521-3217</contrib-id>
        <name>
          <surname>Tabach</surname>
          <given-names>Yuval</given-names>
        </name>
        <address>
          <email>yuval.tabach@mail.huji.ac.il</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qxff017</institution-id><institution-id institution-id-type="GRID">grid.9619.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0538</institution-id><institution>Department of Developmental Biology and Cancer Research, </institution><institution>Institute of Medical Research - Israel-Canada, The Hebrew University of Jerusalem, </institution></institution-wrap>Jerusalem, 9112102 Israel </aff>
      <aff id="Aff2"><label>2</label>Molecular Genetics Lab, Istishari Arab Hospital, Ramallah, Palestine </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04mhzgx49</institution-id><institution-id institution-id-type="GRID">grid.12136.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0546</institution-id><institution>Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine and Sagol School of Neuroscience, </institution><institution>Tel Aviv University, </institution></institution-wrap>Tel Aviv, 6997801 Israel </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03zpnb459</institution-id><institution-id institution-id-type="GRID">grid.414505.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0631 3825</institution-id><institution>Medical Genetics Institute, Shaare Zedek Medical Center, </institution></institution-wrap>Jerusalem, 91031 Israel </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qxff017</institution-id><institution-id institution-id-type="GRID">grid.9619.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0538</institution-id><institution>Faculty of Medicine, </institution><institution>The Hebrew University of Jerusalem, </institution></institution-wrap>Jerusalem, 9112102 Israel </aff>
      <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047cjg072</institution-id><institution-id institution-id-type="GRID">grid.440580.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 1016 7793</institution-id><institution>Hereditary Research Laboratory and Department of Life Sciences, </institution><institution>Bethlehem University, </institution></institution-wrap>Bethlehem, 72372 Palestine </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>4</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>4</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2024</year>
    </pub-date>
    <volume>16</volume>
    <elocation-id>4</elocation-id>
    <history>
      <date date-type="received">
        <day>29</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>12</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© The Author(s) 2023</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Next-generation sequencing (NGS) has significantly transformed the landscape of identifying disease-causing genes associated with genetic disorders. However, a substantial portion of sequenced patients remains undiagnosed. This may be attributed not only to the challenges posed by harder-to-detect variants, such as non-coding and structural variations but also to the existence of variants in genes not previously associated with the patientâs clinical phenotype. This study introduces EvORanker, an algorithm that integrates unbiased data from 1,028 eukaryotic genomes to link mutated genes to clinical phenotypes.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p id="Par2">EvORanker utilizes clinical data, multi-scale phylogenetic profiling, and other omics data to prioritize disease-associated genes. It was evaluated on solved exomes and simulated genomes, compared with existing methods, and applied to 6260 knockout genes with mouse phenotypes lacking human associations. Additionally, EvORanker was made accessible as a user-friendly web tool.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par3">In the analyzed exomic cohort, EvORanker accurately identified the âtrueâ disease gene as the top candidate in 69% of cases and within the top 5 candidates in 95% of cases, consistent with results from the simulated dataset. Notably, EvORanker outperformed existing methods, particularly for poorly annotated genes. In the case of the 6260 knockout genes with mouse phenotypes, EvORanker linked 41% of these genes to observed human disease phenotypes. Furthermore, in two unsolved cases, EvORanker successfully identified <italic>DLGAP2</italic> and <italic>LPCAT3</italic> as disease candidates for previously uncharacterized genetic syndromes.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p id="Par4">We highlight clade-based phylogenetic profiling as a powerful systematic approach for prioritizing potential disease genes. Our study showcases the efficacy of EvORanker in associating poorly annotated genes to disease phenotypes observed in patients. The EvORanker server is freely available at <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>.</p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1186/s13073-023-01276-2.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>EvORanker</kwd>
      <kwd>Gene-based prioritization</kwd>
      <kwd>
        <italic>DLGAP2</italic>
      </kwd>
      <kwd>
        <italic>LPCAT3</italic>
      </kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id>
            <institution>Israel Science Foundation</institution>
          </institution-wrap>
        </funding-source>
        <award-id>3797/21</award-id>
        <principal-award-recipient>
          <name>
            <surname>Tabach</surname>
            <given-names>Yuval</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Koum Foundation</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution> National Institutes of Health/NIDCD</institution>
        </funding-source>
        <award-id>R01DC011835</award-id>
        <principal-award-recipient>
          <name>
            <surname>Kanaan</surname>
            <given-names>Moien</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>Â© BioMed Central Ltd., part of Springer Nature 2024</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par5">The study of Mendelian disorders remains a gold standard for understanding gene function and linking a gene to a particular phenotype [<xref ref-type="bibr" rid="CR1">1</xref>]. Next-generation sequencing technologies (NGS) have revolutionized disease-gene discovery; however, most human genes are yet to be associated with a specific phenotype: Out of ~20,000 human genes, only 4900 genes have an associated phenotype in Online Mendelian Inheritance in Man (OMIM) (as of January 22, 2023) [<xref ref-type="bibr" rid="CR2">2</xref>]. Analyses of evolutionary constraints of human genes and models from mouse genetics suggest that the genetic basis of at least 10,000 Mendelian disorders awaits discovery [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p id="Par6">A typical human whole-exome sequencing (WES) or whole-genome sequencing (WGS) study yields thousands of single nucleotide variants, indels, and copy number variants [<xref ref-type="bibr" rid="CR3">3</xref>]. After filtering out frequent variants, a handful of in silico methods are used to estimate the pathogenicity of the variants. These estimates are based on evolutionary conservation, genomic position, structural features, and predicted function (e.g., impact on regulatory, splicing, or protein level) [<xref ref-type="bibr" rid="CR4">4</xref>â<xref ref-type="bibr" rid="CR7">7</xref>]. However, prioritizing variants solely based on predicted pathogenicity and rarity may not lead to identifying the underlying disease-causing gene. Hence, numerous gene-based computational methods have been developed to prioritize candidate genes contributing to the patientâs disease phenotypes. These methods incorporate patientsâ phenotypic information and omics datasets such as protein-protein interaction, co-expression analysis, cross-species phenotypic similarity analysis, and primary literature in order to provide users with further hints about genes that merit further investigation [<xref ref-type="bibr" rid="CR8">8</xref>â<xref ref-type="bibr" rid="CR12">12</xref>]. Recent approaches incorporate artificial intelligence for candidate gene diagnosis [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Nevertheless, the majority of these approaches depend on existing data and as such work well on studied genes (i.e., the rich get richer phenomenon). However, for poorly annotated genes, their performance may decline. Within the scope of this research, poorly annotated genes are defined as those lacking associations with specific phenotypes in the OMIM database [<xref ref-type="bibr" rid="CR2">2</xref>]. This absence of phenotype correlations underscores a scarcity of available data pertaining to their characteristics, ontology, and interactions [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p id="Par7">One unbiased approach that can infer novel gene function is phylogenetic profiling (PP) [<xref ref-type="bibr" rid="CR15">15</xref>]. PP identifies functionally related genes and protein-protein interactions using comparative genomics [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The phylogenetic profile of a gene describes the pattern of conservation of its orthologs in a set of genomes [<xref ref-type="bibr" rid="CR15">15</xref>]. Those patterns of conservation of protein sequences along evolution reflect protein function [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], interaction with other proteins [<xref ref-type="bibr" rid="CR17">17</xref>], and the crosstalk between the organism and the environment [<xref ref-type="bibr" rid="CR20">20</xref>]. PP relies on the well-established hypothesis that if two or more genes share a similar phylogenetic profile, then they may be functionally related [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>â<xref ref-type="bibr" rid="CR23">23</xref>]. This can further be implemented to annotate uncharacterized genes to a putative function based on the similarity of their PP with those of well-annotated genes [<xref ref-type="bibr" rid="CR24">24</xref>]. Previous studies using PP have succeeded in identifying new functional gene associations, novel disease-causing genes, and new pathway components [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p>
    <p id="Par8">The phylogenetic profile of a gene was originally described as a binary representation of the presence or absence of its orthologs across eukaryotic species [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. However, applying a binary representation to eukaryotes might not fully address the intricacy of eukaryotic protein evolution. Across the tree of life, the sequence similarity between two orthologs is a complex function of their evolutionary distance and the variable selective pressures forced upon them. Therefore, several methods such as normalized phylogenetic profiling (NPP) have been developed [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. NPP uses a continuous metric of conservation, offering an alternative to the binary scoring system. NPP has successfully revealed novel genes in various pathways and human genetic diseases including cancer [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Recently, we found that functionally-related genes can show a strong signal of correlated evolution within specific clades (e.g., animals, mammals, plants, fungi) or segments of the tree of life. These local co-evolution signals better reflect the complexity of pathways and protein evolution. Analyzing correlated evolution among genes both across and in part of the tree of life hence improves our ability to reveal the function of genes in different pathways [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. This âclade-wiseâ NPP approach was used to identify novel DNA repair genes [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and to map potential drugs for <italic>MECP2</italic> [<xref ref-type="bibr" rid="CR31">31</xref>] and <italic>ACE2</italic>-associated disorders [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
    <p id="Par9">In this study, we introduce a gene-prioritization tool, EvORanker (Ev: Evolution, O: Omics) (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). EvORanker integrates clade-wise NPP with omics data (e.g., protein-protein interaction, and co-expression data) obtained from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>] to associate a gene variant present in a patient with the patientâs phenotypes. Our primary objective is to establish an unbiased framework to resolve unsolved exomes/genomes by linking genes and especially poorly annotated genes to the disease phenotype observed in patients. Furthermore, we aimed to assess EvORankerâs efficacy in identifying candidate disease genes that lack human annotation.<fig id="Fig1"><label>Fig.Â 1</label><caption><p>Graphical abstract of the EvORanker pipeline. Starting from a list of annotated variants obtained from a patientâs exome/genome sequencing data and following variant filtering, a list of predicted <italic>patient candidate genes</italic> harboring putatively pathogenic variants are input to EvORanker. The second input is the HPO terms corresponding to the patientâs phenotypes. The first step of the pipeline is to rank the genes listed in the HPO database according to the input HPO terms using the OntologySimilarity tool. If any of the patient candidate genes is a known disease-causing gene or ranked high using <italic>OntologySimilarity</italic>, then a genetic diagnosis is achieved. If not, then each patient candidate gene in addition to the ranked HPO gene list is input into a co-evolution and STRING-based algorithm. The algorithm analyzes two lists of genes, the co-evolving and STRING-interacting genes with each patient candidate gene. A one-sided Kolmogorov-Smirnov (K-S) test is then used to test if the co-evolving and interacting genes rank significantly high within the patientâs <italic>phenotype-related genes</italic>. The <italic>p</italic>-values obtained from running the K-S test using each dataset are combined using Fisherâs combined test. The output is a list of patient candidate genes ranked based on Fisherâs combined test <italic>p</italic>-values (from more significant to less significant). A disease-causing candidate is identified among the patient genes where a significant number of co-evolving and/or interacting genes are enriched towards the genes highly related to the patientâs input phenotypes relative to the genes that are unrelated</p></caption><graphic xlink:href="13073_2023_1276_Fig1_HTML" id="MO1"/></fig></p>
    <p id="Par10">Mouse knockout data serves as a valuable resource for comprehending gene function [<xref ref-type="bibr" rid="CR34">34</xref>]. We, therefore, concentrated on genes with knockout phenotypes in mice that lack corresponding human annotation and demonstrate EvOrankerâs ability to identify disease candidates with limited information. The results of our analysis showed that EvORanker was able to identify disease genes that were ranked low by other gene-based methods, demonstrating the complementarity of EvORanker to those of other gene-based tools. Moreover, we employed EvORanker to investigate two patients with unresolved genetic syndromes. Our analysis revealed <italic>DLGAP2</italic> and <italic>LPCAT3</italic> as potential candidates for disease-causing genes. Notably, only clade-based NPP analysis was able to detect <italic>LPCAT3</italic> as a disease candidate. To enhance its practical utility, we designed EvORanker as a user-friendly gene-prioritization web tool that can be used by researchers and clinicians studying genetic disorders.</p>
  </sec>
  <sec id="Sec2">
    <title>Methods</title>
    <sec id="Sec3">
      <title>The patient exome database</title>
      <p id="Par11">For the purpose of benchmarking EvORanker, we gathered sequencing data of patients who sought clinical whole-exome sequencing at Istishari Arab Hospital in Ramallah for diagnostic purposes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). Each participant presented with a distinct clinical anomaly and was referred to Istishari Hospital by their respective physicians from various Palestinian regions to undergo exome sequencing for the identification of genetic causes. We established a database of 109 patient exomes who had received a known molecular diagnosis, some of which have been published [<xref ref-type="bibr" rid="CR35">35</xref>â<xref ref-type="bibr" rid="CR37">37</xref>]. All of the variants identified to be disease-causing in those patients had been reported as pathogenic/likely pathogenic in the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>]. The patients in this cohort exhibit diverse phenotypes (e.g., skeletal, immunological, neurological, and metabolic) (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>A). The majority of the patients were born to consanguineous parents. Each patient had been clinically diagnosed with a different rare Mendelian disease (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1), of which 91 followed an autosomal or X-linked recessive and 18 followed an autosomal or X-linked dominant mode of inheritance. Familial segregation analysis had been performed for each of the patientsâ families further confirming the diagnosis. In addition to the 109 exomes, we applied EvORanker on two exomes of patients (II-3, Fig. <xref rid="Fig10" ref-type="fig">10</xref>A, II-4, Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A) that had not received a molecular diagnosis. Written informed consent was obtained from all participants, or their parents, before their inclusion in the study. All the study participants, or their parents, provided permission to access their medical records.<fig id="Fig2"><label>Fig.Â 2</label><caption><p>Phenotypic diversity in <bold>A</bold> a cohort of 109 patients from the exome database and <bold>B</bold> a simulated dataset of 300 individuals with 300 pathogenic variants from ClinVar inserted into their genomes. The patients exhibit a wide range of phenotypes. Notably, various shared phenotypes, especially related to metabolic and neurological diseases, are observed among the patients. Key: ID, intellectual disability; GI, gastrointestinal disorders</p></caption><graphic xlink:href="13073_2023_1276_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec4">
      <title>Simulation of cases with disease-causing gene variants</title>
      <p id="Par12">We assessed our approach and compared it to other methods by simulating scenarios where mutations in disease-causing genes exist within a genome. VCF files of 300 individual genomes were downloaded from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>], providing a diverse representation of human populations (<ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>) [<xref ref-type="bibr" rid="CR40">40</xref>]. Variant annotation was performed using ANNOVAR [<xref ref-type="bibr" rid="CR41">41</xref>], and our variant filtering pipeline was applied (see TableÂ <xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>TableÂ 1</label><caption><p>Routine variant filtering criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left"><bold>Autosomal and X-linked recessive mode</bold></th><th align="left"><bold>Autosomal and X-linked dominant mode</bold></th></tr><tr><th align="left"><bold>Filtering criteria</bold></th><th align="left"><bold>Filtering criteria</bold></th></tr></thead><tbody><tr><td align="left" colspan="3"><bold>1. Variant frequency</bold></td></tr><tr><td align="left">âgnomAD [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left">âAF_popmax [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left">âIn-house exome database</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left" colspan="3"><bold>2. Splicing and synonymous variants</bold></td></tr><tr><td align="left">âdbscSNV_RF_SCORE and dbscSNV_ADA_SCORE [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" rowspan="2">dbscSNV_RF_SCOREâ&gt;=â0.5 or dbscSNV_ADA_SCOREâ&gt;=â0.5 or SpliceAIâ&gt;=â0.5</td><td align="left" rowspan="2">dbscSNV_RF_SCOREâ&gt;=â0.5 or dbscSNV_ADA_SCOREâ&gt;=â0.5 or SpliceAIâ&gt;=â0.5</td></tr><tr><td align="left">âSpliceAI [<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left" colspan="3"><bold>3. Nonsynonymous variants</bold></td></tr><tr><td align="left">âPolyphen2_HDIV_score [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td align="left" rowspan="3">Polyphen2_HDIV_scoreâ&gt;=â0.5 or REVEL scoreâ&gt;=â0.5 or SIFT scoreâ&lt;=â0.5</td><td align="left" rowspan="3">Polyphen2_HDIV_scoreâ&gt;=â0.5 or REVEL scoreâ&gt;=â0.5 or SIFT scoreâ&lt;=â0.5</td></tr><tr><td align="left">âREVEL score [<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr><td align="left">âSIFT score [<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr></tbody></table></table-wrap></p>
      <p id="Par13">For each of the 300 genomes, we introduced exonic or splicing pathogenic/likely pathogenic variants from the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>], excluding disease genes already found in the 109-real exome patient dataset. These 300 ClinVar variants were randomly selected from genes associated with diverse disease phenotypes, including complex neoplastic disorders (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>B). Among these variants, 181 followed an autosomal or X-linked recessive mode of inheritance, while 119 variants followed a dominant inheritance pattern. In instances where the mode of inheritance for a ClinVar pathogenic variant was uncertain, or if it could be attributed to both inheritance modes, or if it was not reported in affected patients, we randomly assigned the mode of inheritance. Subsequently, we randomly integrated these 300 sampled variants into the 300 annotated genomes. This process was permutated three times, each time spiking each variant of the set of 300 ClinVar variants into different genomes out of the 300. The outcome is a simulation of 900 artificial patients with 300 unique âgenetic diseasesâ (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2), each with a single mutation in one of 300 genes. This ensured that each disease appeared three times in three different genomes.</p>
      <p id="Par14">Phenotypic information for each spiked ClinVar gene variant was retrieved from the HPO (Human Phenotype Ontology) database [<xref ref-type="bibr" rid="CR46">46</xref>]. Additionally, to evaluate the robustness of EvORanker, we conducted validation through three independent spike shuffles (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S7).</p>
    </sec>
    <sec id="Sec5">
      <title>Genomics and variant-based prioritization of the patientsâ exome to map the patient candidate genes</title>
      <p id="Par15">Whole-exome sequencing was performed on the patients described in this study using the Truseq Capture Exome Kit (IlluminaÂ®). The captured and the amplified libraries were sequenced on the Illumina Nextseq500 platform according to the manufacturerâs protocol. Briefly, paired-end sequences were obtained at a read length of 150 bps. Sequence reads were then aligned to the reference human genome (hg19) using BWA aligner [<xref ref-type="bibr" rid="CR47">47</xref>]. Alignments then underwent preprocessing steps by PCR duplicate removal, base quality recalibration, and realignment around indels. The variants were finally called by GATK (Genome Analysis Toolkit) [<xref ref-type="bibr" rid="CR48">48</xref>] and annotated by ANNOVAR [<xref ref-type="bibr" rid="CR41">41</xref>]. For both the patient exomes and simulated genomes, we excluded intronic, untranslated region (UTR), and ncRNA variants. Nonsense, frameshift, nonsynonymous, and splice-site variants were prioritized by excluding frequent variants based on their minor allele frequency in gnomAD and AF_popmax [<xref ref-type="bibr" rid="CR42">42</xref>] and Istishari hospitalâs in-house exome database (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). In addition, variants predicted to be benign by variant effect predictor tools such as PolyPhen-2 [<xref ref-type="bibr" rid="CR5">5</xref>] and REVEL [<xref ref-type="bibr" rid="CR6">6</xref>] were excluded from the analysis (TableÂ <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR49">49</xref>]. For the patient exomes, copy number variations were called from the exome data using XHMM software [<xref ref-type="bibr" rid="CR50">50</xref>]. In this study, the genes that passed the variant filtering criteria are referred to as the <italic>patient candidate genes</italic>. Co-segregation analysis was performed by Sanger sequencing on an ABI 3130 Genetic Analyzer (Applied Biosystems). Primers used for validation and family segregation of the <italic>DLGAP2</italic> variant are as follows: Forward: CGGTAGAGACTGGGAGGATG and Reverse: ACTTACCTGACAAAACACACACA. Primers used for validation and family segregation of the <italic>LPCAT3</italic> variant are as follows: Forward<italic>:</italic> CGCATAGGGGTGACATGGTA and Reverse<italic>:</italic> TATGCATTTTGACGGGCCTG.</p>
    </sec>
    <sec id="Sec6">
      <title>Ranking the patient candidate genes according to their association with each patientâs disease-phenotypes</title>
      <p id="Par16">In order to retrieve a list of genes already reported to be associated with each patientâs clinical condition, we encoded the abnormalities reported in each patientâs medical report (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) to standard HPO terms [<xref ref-type="bibr" rid="CR46">46</xref>]. The combination of the patient HPO terms was then input into the OntologySimilarity package in R, a semantic similarity-based tool [<xref ref-type="bibr" rid="CR51">51</xref>], and used to identify and rank the genes listed in the HPO database based on their associations with the queried HPO terms. According to the recommended parameters in the toolâs documentation [<xref ref-type="bibr" rid="CR51">51</xref>], the semantic similarity score was calculated using Linâs definition of semantic similarity in combination with the âbest-match-averageâ approach. Additional semantic similarity measures, such as the product measure based on Resnikâs similarity expression, were also evaluated, yielding results that were nearly identical (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1). The output is a ranked list of the 4900 genes listed in the HPO database (as of January 2023) scored between zero and one (termed HPO-ranked genes). This score is based on the degree of similarity between the patientâs set HPO terms and the HPO terms annotated to each gene in the HPO database. The higher-scoring genes, referred to as <italic>phenotype-related genes</italic> in this study, are defined as genes that exhibit stronger associations with the queried phenotypes.</p>
      <p id="Par17">Defining an exact threshold for the output of OntologySimilarity [<xref ref-type="bibr" rid="CR51">51</xref>] is challenging. In most cases, it is hard to point to a clear threshold that above which the genes are âphenotype-related.â Furthermore, such a potential threshold is highly dependent on the user-defined HPO terms as HPOs are variable in their level of complexity and how well they are defined or studied. As such in our analysis, the genes were ranked and ordered based on their association with the set of input phenotypes, ranging from highly associated to not associated (top to bottom). We utilized a one-sided Kolmogorov-Smirnov test to assess the significance of a skewed distribution of co-evolved (or interacting genes) towards the upper end of the ranked genes (see below).</p>
    </sec>
    <sec id="Sec7">
      <title>Building the EvORanker algorithm</title>
      <p id="Par18">The main goal of EvORanker is to establish a link between the <italic>patient candidate genes</italic> and the patientâs phenotype. This link was evaluated based on two different sources of data on known and predicted gene functional interactions:, clade-wise phylogenetic profiling, and the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. Our working hypothesis is that of the <italic>patient candidate genes</italic>, the disease-causing gene would be functionally linked to the genes that cause similar phenotypes to those of the patient (e.g., the disease-causing gene in a patient with ciliopathy would show significant co-evolution/co-expression/interaction with cilia genes). We used the 109-patient exome and 900-simulated datasets to tune the parameters of the algorithm using exclusively phylogenetic profiling (PP). Subsequently, we compared and eventually integrated the PP-based analysis with the STRING-based analysis to maximize the performance of EvORanker.</p>
    </sec>
    <sec id="Sec8">
      <title>Clade-based phylogenetic profiling</title>
      <p id="Par19">The normalized phylogenetic profiling (NPP) matrix was constructed as previously described [<xref ref-type="bibr" rid="CR24">24</xref>]. Briefly, a matrix of BLASTP scores for all human genes against the genomes of 1,028 eukaryotic species was constructed. First, the bitscore of each best BLAST hit was normalized by the bitscore of the query protein self-hit. Then log2 transformation of the normalized bitscore was applied. Finally, to avoid any biases due to phylogenetic distance, the conservation score was scaled for each species to their overall distribution by transforming the values in the column (corresponding to a species) into <italic>z</italic>-scores.</p>
      <sec id="Sec9">
        <title>Clade-based analysis</title>
        <p id="Par20">To have a comprehensive mapping of protein-correlated evolution, we used 16 representative clades spanning the eukaryotic tree as previously described [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In addition to including all eukaryotes, the following clades were used: <italic>Chordata</italic>, <italic>Ecdysozoa</italic>, <italic>Platyhelminthes</italic>, <italic>Alveolates</italic>, <italic>Stramenopiles</italic>, <italic>Fungi</italic>, <italic>Viridiplantae</italic>, <italic>Mammalia</italic>, <italic>Archelosuria</italic>, <italic>Arthropoda</italic>, <italic>Nematoda</italic>, <italic>Basidiomycota</italic>, <italic>Ascomycota</italic>, <italic>Fungi incertae sedis</italic>, <italic>Liliopsida</italic>, and <italic>Eudicotyledons</italic> [<xref ref-type="bibr" rid="CR24">24</xref>]. These 16 representative clades spanning the eukaryotic tree show wide coverage (span most of the eukaryotic tree), mutual exclusivity (preferring non-nested clades), and uniformness (similar depth in the tree) in clade types (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2) [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
      </sec>
      <sec id="Sec10">
        <title>Retrieving coevolving genes for each patient candidate gene</title>
        <p id="Par21">The degree of co-evolution between two genes was evaluated using the Pearson correlation coefficient between their respective rows in the NPP matrix. As we demonstrated before [<xref ref-type="bibr" rid="CR24">24</xref>], for each <italic>patient candidate gene</italic>, we selected the genes with the top 100 correlation coefficients in each clade and ranked them from 1 to 100 according to the correlation coefficient in each clade where the gene is found to have an ortholog.</p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Using the Kolmogorov-Smirnov test to prioritize patient candidate genes based on phylogenetic profiling</title>
      <p id="Par22">Per patient exome/simulated genome, we analyzed each of the <italic>patient candidate genes</italic> separately. For each of these genes, we determined whether the genes that co-evolve with it were associated with the patientâs phenotype (i.e., the co-evolved genes were significantly enriched towards the <italic>phenotype-related genes</italic>). For that, we examined the ranking of the coevolving genes in the list of the <italic>HPO-ranked genes</italic> using a one-tailed, two-sample Kolmogorov-Smirnov (K-S) test [<xref ref-type="bibr" rid="CR52">52</xref>].</p>
      <p id="Par23">The K-S test is used to test whether two samples come from the same distribution. The K-S <bold><italic>D</italic></bold> statistic quantifies the distance between the empirical cumulative distribution function (ECDF) of the sample and the cumulative distribution function of the reference distribution. Let <italic>i</italic> denote the co-evolving genes and <italic>j</italic> denote the <italic>ranked HPO genes</italic>.</p>
      <p id="Par24">The null hypothesis: H0:<italic>Fi(x)</italic>ââ¥â<italic>Fj(x)</italic></p>
      <p id="Par25">The alternative hypothesis: H1:<italic>Fi(x)</italic>â&lt;â<italic>Fj(x)</italic></p>
      <p id="Par26">The D statistic: <bold><italic>D-</italic></bold>â=âmax<sub><italic>x</italic></sub>{<italic>Fj</italic>(<italic>x</italic>)-<italic>Fi</italic>(<italic>x</italic>)} where <italic>Fj</italic> is the ECDF of <italic>j</italic> and similarity for <italic>Fi</italic></p>
      <p id="Par27">The H1 hypothesis for the one-sided K-S test is that the cumulative distribution function of the ranking of the coevolving genes is enriched within the higher-scoring side of <italic>HPO-ranked genes (the phenotype-related genes)</italic>. A <italic>p</italic>-value was computed using the ks.test function in the stats package in R [<xref ref-type="bibr" rid="CR53">53</xref>]. The <italic>patient candidate genes</italic> were finally ranked by the resulting K-S test <italic>p</italic>-value (from more significant to less significant).</p>
    </sec>
    <sec id="Sec12">
      <title>Tuning the parameters of the EvORanker phylogenetic profiling-based analysis</title>
      <p id="Par28">We evaluated the performance phylogenetic profiling-based analysis to identify the âtrueâ disease-causing gene using the 109-patient exome and the 900-simulated databases.Â We examined different parameters and cutoff values using phylogenetic profiling. We compared different cutoff values of the ranked coevolving genes (top 10, 25, 50, 75, 100) with each <italic>patient candidate gene</italic>. In both datasets, a threshold of the top 50 coevolved genes yielded slightly better accuracy in ranking the âtrueâ gene in comparison to the other patient candidate genes (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S3), which we used for the rest of the analysis.</p>
    </sec>
    <sec id="Sec13">
      <title>Applying the Kolmogorov-Smirnov test using STRING-interacting genes</title>
      <p id="Par29">In addition to phylogenetic profiling, other known and predicted functionally associated genes (protein-protein interactions, text mining, and co-expression) were retrieved from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. STRING uses a scoring system that reflects the evidence of predicted interactions. We included interactions with a combined score of at least 0.5, which corresponds to a medium-confidence network. For each patient exome/simulated genome in the datasets, we applied the K-S test. The analysis was done for each <italic>patient candidate gene</italic>, with the STRING-interacting genes similarly as described above. We examined whether a substantial portion of string-interacting genes were also linked to phenotypes resembling those found in the patient.</p>
    </sec>
    <sec id="Sec14">
      <title>The final EvORanker gene prediction scoring system</title>
      <p id="Par30">The two <italic>p</italic>-values obtained from each K-S test using phylogenetic profiling and STRING were finally combined by Fisherâs combined probability test [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>] (Eq.Â <xref rid="Equ1" ref-type="disp-formula">1</xref>) which is the final EvORanker scoring system. Additionally, we assessed Simesâ method for combining the <italic>p</italic>-values, which produced similar results (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1). The Fisherâs combined probability test was computed using the combine.test function in the survcomp package in R [<xref ref-type="bibr" rid="CR56">56</xref>].<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${X}_{2k}^{2}\sim -2\sum_{i=1}^{k}{\text{log}}\left({p}_{i}\right)$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>â¼</mml:mo><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:munderover><mml:mo>â</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>k</mml:mi></mml:munderover><mml:mtext>log</mml:mtext><mml:mfenced close=")" open="("><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="13073_2023_1276_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p>
    </sec>
    <sec id="Sec15">
      <title>Applying EvORanker on genes with knockout phenotypes in mice that lack corresponding human annotation</title>
      <p id="Par31">A list of 6395 human genes with mouse knockout phenotypes but not yet associated with a phenotype in humans was compiled from Jackson laboratoryâs Mouse Genome Informatics (MGI) [<xref ref-type="bibr" rid="CR57">57</xref>], (downloaded, March 1, 2023). The knockout mouse gene phenotype terms were then mapped to human HPO terms using uPheno ontology inter-ontology closest matches obtained from the OBO Phenotype Ontology Github repository [<xref ref-type="bibr" rid="CR58">58</xref>] ending up with 6260 genes with mapped HPO terms. Then, for each gene, the corresponding HPO terms and a list of randomly sampled genes were input to EvORanker. The same data was input to Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>] for comparison. We were unable to compare to other tools (e.g., ExomeWalker or PHIVE) due to the impracticability of simulating 6,260âÃâ100 variants in 6,260.vcf files as input.</p>
    </sec>
    <sec id="Sec16">
      <title>Tool comparison</title>
      <p id="Par32">We compared EvORanker to the gene prioritization stage (second stage) of ExomeWalker and PHIVE algorithms [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. We used the 109-patient exome and 900-simulated benchmarking datasets to compare the tools with the same input HPO terms and <italic>patient candidate genes</italic>. We omitted one exome from the exome dataset where a large deletion was identified containing the <italic>NPRL3</italic> gene, leaving us with 108 exomes. We used.vcf files for each of the 108 patient exomes and the 900 genomes as input for Exomiser which includes ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>]. Additionally, we created.yml files containing the same HPO terms as input for each patient exome and simulated genome.</p>
    </sec>
    <sec id="Sec17">
      <title>In vitro splicing analysis</title>
      <p id="Par33">In vitro splicing, minigene assays were carried out as previously described [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Briefly, the genomic sequence at chr8:1626251-1627026 (hg19) which includes exon 9 (417Â bp) plus 128 and 231 nucleotides from the 5â² and 3â² flanking sequences, respectively, of <italic>DLGAP2</italic> (NM_001346810) was PCR amplified from a DNA sample homozygous (II-3, Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A) and wildtype (II-2, Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A) for the c.2702 Aâ&gt;âT variant using gene-specific primers designed with embedded XhoI and BamHI restriction enzyme recognition sites. After digestion, the PCR fragments were ligated into a pre-constructed pET01 Exontrap vector (MoBiTec, Goettingen, Germany). Selected colonies were then sequenced to confirm the proper orientation of the cloned fragment and identify both wild-type and variant colonies. Subsequently, the variant and wild-type minigenes were transfected into HEK293 cells in triplicate, followed by total RNA extraction 48Â h post-transfection, using the Quick-RNA MiniPrep Plus kit (ZYMO Research). cDNA was then synthesized using the qScript Flex cDNA synthesis kit (Quanta Biosciences) with a specific primer to the 3â² native exon of the pET01 Exontrap vector. Following PCR amplification, the products were then visualized on a 1.5% agarose gel and were later extracted and then Sanger sequenced. The primer sequences used for the PCR amplification (XhoIâ+âBamHI) are Forward: AAA-<underline>CTCGAG</underline>-AACACTACCTGCCCTTGAGC, and Reverse: AAA-<underline>GGATCC</underline>-ACTTACCTGACAAAACACACACA.</p>
    </sec>
    <sec id="Sec18">
      <title>Data analysis and figure creation</title>
      <p id="Par34">All data in this study were analyzed using R software [<xref ref-type="bibr" rid="CR53">53</xref>]. The EvORanker web interface was created using the R Shiny package [<xref ref-type="bibr" rid="CR62">62</xref>]. The majority of the figures were created using R software. FiguresÂ <xref rid="Fig9" ref-type="fig">9</xref>D and <xref rid="Fig10" ref-type="fig">10</xref>D were created using Cytoscape v3.9.1 [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
    </sec>
  </sec>
  <sec id="Sec19">
    <title>Results</title>
    <sec id="Sec20">
      <title>Overview</title>
      <p id="Par35">In this work, we developed EvORanker, a phylogenetic profiling-based algorithm, to identify disease-causing genes. To optimize and evaluate the performance of EvORanker, we employed three different approaches: (1) analyzing a private cohort of well phenotypically characterized patients with rare diseases; (2) simulating a dataset of 900 patients with 300 unique âgenetic diseasesââby spiking disease-causing mutations into real genomes; (3) evaluating EvORankerâs ability to identify human disease candidate genes using genes with knockout phenotypes in mice that lack corresponding human annotation. We demonstrate the contribution of clade-based phylogenetic profiling (PP) to the improved prediction of the disease-causing gene. This unbiased approach was compared and integrated with gene interaction data obtained from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. To evaluate the potential for bias in disease-gene prediction, we compared well-annotated genes to recently published ones. Finally, EvORanker was compared to other gene-based prioritization tools and applied to two unresolved exomes to demonstrate its efficacy in disease gene discovery.</p>
    </sec>
    <sec id="Sec21">
      <title>Benchmarking EvORanker using an exome-patient dataset</title>
      <p id="Par36">We analyzed an in-house database of 109 patient exomes with a genetic diagnosis. The patients suffer from various rare hereditary diseases, exhibiting diverse phenotype groups (e.g., skeletal, immunological, neurological, and metabolic diseases) (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>A). The dataset included 91 recessive and 18 dominant gene variants that explained the patientsâ phenotype (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). All these variants are reported to be pathogenic/likely pathogenic in the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>] and co-segregated with the phenotype in each corresponding family. The dataset includes 108 unique known disease genes (the <italic>CLCN1</italic> gene appears twice, once as autosomal recessive and once as autosomal dominant). For each patient in the exome dataset, we encoded each of the clinical abnormalities found in the patientâs medical record into Human Phenotype Ontology (HPO) [<xref ref-type="bibr" rid="CR46">46</xref>] terms (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p>
    </sec>
    <sec id="Sec22">
      <title>Benchmarking EvORanker using a simulated dataset</title>
      <p id="Par37">Next, we aimed to assess our ability to identify disease-causing mutations in simulated data. Simulating genetic diseases can be achieved by introducing pathogenic mutations into genomic data from an unaffected individual. To accomplish this, we utilized 300 unaffected genomes sourced from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>] as a benchmark for our evaluations. To introduce pathogenicity, we randomly integrated 300 distinct pathogenic/likely pathogenic variants from the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>] into the annotated genomes. These ClinVar variants are associated with genes showcasing diverse phenotypes including complex neoplastic disorders (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>B). Of these variants, 181 followed an autosomal or X-linked recessive mode of inheritance, while 119 variants followed a dominant inheritance pattern (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). Phenotypic information for each spiked ClinVar gene variant was obtained from the HPO database (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) and was assigned to the respective âpatient.â We conducted this process thrice, simulating a total of 900 artificial patients with 300 different genetic diseases. Each pathogenic mutation was inserted into three distinct genomes.</p>
      <sec id="Sec23">
        <title>Ranking genes based on each patientâs set of phenotypes</title>
        <p id="Par38">Using each set of patient HPO terms, we calculated the semantic similarity score [<xref ref-type="bibr" rid="CR51">51</xref>] (see the â<xref rid="Sec2" ref-type="sec">Methods</xref>â section) for each gene in the HPO database [<xref ref-type="bibr" rid="CR46">46</xref>]. The output is a list of genes scored from lower association to higher association with the patientâs set of HPO terms (which we term the phenotype-related genes).</p>
      </sec>
      <sec id="Sec24">
        <title>Retrieving the patientâs candidate genes</title>
        <p id="Par39">We applied our routine variant filtering criteria [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] to the annotated variants for each of the 109 exomes and simulated genomes (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). After variant filtering, each exome/genome contained gene variants that are considered to be pathogenic and predicted to affect protein function (we term the genes in which these variants were observed as <italic>patient candidate genes</italic>). In autosomal and X-linked recessive cases, each patient harbored 11â80 homozygous/hemizygous or compound heterozygous deleterious variants, while 80â170 heterozygous/hemizygous deleterious variants were observed in autosomal and X-linked dominant cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S4). We confirmed that all the âtrueâ causative variants passed the filtering criteria and remained within the gene variant list for each patient exome.</p>
      </sec>
      <sec id="Sec25">
        <title>Using multi-clade phylogenetic profiling to rank the patientâs candidate genes according to the patientâs phenotype</title>
        <p id="Par40">Our working hypothesis is that out of all the patient candidate genes, the one responsible for the disease will be associated (e.g., co-evolved) with other genes that are known to be associated with the disease (phenotype-related gene). For each <italic>patient candidate gene</italic>, we obtained a list of 50 co-evolved genes that exhibit a strong correlation based on global and local co-evolution signatures across 1028 eukaryotic species (details in the â<xref rid="Sec2" ref-type="sec">Methods</xref>â section) [<xref ref-type="bibr" rid="CR24">24</xref>]. For each <italic>patient candidate gene</italic>, we retrieved the top co-evolving genes in 16 clades (<italic>Chordata</italic>, <italic>Ecdysozoa</italic>, <italic>Platyhelminthes</italic>, <italic>Alveolates</italic>, <italic>Stramenopiles</italic>, <italic>Fungi</italic>, <italic>Viridiplantae</italic>, <italic>Mammalia</italic>, <italic>Archelosuria</italic>, <italic>Arthropoda</italic>, <italic>Nematoda</italic>, <italic>Basidiomycota</italic>, <italic>Ascomycota</italic>, <italic>Fungi incertae sedis</italic>, <italic>Liliopsida</italic>, and <italic>Eudicotyledons</italic>) (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2). The output per <italic>patient candidate gene</italic> is a table of genes that are strongly co-evolved with it in each clade in addition to all Eukaryotes.</p>
        <p id="Par41">To determine which of the <italic>patient candidate genes</italic> is most likely linked to the patientâs disease phenotype, we evaluated the intersection between the co-evolved genes and the phenotype-ranked genes using a one-sided <italic>Kolmogorov-Smirnov</italic> (K-S) test (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). A significant <italic>p</italic>-value is obtained if the co-evolving genes rank high within the <italic>phenotype-related genes</italic>. For each patient exome/simulated genome in our dataset, we ranked the <italic>patient candidate genes</italic> based on the resulting <italic>p</italic>-value, with the most significant <italic>p</italic>-value ranked first. By analyzing the co-evolved genes across the 16 clades in addition to all Eukaryotes, the âtrueâ disease-causing gene was ranked as the top gene in 46% of the autosomal and X-linked recessive cases and within the top 5 in 72% (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>). In autosomal and X-linked dominant cases, the âtrueâ gene was ranked as the top gene in 50% of the cases and within the top 10 genes in 78%. These results surpass those obtained from using only the co-evolving genes across Eukaryotes or within the Animalia clades (<italic>Chordata</italic>, <italic>Mammalia</italic>, <italic>Archelosauria</italic>, <italic>Ecdysozoa</italic>, <italic>Nematoda</italic>, <italic>Arthropoda</italic>, and <italic>Platyhelminthes</italic>) (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>). This indicates the added value of incorporating all 16 clades in the analysis. The same analysis was applied on the simulated genomes, yielding results consistent with those obtained from the real exome dataset (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.Â 3</label><caption><p>Using clades improves the performance of EvORanker phylogenetic profiling-based analysis. For each patient candidate gene list in the 109-patient exome and the 900-simulated genomes datasets (300 unique genetic disorders), we compared the accuracy of the phylogenetic profiling-based algorithm by retrieving the top 50 coevolved genes with each <italic>patient candidate gene</italic> across all Eukaryotes versus: (1) using all 16 clades where the query gene has an ortholog in addition to Eukaryotes. (2) Across only Animalia clades (<italic>Chordata</italic>, <italic>Mammalia</italic>, <italic>Archelosauria</italic>, <italic>Ecdysozoa</italic>, <italic>Nematoda</italic>, <italic>Arthropoda</italic>, and <italic>Platyhelminthes</italic>). Performance was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other patient candidate genes. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right). The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested clades, and the <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top or within the top 3 or top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage is for the âtrueâ gene being ranked at the top or within the top 10 genes. Overall, the best performance of ranking the âtrueâ causative gene was achieved by merging together the co-evolving genes within all clades (the 16 clades in addition to all Eukaryota) in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig3_HTML" id="MO6"/></fig></p>
      </sec>
      <sec id="Sec26">
        <title>Phylogenetic profiling analysis in different evolutionary scales improves the prediction of the disease-causing gene</title>
        <p id="Par42">We then aimed to assess the contribution of each of the 16 clades, in addition to all <italic>Eukaryota</italic>, towards the prediction of the âtrueâ disease-causing gene. Using the 109 patient exomes, this was accomplished by focusing on the genes that obtained a significant <italic>p</italic>-value (&lt;â0.05) through co-evolution analysis totaling 71 identified genes. We applied the K-S test to these 71 genes using the co-evolving genes within each clade. Results showed that each clade outperformed others in at least one case, thus highlighting the importance of combining information from different clades to enhance the performance of EvORanker (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>). Interestingly, the <italic>Fungi Incertae Sedis</italic> clade outperformed other clades in 14% (10/71) of the cases, followed by <italic>Chordata</italic>, <italic>Ascomycota</italic>, <italic>Arthropoda</italic>, and <italic>Eukaryota</italic>, each outperforming others in 10% of the cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S5). Taken together, these results emphasize that clades differentially specialize in detecting functional interactions in different pathways [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].<fig id="Fig4"><label>Fig.Â 4</label><caption><p>Each of the 16 clades in addition to <italic>Eukaryota</italic> contributes to the correct identification of the disease-causing gene. Each column in the heatmap represents a clade while each row represents the âtrueâ disease-causing gene in a patient exome from the 109-exome patient dataset. Only the genes that achieved an overall significant K-S test <italic>p</italic>-value (&lt;â0.05) using the co-evolution analysis are displayed (71 cases). Each entry in the heatmap is colored by the -log 10 of the K-S test <italic>p</italic>-value that was run on each clade separately. The entries colored in red represent the significant <italic>p</italic>-values (&gt;â-log10(0.05)). Light grey entries indicate non-significant <italic>p</italic>-values. Entries, where the gene is not found to have an ortholog in a certain clade, are colored off-white. The rows are clustered according to the <italic>p</italic>-values. The column on the left indicates the combined -log10 of the <italic>p</italic>-value obtained by running the K-S test after merging together the coevolving genes across the clades. In four cases (<italic>HUWE1</italic>, <italic>COL3A1</italic>, <italic>MYO7A</italic>, and <italic>CYP21A2</italic>), a significant <italic>p</italic>-value was obtained by none of the clades, but a significant combined <italic>p</italic>-value was still achieved by merging the co-evolving genes from all the clades</p></caption><graphic xlink:href="13073_2023_1276_Fig4_HTML" id="MO7"/></fig></p>
      </sec>
      <sec id="Sec27">
        <title>Phylogenetic profiling is complementary to other existing omics datasets</title>
        <p id="Par43">NPP represents an unbiased approach that can annotate gene function independently of the literature. We sought to evaluate whether clade-wise NPP could identify disease-associated genes that are overlooked by other existing omics. For that, we chose to use the STRING database since it integrates information on protein associations from multiple sources, including interaction experiments, known complexes and pathways, scientific literature, co-expression studies, and conserved genomic context [<xref ref-type="bibr" rid="CR33">33</xref>]. We conducted a comparison between the NPP and STRING-based analysis [<xref ref-type="bibr" rid="CR33">33</xref>] using both the patient exome and simulated datasets (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). NPP outperformed STRING in 29/109 (27%) of the cases, whereas STRING outperformed NPP in 50/109 (46%) of the cases (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6).<fig id="Fig5"><label>Fig.Â 5</label><caption><p>Comparative performance of NPP, STRING, and EvORanker using the 109-patient exome and the simulated datasets. The performance of each dataset was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other genes in each exome/genome in both datasets. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right), The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested datasets: NPP (using the top 50 coevolved genes), STRING versions 9.1, 11.5, and EvORanker (combining NPP and the newer version of STRING). The <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top, or within the top 3 or top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage is for the âtrueâ gene being ranked at the top or within the top 10 genes. Overall, the best performance was achieved using the combined approach (EvORanker) in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig5_HTML" id="MO8"/></fig></p>
        <p id="Par44">Considering the presence of complementarity of co-evolution and the STRING-based analysis, we integrated the two datasets by combining their respective <italic>p</italic>-values using Fisherâs combined probability test [<xref ref-type="bibr" rid="CR54">54</xref>]. This combined scoring system, which we termed EvORanker, yielded the highest accuracy in comparison to each dataset alone (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). Using the exome dataset, we showed that integrating NPP and STRING improved the results by 43% compared to NPP alone and by 30% compared to STRING alone (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6). Overall, in autosomal and X-linked recessive cases, EvORanker ranked the âtrueâ disease-causing gene as the top gene in 63/91 (69%) and within the top 5 genes in 86/91 (95%) cases (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). In autosomal and X-linked dominant cases, the âtrueâ gene was ranked as the top gene in 12/18 (67%) cases and among the top 10 genes in 17/18 (95%) (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). On the other hand, the âtrueâ disease genes did not achieve high scores in a total of 6/109 (5.5%) of the exomes (within the top 5 for recessive diseases and within the top 10 for dominant diseases); 5/91 recessive cases, and 1/18 dominant cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6).</p>
        <p id="Par45">We observed similar trends when analyzing the simulated dataset, providing further validation and affirming the consistency of our findings (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). In autosomal and X-linked recessive cases within the simulated dataset, EvORanker ranked the âtrueâ disease-causing gene as the top gene in 75% of cases and within the top 5 in 96% of cases. Conversely, for autosomal and X-linked dominant cases, the âtrueâ gene held the top position in 55% of cases and was within the top 10 in 85% of cases. This parallel in results strongly underscores the robustness of EvORanker across both real and simulated datasets. Furthermore, to validate the stability of our method, we conducted three independent spike shuffles, consistently yielding coherent and reliable results (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S7).</p>
      </sec>
    </sec>
    <sec id="Sec28">
      <title>Performance of phylogenetic profiling versus STRING on new gene entries (2020â2022)</title>
      <p id="Par46">As STRING is based on publicly available data, it is suited to identify well-researched genes. We hypothesized that STRING performance would be better the more information it has accrued over time and that our unbiased PP approach would have a particular advantage for genes that have not been extensively characterized. To test this hypothesis, we compared the performance of STRING version v.11.5 [<xref ref-type="bibr" rid="CR33">33</xref>] with that of the older version STRING v.9.1 [<xref ref-type="bibr" rid="CR64">64</xref>] (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). We found that the performance of the newer version was indeed better than that of the older version. Furthermore, the performance of STRING v11.5 decreased dramatically for genes that only recently became associated with disease. For example, the performance of STRING in ranking the âtrueâ disease gene within the top 5 is around 85% for genes identified by the end of 2015 compared to 29% for genes identifiedÂ between 2016â2020 (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S8).<fig id="Fig6"><label>Fig.Â 6</label><caption><p>The effect of years elapsed on the performance of NPP versus STRING, using the 109-patient exome dataset. The <italic>x</italic>-axis indicates the calendar years (divided into 5-year windows) in which a gene was described to be associated with a disease phenotype. The <italic>y</italic>-axis indicates the percentage of âtrueâ disease genes that ranked at the top (top 1) relative to the other <italic>patient candidate</italic> using NPP (red bars) or STRING (blue bars)</p></caption><graphic xlink:href="13073_2023_1276_Fig6_HTML" id="MO9"/></fig></p>
      <p id="Par47">We then evaluated the performance of NPP and STRING on newly discovered or recently published genes. We retrieved a list of 94 new gene entries that were added to the most recent version of the HPO database (2022) compared to an older version (2020) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3). We then applied the K-S test separately using NPP and STRING and the HPO terms associated with each gene as input. We found that for those genes newly associated with human phenotypes, the K-S test yielded significant <italic>p</italic>-values using NPP in 45% of the genes compared to 38% using STRING (Fig. <xref rid="Fig7" ref-type="fig">7</xref>A, B). These results emphasize the success of phylogenetic profiling in predicting the phenotype associations of newly discovered or less studied genes and highlight the complementarity observed when comparing these two datasets.<fig id="Fig7"><label>Fig.Â 7</label><caption><p>Comparison of NPP versus STRING for genes with recent (2020â2022) annotation. <bold>A</bold> The <italic>x</italic>-axis indicates -log(10) <italic>p</italic>-values obtained from running the K-S test using NPP. The <italic>y</italic>-axis indicates -log(10) <italic>p</italic>-values obtained from running the K-S test using the STRING dataset. The red dots represent the genes where NPP performed better than STRING, while the blue dots indicate the opposite. The marginal histogram indicates the distribution of the -log(10) <italic>p</italic>-values of both datasets. The correlation score between the two datasets is 0.046, suggesting that the two datasets exhibit a complex relationship, where a subset of the data displays complementarity, while another subset shows correlation. <bold>B</bold> Density distribution of the -log(10) <italic>p</italic>-values obtained from the K-S test using the NPP, STRING, and both (combined). Significance was calculated using the Wilcoxon test (*<italic>p</italic>-valueâ&lt;â0.05, **<italic>p</italic>-valueâ&lt;â0.01; ns, nonsignificant). Combining NPP and STRING achieved significantly more significant results that either approach alone</p></caption><graphic xlink:href="13073_2023_1276_Fig7_HTML" id="MO10"/></fig></p>
    </sec>
    <sec id="Sec29">
      <title>Performance of EvORanker on genes with knockout phenotypes in mice that lack corresponding human annotation</title>
      <p id="Par48">We aimed to assess EvORankerâs capability to identify disease candidate genes that lack a known phenotype association in humans but possess mouse orthologs linked to phenotypes. Specifically, we aimed to identify human genes without established phenotype links, yet having a corresponding mouse ortholog with a phenotype association. These genes were considered as the âtrueâ disease gene candidates for the purpose of this evaluation. We compiled a list of 6260 human ortholog genes with mouse knockout phenotypes, yet not associated with a phenotype in humans. For each of these genes, we input a set of HPOs mapped from the respective mouse knockout phenotypes. The goal was to evaluate EvORankerâs ability to correctly pinpoint the âtrueâ disease gene candidate in comparison to 100 randomly sampled human genes. The same dataset was used as input for Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>] for comparative analysis.</p>
      <p id="Par49">EvORanker yielded significant <italic>p</italic>-values for 41% of the tested genes (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>A). Moreover, both EvORanker and Phenolyzer ranked the âtrue geneâ among the top 10 in 16% of the cases (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>B). Notably, EvORanker identified genes that Phenolyzer failed to identify, and vice versa, highlighting the complementarity of the tools (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S9).<fig id="Fig8"><label>Fig.Â 8</label><caption><p>EvORankerâs performance in identifying candidate disease genes using mouse knockout genes without corresponding human annotation. <bold>A</bold> The graph shows the percentage of genes with mouse knockout phenotypes that were tested for significant <italic>p</italic>-values using EvORanker. Out of 6260 genes, 41% showed significant <italic>p</italic>-values. <bold>B</bold> Comparison of EvORanker and Phenolyzer [<xref ref-type="bibr" rid="CR49">49</xref>] in identifying true disease gene candidates. The graph shows the count of genes with mouse knockout phenotypes and their respective ranking, each in comparison to 100 randomly sampled genes by EvORanker and Phenolyzer. Among the tested genes, 16% were ranked in the top 10 by both tools</p></caption><graphic xlink:href="13073_2023_1276_Fig8_HTML" id="MO11"/></fig></p>
    </sec>
    <sec id="Sec30">
      <title>Tool comparison</title>
      <p id="Par50">Using the 109-exome and simulated datasets, we compared the performance of EvORanker to the gene-prioritization stage of ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>]. ExomeWalker prioritizes genes based on protein-protein interaction, while PHIVE uses mouse phenotypic data. To ensure a fair comparison, we chose to compare to ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] because both adopt a similar strategy to EvORanker. Unlike Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>], these methods do not rely on pre-existing knowledge about known disease genes. The comparison was performed using the exome and simulated datasets with the same input HPO terms. However, since ExomeWalker and PHIVE are not well-suited for CNV analysis, we omitted from this analysis one exome where the causative variant was a large deletion encompassing the <italic>NPRL3</italic> gene. The results of the 108-exome dataset showed that EvORanker outperformed either one or both ExomeWalker and PHIVE in 74% (80/108) of the cases and outperformed both tools in 30% (32/108) of the cases (Fig.Â <xref rid="Fig9" ref-type="fig">9</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S10). On the other hand, either one or both of the other tools outperformed EvORanker in 20% (22/108) of the cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S10). For the simulated dataset, EvORanker outperformed both ExomeWalker and PHIVE (Fig.Â <xref rid="Fig9" ref-type="fig">9</xref>).<fig id="Fig9"><label>Fig.Â 9</label><caption><p>EvORanker outperforms two other algorithms (ExomeWalker and PHIVE). The performance of each algorithm in the 108-exome dataset and the simulated dataset (shuffled three times) was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other patient genes. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right). The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested algorithms, and the <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top or within the top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage indicates whether the âtrueâ gene was ranked at the top or within the top 10 genes. EvORanker outperformed ExomeWalker and PHIVE in both recessive and dominant diseases in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig9_HTML" id="MO5"/></fig></p>
    </sec>
    <sec id="Sec31">
      <title>Solving the unsolved: candidate genes in reanalysis of patient exomes</title>
      <p id="Par51">We then initiated the application of EvORanker to identify novel disease-causing candidate genes in families with negative clinical exome results. To illustrate its effectiveness, we present two cases where we successfully resolved previously unsolved exomes.</p>
      <sec id="Sec32">
        <title>Family 1</title>
        <p id="Par52">We utilized EvORanker to analyze the exome data of a patient with an undiagnosed neurodevelopmental disorder for which no disease-causing variant was identified. The patient and one of her siblings displayed symptoms of global psychomotor delay, dysphasia, and attention-deficit hyperactivity disorder (ADHD) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A). By employing the previously described analysis steps and inputting the HPO terms HP:0001263, HP:0002357, HP:0000752, and HP:0000736, EvORanker prioritized <italic>DLGAP2</italic> as the top candidate gene (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>B). Further analysis revealed a strong correlation between <italic>DLGAP2</italic> and several genes related to similar phenotypes to that of the patient, such as <italic>GRIN2A</italic>, <italic>NLGN1</italic>, <italic>CNTNAP2</italic>, <italic>SRPX2</italic>, <italic>SYNGAP1</italic>, <italic>GABRA5</italic>, <italic>DLG3</italic>, <italic>SATB1</italic>, <italic>PTCHD1</italic>, <italic>ARHGEF6</italic>, and <italic>NLGN4X</italic> (Fig. <xref rid="Fig10" ref-type="fig">10</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S11). These âphenotype-relatedâ genes were significantly enriched within the top co-evolving and STRING-interacting genes with <italic>DLGAP2</italic> (combined Fisher <italic>p</italic>-valueâ=â1.65âÃâ10<sup>â6</sup>) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S11). Additionally, <italic>DLGAP2</italic> was ranked as the top gene by both PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] and ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] but ranked 10th by Phenolyzer tool [<xref ref-type="bibr" rid="CR59">59</xref>].<fig id="Fig10"><label>Fig.Â 10</label><caption><p>EvORanker identifies <italic>DLGAP2</italic> as a novel gene underlying a neurodevelopmental phenotype. <bold>A</bold> Pedigree: In a consanguineous family affected children have psychomotor delay and dysphasia, hyperactivity, and poor attention span. Shown is the segregation of the <italic>DLGAP2</italic> NM_001346810:c.A2702T, p.Glu901Val variant. N, normal allele; V, variant allele. <bold>B</bold> EvORanker results: <italic>DLGAP2</italic> is ranked as the top candidate relative to the other patient candidates. The <italic>x</italic>-axis indicates the proband (patient II-3), and the <italic>y</italic>-axis indicates the EvORanker -log(10) <italic>p</italic>-value obtained from running the K-S test using the co-evolved and STRING-interacting genes with each patient gene. Red dots indicate significant <italic>p</italic>-values, and dark blue dots indicate non-significant <italic>p</italic>-values. <italic>DLGAP2</italic> was the only gene that co-segregated with the phenotype in family 1. <bold>C</bold> One-sided, two-sample KolmogorovâSmirnov model. The <italic>x</italic>-axis indicates the semantic similarity score obtained by the <italic>OntologySimilarity</italic> tool in relation to the patientâs (II-3, family 1) phenotypes (HP:0001263, HP:0002357, HP:0000752, HP:0000736). The <italic>y</italic>-axis indicates the cumulative distribution. The orange line corresponds to the empirical distribution of all genes listed in the HPO database, ranked according to semantic similarity. The red line represents the empirical distribution of the genes coevolved with <italic>DLGAP2</italic>, and the blue line represents the empirical distribution of the genes interacting with <italic>DLGAP2</italic> based on STRING. The red dashed line indicates the D statistic representing the maximum vertical distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes coevolved with <italic>DLGAP2</italic>. The blue dashed line indicates the D statistic measured by the distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes interacting with <italic>DLGAP2</italic> based on STRING. Both coevolution and STRING-based analysis yielded significant <italic>p</italic>-values corresponding to the D statistic. <bold>D</bold> Coevolution and STRING-based subnetwork showing the patientâs phenotype-related genes coevolving with the <italic>DLGAP2</italic> gene. The dark grey node in the network indicates <italic>DLGAP2</italic> and the light grey nodes represent the phenotype-related genes. The black edges represent STRING interactions, and the colored edges represent the clade where two genes co-evolve. The network exhibits a group of phenotype-related correlated genes that have not been identified by the STRING database (<italic>EHMT1</italic>, <italic>IL1RAPL1</italic>, <italic>SATB2</italic>, <italic>GABRA5</italic>, <italic>SRPX2</italic>, <italic>SEMA3E</italic>, <italic>CACNG2</italic>)</p></caption><graphic xlink:href="13073_2023_1276_Fig10_HTML" id="MO3"/></fig></p>
        <p id="Par53">The high ranking of <italic>DLGAP2</italic> by EvORanker prompted us to further research the <italic>DLGAP2</italic> variant. The <italic>DLGAP2</italic> variant (NM_001346810:c.A2702T, p.Glu901Val) is strongly conserved and not found in the gnomAD population frequency database [<xref ref-type="bibr" rid="CR42">42</xref>] nor in our in-house database. Both affected siblings were homozygous for the variant, and it was the only variant that co-segregated with the phenotype in the family (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A). The variant is positioned on the third nucleotide preceding the splice donor site within exon 9 (out of 12 exons) of the <italic>DLGAP2</italic> gene. It is predicted to alter gene splicing by different prediction tools (e.g., SpliceAI [<xref ref-type="bibr" rid="CR44">44</xref>]). Since the <italic>DLGAP2</italic> gene is minimally expressed in whole blood, a minigene splicing assay was performed to assess the effect of the c.A2702T variant on gene splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). The minigene assay results showed that the variant led to the activation of a cryptic splice site and aberrant splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). Sequencing of the RT-PCR product of the mutant construct showed a 4-bp deletion (GAAA del) (Chr8:1,626,792â1,626,795), resulting in a frameshift and premature termination after 59 codons (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12).</p>
      </sec>
      <sec id="Sec33">
        <title>Family 2</title>
        <p id="Par54">We applied EvORanker to the exome data of a patient diagnosed with a multisystem disease including failure to thrive, recurring abdominal pain, chronic diarrhea, skeletal muscle wasting, elevated liver enzymes, and high levels of creatine kinase (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). The patient is of consanguineous parentage and is the sole affected individual in the family (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). Using HPO terms corresponding to the patientâs phenotype (HP:0001508, HP:0002910, HP:0002574, HP:0002028, HP:0003236, HP:0003202), EvORanker prioritized <italic>LPCAT3</italic> as the top patient candidate gene (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>B). <italic>LPCAT3</italic> demonstrated strong coevolution signals with genes related to the patientâs phenotype (<italic>PYGL</italic>, <italic>DLD</italic>, <italic>TXNRD2</italic>, <italic>COG8</italic>, <italic>SUCLG1</italic>, <italic>MVK</italic>, <italic>SMAD4</italic>, <italic>CPT1A</italic>) in the plant (<italic>Viridiplantae</italic> and <italic>Eudicotyledons</italic>), <italic>Mammalia</italic>, and <italic>Fungi</italic> kingdoms (Fig. <xref rid="Fig11" ref-type="fig">11</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figs. S13, S14 and S15). The genes that showed the strongest coevolution with <italic>LPCAT3</italic> were significantly enriched within the <italic>phenotype-related genes</italic> (<italic>p</italic>-valueâ=â7.93âÃâ10<sup>â15</sup>) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). Conversely, the genes that interacted with <italic>LPCAT3</italic> through STRING did not exhibit significant enrichment within the <italic>phenotype-related genes</italic> (<italic>p</italic>-valueâ=â0.53) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). Despite this, <italic>LPCAT3</italic> still had the most significant <italic>p</italic>-value among all candidates based on the combined EvORanker score (Fisher combined <italic>p</italic>-valueâ=â1.42âÃâ10<sup>â13</sup>). <italic>LPCAT3</italic> was ranked third by ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>], excluded by PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] and ranked 8th by Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>]. The proband (II-4) was homozygous for a truncating variant in exon 9 of the <italic>LPCAT3</italic> gene (NM_005768:c.G939A, p.W313X) (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). This variant was not found in the gnomAD population frequency database [<xref ref-type="bibr" rid="CR42">42</xref>] nor in our in-house database. The <italic>LPCAT3</italic> variant was the only variant among the <italic>patient candidate genes</italic> that co-segregated with the phenotype in the family (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A).<fig id="Fig11"><label>Fig.Â 11</label><caption><p>EvORanker identifies <italic>LPCAT3</italic> as a novel gene underlying a multisystem disorder. <bold>A</bold> Pedigree of a consanguineous family. The affected son has failure to thrive, chronic diarrhea with recurrent abdominal pain, muscle atrophy, elevated liver enzymes, and high creatine kinase levels. Shown is the segregation of the <italic>LPCAT3</italic> NM_005768:c.G939A, p.Trp313Ter variant. N, normal allele; V, variant allele. <bold>B</bold> EvORanker results: <italic>LPCAT3</italic> is ranked as the top candidate relative to other candidate genes. The <italic>x</italic>-axis indicates the proband (patient II-4), and the <italic>y</italic>-axis indicates the combined -log10 <italic>p</italic>-value obtained from running the K-S test using the co-evolved and STRING-interacting genes with each patient gene. Red dots indicate significant <italic>p</italic>-values, and dark blue dots indicate non-significant <italic>p</italic>-values. <italic>LPCAT3</italic> was the only gene that co-segregated with the phenotype in family 2. <bold>C</bold> One-sided, two-sample KolmogorovâSmirnov model. The <italic>x</italic>-axis indicates the semantic similarity score obtained by the OntologySimilarity tool in relation to the patientâs (II-4, family 2) phenotypes (HP:0001508, HP:0002910, HP:0002574, HP:0002028, HP:0003236, HP:0003202). The <italic>y</italic>-axis indicates the cumulative distribution. The orange line corresponds to the empirical distribution of all genes listed in the HPO database, ranked according to semantic similarity. The red line indicates the empirical distribution of the genes coevolved with <italic>LPCAT3</italic>, and the blue line indicates the empirical distribution of the genes interacting with <italic>LPCAT3</italic> based on STRING. The red dashed line indicates the D statistic representing the maximum vertical distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes coevolved with <italic>LPCAT3</italic>. The blue dashed line indicates the D statistic measured by the distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes interacting with <italic>LPCAT3</italic> based on STRING. Only coevolution-based analysis yielded significant <italic>p</italic>-values corresponding to the D statistic. <bold>D</bold> Coevolution and STRING-based subnetwork showing the patientâs phenotype-related genes coevolving with the <italic>LPCAT3</italic> gene. The yellow node in the network indicates <italic>LPCAT3</italic> and the light grey nodes represent the phenotype-related genes. The black edges represent STRING interactions, and the colored edges represent the clade where two genes co-evolve. We demonstrate that our clade-wise NPP approach uncovered correlations between <italic>LPCAT3</italic> and <italic>phenotype-related genes</italic> that were not captured by STRING</p></caption><graphic xlink:href="13073_2023_1276_Fig11_HTML" id="MO4"/></fig></p>
        <p id="Par55">Complete knockout of <italic>LPCAT3</italic> in mice results in premature death. However, tissue-specific knockouts in the liver and intestines have been documented, with the latter causing impaired growth and abnormal enterocyte morphology along with enterocyte lipid accumulation (Rong et al., 2015). Liver-specific knockouts in mice display a decrease in plasma triglycerides and an occurrence of hepatosteatosis (Rong et al., 2015). The patient from family 2 demonstrated anomalies in both the intestine and liver. Duodenal biopsies showed nodular lesions in the duodenal bulb and the descending portion of the duodenum with atrophic mucosa suggestive of severe enteropathy. Fragments of duodenal mucosa showed partial villous blunting with a mild increase of lamina propria lymphoplasmacytic cell infiltrate. Liver enzymes revealed a reduced ratio of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, suggesting fatty liver disease, along with reduced plasma triglycerides (34Â mg/dL) and HDL levels (27.1Â mg/dL). These findings suggest <italic>LPCAT3</italic> as a potential causative gene for the disease in the proband of this family.</p>
      </sec>
    </sec>
    <sec id="Sec34">
      <title>EvORanker web tool</title>
      <p id="Par56">The EvORanker web tool (<ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>) is an easy-to-use and user-friendly decision support tool built for geneticists and researchers in the NGS field (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S16). The user submits a set of HPO terms describing the patientâs medical condition and the patientâs candidate genes, preferably genes that survived variant filtering. The algorithm then performs the aforementioned analyses and returns the outputs in two stages:<list list-type="order"><list-item><p id="Par57">Step 1: If the queried gene is already listed in the HPO database, a semantic similarity score (ranging from 0 to 1) reflecting the similarity of the geneâs associated HPO terms to the userâs input HPO terms is calculated using the OntologySimilarity package [<xref ref-type="bibr" rid="CR51">51</xref>] and is indicated in a table output in the âStep 1: Semantic Similarity-based Prioritizationâ tab.</p></list-item><list-item><p id="Par58">Step 2: In the case where none of the queried genes are listed in the HPO dataset or where none had a high or sufficient semantic similarity score (i.e., a non-diagnostic case), the user can navigate to co-evolution and STRING-based gene prioritization. The output is a table containing each queried gene and the corresponding EvORanker <italic>p</italic>-value. The EvORanker <italic>p</italic>-value is the result of Fisherâs combined test obtained by integration of multi-clade phylogenetic profiling and STRING-based analysis as described above.</p></list-item></list></p>
      <p id="Par59">EvORanker also provides useful visualizations of the results, including a bar plot of the ranked genes by EvORanker, and a co-evolution and STRING subnetwork generated upon click of any queried gene in the âStep 2â results table. The network highlights the HPO-related genes co-evolving with the query gene in addition to edges representing STRING interactions. Additionally, the user can retrieve more detailed co-evolutionary information including the clade where every two genes co-evolve, the co-evolutionary rank of the HPO-related genes with each query gene, and can inspect gene enrichment results of the coevolving genes and STRING-interacting genes with each query gene. The web interface is available at the following link: <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>. Recognizing the need to analyze a larger number of genes than recommended for the web tool due to memory constraints, we have established a GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>) [<xref ref-type="bibr" rid="CR65">65</xref>]. This repository allows users to access the tool and input an expanded number of genes, accommodating their requirements.</p>
    </sec>
  </sec>
  <sec id="Sec35">
    <title>Discussion</title>
    <p id="Par60">Clinical elucidation of genetic variants in connection to a patientâs phenotype is a time-consuming and costly element in the genomic diagnosis of rare genetic diseases. To address this issue, several computational algorithms have been developed over the years to prioritize candidate genes based on the patientâs phenotype using different sources of information, such as protein-protein interactions, data mining, and gene expression [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>â<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>â<xref ref-type="bibr" rid="CR14">14</xref>]. Nevertheless, although PP was successfully used to identify novel disease genes [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR66">66</xref>], we are not aware of any tool that systematically utilizes clade-based phylogenetic profiling to prioritize patient candidate genes. Herein, we described EvORanker, an algorithm that employs multi-scale phylogenetic profiling and gene interaction data from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>] to analyze âunsolvedâ WES/WGS cases in search of novel genetic causes of disease. This algorithm integrates unbiased comparative genomic analysis with publicly available gene data, including function and interactions.</p>
    <p id="Par61">Multi-scale phylogenetic profiling is particularly valuable for identifying disease associations for poorly annotated genes. The ability to conduct analysis of every gene independently of existing knowledge expands the scope of disease-gene discovery. This is particularly important in light of the ârich get richerâ phenomenon, where genes that have already been studied receive disproportionate attention, while poorly annotated genes are often overlooked. Among the 6260 tested knockout genes that exhibit a phenotype in mice and have an ortholog in humans, EvORanker was able to link 41% of these genes to the disease phenotype observed in mice (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: S9). This highlights the potential of EvORanker to discover new disease genes and expand our understanding of disease mechanisms.</p>
    <p id="Par62">Furthermore, our study demonstrates the power of our multi-clade concept in capturing co-evolution, as shown by our ability to more effectively identify the âtrueâ disease-causing genes across multiple clades, beyond just Eukaryota or Animalia clades (Figs. <xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S5). This is aligned with the notion that multi-clade phylogenetic profiling-based methods more effectively capture co-evolution [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Importantly, our clade-wise NPP approach revealed correlations between genes that could not be anticipated using other omics (Fig. <xref rid="Fig11" ref-type="fig">11</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). The integration of NPP with STRING leads to increased efficiency of EvORanker (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>), especially for newly annotated genes, and highlights the complementarity of these two datasets. In future studies, we may contemplate incorporating additional datasets into the algorithm, such as mouse and zebrafish knockout data, and other sources for protein-protein interaction networks, by utilizing similar concepts.</p>
    <p id="Par63">We benchmarked our tool using both real patient exome data, in addition to simulated data. The utilization of actual patient data enhances the translational potential of our findings and underscores the clinical relevance of our tool. EvORanker ranked the âtrueâ gene within the top 5 in 95% of the patient-exome dataset. On the other hand, failed to rank the âtrueâ gene within the top 5 for recessive diseases and within the top 10 for dominant diseases in 6/109 exomes. Further investigation revealed that in 3 of those cases (<italic>TBL1XR1</italic>, <italic>NHLRC2</italic>, <italic>ADGRG1</italic>), the HPO terms used as input into the algorithm were both insufficient and non-specific (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). This highlights the importance of precise selection of HPO terms to achieve accurate results. Notably, our results remained consistent across both the real-patient and simulation datasets, further validating the practical utility and effectiveness of our tool in real-world applications.</p>
    <p id="Par64">We applied EvORanker on two unresolved exomes in which previous clinical whole exome sequencing (WES) did not identify a known genetic cause. In the first case (family 1), the <italic>DLGAP2</italic> gene was ranked as the top candidate for a proband with a neurodevelopmental disorder (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>B). <italic>DLGAP2</italic> plays a role in the molecular organization of neuronal synapses and neuronal cell signaling [<xref ref-type="bibr" rid="CR67">67</xref>]. The pathogenicity of the NM_001346810:c.A2702T, p.Glu901Val variant observed in <italic>DLGAP2</italic> was validated by demonstrating its effect on splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). Homozygous knockout mice for <italic>DLGAP2</italic> exhibit novelty-induced hyperactivity, increased aggression, impaired reverse learning, decreased dendritic spine density, and synaptopathy [<xref ref-type="bibr" rid="CR68">68</xref>] providing further support for the association of <italic>DLGAP2</italic> with the patientâs phenotype. Furthermore, <italic>DLGAP2</italic> was hypothesized to be a strong candidate for neurodevelopmental and behavioral phenotypes observed in patients harboring 8p23.2-pter microdeletions including <italic>DLGAP2</italic> and four other genes [<xref ref-type="bibr" rid="CR69">69</xref>]. Notably, our analysis using NPP revealed a group of <italic>DLGAP2</italic>-associated genes not detected by STRING (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>D), providing new avenues for investigating the role of <italic>DLGAP2</italic> in the nervous system.</p>
    <p id="Par65">In the second âunsolvedâ exome, only NPP ranked the <italic>LPCAT3</italic> gene as the top candidate (family 2, Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). This ranking of <italic>LPCAT3</italic> was achieved by the detection of novel functional associations with <italic>phenotype-related genes</italic> based on co-evolution (<italic>PYGL</italic>, <italic>DLD</italic>, <italic>TXNRD2</italic>, <italic>COG8</italic>, <italic>SUCLG1</italic>, <italic>MVK</italic>, <italic>SMAD4</italic>, <italic>CPT1A</italic>) (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>D). These <italic>phenotype-related genes</italic> showed significant coevolution with <italic>LPCAT3</italic> in the clades of <italic>Viridiplantae</italic>, <italic>Eudicotyledons</italic>, <italic>Mammalia</italic>, and <italic>Fungi</italic> (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figs. S11 and S14), pointing towards novel associations not captured by STRING [<xref ref-type="bibr" rid="CR33">33</xref>]. These findings are supported by phenotypic similarities between the patient and liver and intestinal knockout mice [<xref ref-type="bibr" rid="CR70">70</xref>], including failure to thrive, enteropathy, and low levels of triglycerides and high-density lipoprotein. <italic>LPCAT3</italic> nullizygous mice exhibit postnatal death [<xref ref-type="bibr" rid="CR70">70</xref>], making it difficult to study the global effects of <italic>LPCAT3</italic> knockdown. Although a recent report linked <italic>LPCAT3</italic> overexpression to skeletal muscle myopathy [<xref ref-type="bibr" rid="CR71">71</xref>], further research is needed to understand the role and mechanism of <italic>LPCAT3</italic> in this condition. Taken together, these results underscore the potential of clade-based NPP to predict functional associations with phenotype-relevant genes. Further validation in additional patients with variants in these genes is warranted to confirm their roles as novel disease-associated genes. Subsequent functional validation studies are crucial to better understand the mechanisms of disease pathogenesis.</p>
    <p id="Par66">EvORanker is entirely gene-based, making it adaptable to various sequencing experiments and accessible for users with minimal computational knowledge. In addition to providing a ranked gene list, EvORanker offers the ability to explore evolutionary and STRING-based gene networks across multiple clades. A recommended strategy for users is to first examine the ranking of genes based on the OntologySimilarity semantic similarity score [<xref ref-type="bibr" rid="CR51">51</xref>], in the event that one of the candidate genes is already listed in the HPO database. If not, the user can then evaluate the ranking of genes based on the EvORanker score, where a novel association between the gene and input phenotypes may be discovered. The EvORanker server is freely available at <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>, which will be updated on a regular basis. We also created a GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>) [<xref ref-type="bibr" rid="CR65">65</xref>] which allows users to access the tool and input an expanded number of genes.</p>
  </sec>
  <sec id="Sec36">
    <title>Conclusions</title>
    <p id="Par67">In summary, our work introduces EvORanker as a powerful tool in the genomic diagnostic landscape. By integrating multi-scale phylogenetic profiling and STRING-based gene interaction data, EvORanker offers a unique and effective approach to prioritize candidate genes in âunsolvedâ cases identified through whole-exome and whole-genome sequencing. Our validation using real patient exome data and simulation data demonstrates EvORankerâs robust capability to consistently prioritize the âtrueâ gene, showcasing its reliability and translational potential in research applications.</p>
    <p id="Par68">The effectiveness of EvORanker in identifying candidate disease genes, as demonstrated by the identification of <italic>DLGAP2</italic> and <italic>LPCAT3</italic> in previously unresolved cases, highlights its potential to contribute to our understanding of disease mechanisms. Moreover, its adaptability, user-friendly interface, and accessibility without extensive computational expertise make EvORanker a valuable asset for researchers. As we navigate the intricate landscape of rare genetic diseases, EvORanker stands as a promising tool, offering not only a ranked gene list but also insights into STRING-based and evolutionary gene networks across multiple clades. We believe that the adoption of EvORanker will contribute significantly to advancing genomic diagnostics in the pursuit of unraveling the genetic mysteries underlying rare diseases.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <sec id="Sec37">
      <title>Supplementary Information</title>
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="13073_2023_1276_MOESM1_ESM.xlsx">
            <caption>
              <p><bold>Additional file 1: Table S1.</bold> Clinical and Genetic Characteristics of the 109-Patient Exome Dataset. <bold>Table S2.</bold> ClinVar-Simulated Genetic Variants and Associated Phenotypes. <bold>Table S3.</bold> Newly added disease-gene entries in the Human Phenotype Ontology (HPO) database.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="13073_2023_1276_MOESM2_ESM.docx">
            <caption>
              <p><bold>Additional file 2: Figure S1.</bold> Parameter combinations and EvORanker performance. <bold>Figure S2.</bold> The 16 clades used in the phylogenetic profiling-based algorithm. <bold>Figure S3.</bold> Cutoff values and EvORanker performance. <bold>Figure S4.</bold> Distribution of the number of<italic> patient candidate genes</italic> that passed the variant filtering criteria in autosomal and x-linked recessive (red) and dominant (dark blue) cases in the (A) patient exome dataset and the (B) simulated dataset (shuffled three times). <bold>Figure S5.</bold> Contribution of each of the 16 clades to the overall performance of the EvORanker. <bold>Figure S6.</bold> Radar plot showing the ranking of the âtrueâ disease-causing gene (top 1, top 10, or NULL) using EvORanker (red), NPP (golden), and STRING (dark blue). <bold>Figure S7.</bold> Evaluating EvORanker Performance across three independent spike shuffles. <bold>Figure S8.</bold> Performance of NPP versus STRING using the 109-patient exome dataset across the years. <bold>Figure S9.</bold> Comparison of EvORanker and Phenolyzer in identifying true disease gene candidates. <bold>Figure S10.</bold> Radar plot showing the ranking of the âtrueâ disease-causing gene (top 1, top 10, or NULL) using EvORanker (red), PHIVE (golden), and ExomeWalker (blue). <bold>Figure S11.</bold> Distributions of the <italic>HPO-ranked genes</italic>, the co-evolved genes, and STRING-interacting genes with <italic>DLGAP2</italic>. <bold>Figure S12.</bold> Effect of <italic>DLGAP2</italic> p.E901V on splicing. <bold>Figure S13.</bold> Density distributions of the <italic>HPO-ranked genes</italic>, the co-evolved genes, and STRING-interacting genes with <italic>LPCAT3</italic>. <bold>Figure S14.</bold> Clades differentially predict the functional interaction between the <italic>phenotype-related genes</italic> and <italic>LPCAT3</italic>. <bold>Figure S15.</bold> The Phylogenetic profiles of <italic>LPCAT3</italic> and patient HPO-related genes across 1,028 eukaryotes. <bold>Figure S16.</bold> Homepage of the EvoRanker web interface.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisherâs Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Dana Sherill-Rofe and Lara Kamal contributed equally to this work.</p>
    </fn>
    <fn>
      <p>Ephrat Levy-Lahad, Moien Kanaan andÂ Yuval Tabach contributed equally to this work.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>We would like to acknowledge The Carole and Andrew Harper Diversity Program for their support in this research.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authorsâ contributions</title>
    <p>Conceptualization: CC, DSR, YT, MK, PR, and ELL. Algorithm development: CC, IB, DSR, ES, BT, and YT. Web-tool development: CC. Bioinformatics and data analysis: CC and FZ. Exome sequencing and subsequent data analysis for the benchmarking dataset comprising 109 cases, as well as the two âunsolvedâ cases, along with collaboration and communication with clinicians: CC, LK, GR, MK, HK, and MK. In vitro splicing assay: LK, KBA, and IAA. Supervision: YT, ELL, MK, and PR. Manuscript: CC wrote the manuscript with help from YT, DSR, and ELL. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This study was supported by the Israel Science Foundation (grant no. 3797/21) to Yuval Tabach, Ephrat Levy-Lahad, and Paul Renbaum; The Koum Foundation to Ephrat Levy-Lahad and Paul Renbaum; The National Institutes of Health/NIDCD (R01DC011835) to Karen B. Avraham and Moien Kanaan; The Ministry of Innovation, Science and Technology (grant no. 3-17417) to Yuval Tabach.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>All the algorithm-related data files on which the conclusions of the paper rely on are publicly available on GitHub at the following link: <ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link> [<xref ref-type="bibr" rid="CR65">65</xref>].</p>
    <p>The dataset comprising the exome sequencing data of 109 patients at Istishari Arab Hospital in Ramallah, Palestine, is available through Professor Moien Kanaan. It was employed for benchmarking purposes in the current study. However, due to licensing constraints, these data are not publicly accessible. Researchers interested in accessing the dataset may do so upon making a reasonable request. To initiate the request, individuals are required to contact Professor Moien Kanaan directly via email (moien.kanaan@iah.ps). Please note that the process of obtaining access involves a meeting with professor Moien Kanaan, during which the interested party will be required to provide details on how the data will be utilized, secured, and maintained to ensure the privacy and confidentiality of the patients. This may include a discussion on data security measures, protocols for restricting access to authorized personnel, and assurances that the data will not be made available to third parties. The timeline for granting access will be determined on a case-by-case basis, taking into consideration the nature of the request and the required ethical and legal approvals.</p>
    <p>The VCF files for the 300 genomes utilized in the simulation analysis were obtained from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>], accessible at (<ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>) [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par69">The studies involving human participants received ethical approval from the Institutional Review Board (IRB) of the Shaare Zedek Medical Center, Jerusalem, Israel (IRB no. 20/10). All procedures were conducted in accordance with the principles outlined in the Declaration of Helsinki. Prior to their inclusion in the study, written informed consent was obtained from all participants or their parents. Additionally, participants or their parents granted permission to access their medical records. The study was conducted with due consideration of ethical guidelines, ensuring the confidentiality and voluntary participation of all individuals involved.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par70">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par71">The authors declare that they have no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bamshad</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Nickerson</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Chong</surname>
            <given-names>JX</given-names>
          </name>
        </person-group>
        <article-title>Mendelian gene discovery: fast and furious with no end in sight</article-title>
        <source>Am J Hum Genet</source>
        <year>2019</year>
        <volume>105</volume>
        <fpage>448</fpage>
        <lpage>455</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2019.07.011</pub-id>
        <?supplied-pmid 31491408?>
        <pub-id pub-id-type="pmid">31491408</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <mixed-citation publication-type="other">Online Mendelian Inheritance in Man, OMIMÂ®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). 2023. <ext-link ext-link-type="uri" xlink:href="https://omim.org/">https://omim.org/</ext-link>. Accessed 18 Sept 2023.</mixed-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Oellrich</surname>
            <given-names>A</given-names>
          </name>
          <collab>Project SMG</collab>
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Mungall</surname>
            <given-names>CJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Improved exome prioritization of disease genes through cross-species phenotype comparison</article-title>
        <source>Genome Res</source>
        <year>2014</year>
        <volume>24</volume>
        <fpage>340</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.160325.113</pub-id>
        <?supplied-pmid 24162188?>
        <pub-id pub-id-type="pmid">24162188</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Davydov</surname>
            <given-names>EV</given-names>
          </name>
          <name>
            <surname>Goode</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Sirota</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cooper</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Sidow</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Batzoglou</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Identifying a high fraction of the human genome to be under selective constraint using GERP++</article-title>
        <source>PLoS Comput Biol</source>
        <year>2010</year>
        <volume>6</volume>
        <fpage>e1001025</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1001025</pub-id>
        <?supplied-pmid 21152010?>
        <pub-id pub-id-type="pmid">21152010</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Adzhubei</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Jordan</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Sunyaev</surname>
            <given-names>SR</given-names>
          </name>
        </person-group>
        <article-title>Predicting functional effect of human missense mutations using PolyPhen-2</article-title>
        <source>Curr Protoc Hum Genet</source>
        <year>2013</year>
        <volume>Chapter 7</volume>
        <fpage>Unit7.20</fpage>
        <?supplied-pmid 23315928?>
        <pub-id pub-id-type="pmid">23315928</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ioannidis</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Rothstein</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Pejaver</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Middha</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McDonnell</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Baheti</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>REVEL: an ensemble method for predicting the pathogenicity of rare missense variants</article-title>
        <source>Am J Hum Genet</source>
        <year>2016</year>
        <volume>99</volume>
        <fpage>877</fpage>
        <lpage>885</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.08.016</pub-id>
        <?supplied-pmid 27666373?>
        <pub-id pub-id-type="pmid">27666373</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Labes</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wagner</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Lotem</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lahad</surname>
            <given-names>EL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Machine-learning of complex evolutionary signals improves classification of SNVs</article-title>
        <source>NAR Genomics Bioinform</source>
        <year>2022</year>
        <volume>4</volume>
        <fpage>lqac025</fpage>
        <pub-id pub-id-type="doi">10.1093/nargab/lqac025</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Smedley</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Czeschik</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Amberger</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bocchini</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hamosh</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Walking the interactome for candidate prioritization in exome sequencing studies of Mendelian diseases</article-title>
        <source>Bioinformatics Oxf Engl</source>
        <year>2014</year>
        <volume>30</volume>
        <fpage>3215</fpage>
        <lpage>3222</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu508</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zemojtel</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mackenroth</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>JÃ¤ger</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hecht</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Krawitz</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome</article-title>
        <source>Sci Transl Med</source>
        <year>2014</year>
        <volume>6</volume>
        <fpage>252ra123</fpage>
        <pub-id pub-id-type="doi">10.1126/scitranslmed.3009262</pub-id>
        <?supplied-pmid 25186178?>
        <pub-id pub-id-type="pmid">25186178</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tranchevent</surname>
            <given-names>L-C</given-names>
          </name>
          <name>
            <surname>Ardeshirdavani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>ElShal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Alcaide</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Aerts</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Auboeuf</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Candidate gene prioritization with Endeavour</article-title>
        <source>Nucleic Acids Res</source>
        <year>2016</year>
        <volume>44</volume>
        <fpage>W117</fpage>
        <lpage>121</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkw365</pub-id>
        <?supplied-pmid 27131783?>
        <pub-id pub-id-type="pmid">27131783</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <mixed-citation publication-type="other">Zolotareva O, Kleine M. A Survey of gene prioritization tools for Mendelian and complex human diseases. J Integr Bioinform. 2019;16:/j/jib.2019.16.issue-4/jib-2018-0069/jib-2018-0069.xml.</mixed-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Birgmeier</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Haeussler</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Deisseroth</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Steinberg</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Jagadeesh</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Ratner</surname>
            <given-names>AJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>AMELIE speeds Mendelian diagnosis by matching patient phenotype and genotype to primary literature</article-title>
        <source>Sci Transl Med</source>
        <year>2020</year>
        <volume>12</volume>
        <fpage>eaau9113</fpage>
        <pub-id pub-id-type="doi">10.1126/scitranslmed.aau9113</pub-id>
        <?supplied-pmid 32434849?>
        <pub-id pub-id-type="pmid">32434849</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Torkamani</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Artificial intelligence in clinical and genomic diagnostics</article-title>
        <source>Genome Med</source>
        <year>2019</year>
        <volume>11</volume>
        <fpage>70</fpage>
        <pub-id pub-id-type="doi">10.1186/s13073-019-0689-8</pub-id>
        <?supplied-pmid 31744524?>
        <pub-id pub-id-type="pmid">31744524</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>De La Vega</surname>
            <given-names>FM</given-names>
          </name>
          <name>
            <surname>Chowdhury</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Frise</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>McCarthy</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hernandez</surname>
            <given-names>EJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases</article-title>
        <source>Genome Med</source>
        <year>2021</year>
        <volume>13</volume>
        <fpage>153</fpage>
        <pub-id pub-id-type="doi">10.1186/s13073-021-00965-0</pub-id>
        <?supplied-pmid 34645491?>
        <pub-id pub-id-type="pmid">34645491</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pellegrini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Marcotte</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Eisenberg</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Yeates</surname>
            <given-names>TO</given-names>
          </name>
        </person-group>
        <article-title>Assigning protein functions by comparative genome analysis: protein phylogenetic profiles</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>1999</year>
        <volume>96</volume>
        <fpage>4285</fpage>
        <lpage>4288</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.96.8.4285</pub-id>
        <?supplied-pmid 10200254?>
        <pub-id pub-id-type="pmid">10200254</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Enault</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Suhre</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Poirot</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Abergel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Claverie</surname>
            <given-names>J-M</given-names>
          </name>
        </person-group>
        <article-title>Phydbac2: improved inference of gene function using interactive phylogenomic profiling and chromosomal location analysis</article-title>
        <source>Nucleic Acids Res</source>
        <year>2004</year>
        <volume>32</volume>
        <fpage>W336</fpage>
        <lpage>339</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkh365</pub-id>
        <?supplied-pmid 15215406?>
        <pub-id pub-id-type="pmid">15215406</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Subramaniam</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Locally defined protein phylogenetic profiles reveal previously missed protein interactions and functional relationships</article-title>
        <source>Proteins</source>
        <year>2006</year>
        <volume>62</volume>
        <fpage>1115</fpage>
        <lpage>1124</lpage>
        <pub-id pub-id-type="doi">10.1002/prot.20830</pub-id>
        <?supplied-pmid 16385560?>
        <pub-id pub-id-type="pmid">16385560</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eisen</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic analysis and gene functional predictions: phylogenomics in action</article-title>
        <source>Theor Popul Biol</source>
        <year>2002</year>
        <volume>61</volume>
        <fpage>481</fpage>
        <lpage>487</lpage>
        <pub-id pub-id-type="doi">10.1006/tpbi.2002.1594</pub-id>
        <?supplied-pmid 12167367?>
        <pub-id pub-id-type="pmid">12167367</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Protein function predictions based on the phylogenetic profile method</article-title>
        <source>Crit Rev Biotechnol</source>
        <year>2008</year>
        <volume>28</volume>
        <fpage>233</fpage>
        <lpage>238</lpage>
        <pub-id pub-id-type="doi">10.1080/07388550802512633</pub-id>
        <?supplied-pmid 19051102?>
        <pub-id pub-id-type="pmid">19051102</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dey</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic profiling for probing the modular architecture of the human genome</article-title>
        <source>Cell Syst</source>
        <year>2015</year>
        <volume>1</volume>
        <fpage>106</fpage>
        <lpage>115</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cels.2015.08.006</pub-id>
        <?supplied-pmid 27135799?>
        <pub-id pub-id-type="pmid">27135799</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Billi</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Hayes</surname>
            <given-names>GD</given-names>
          </name>
          <name>
            <surname>Newman</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Zuk</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Gabel</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of small RNA pathway genes using patterns of phylogenetic conservation and divergence</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>493</volume>
        <fpage>694</fpage>
        <lpage>698</lpage>
        <pub-id pub-id-type="doi">10.1038/nature11779</pub-id>
        <?supplied-pmid 23364702?>
        <pub-id pub-id-type="pmid">23364702</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Golan</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>HernÃ¡ndez-HernÃ¡ndez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Messer</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Fukuda</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kouznetsova</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Human disease locus discovery and mapping to molecular pathways through phylogenetic profiling</article-title>
        <source>Mol Syst Biol</source>
        <year>2013</year>
        <volume>9</volume>
        <fpage>692</fpage>
        <pub-id pub-id-type="doi">10.1038/msb.2013.50</pub-id>
        <?supplied-pmid 24084807?>
        <pub-id pub-id-type="pmid">24084807</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dey</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Jaimovich</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Seki</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Systematic discovery of human gene function and principles of modular organization through phylogenetic profiling</article-title>
        <source>Cell Rep</source>
        <year>2015</year>
        <volume>10</volume>
        <fpage>993</fpage>
        <lpage>1006</lpage>
        <pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.025</pub-id>
        <?supplied-pmid 25683721?>
        <pub-id pub-id-type="pmid">25683721</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tsaban</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sherill-Rofe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Schueler-Furman</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CladeOScope: functional interactions through the prism of clade-wise co-evolution</article-title>
        <source>NAR Genomics Bioinform</source>
        <year>2021</year>
        <volume>3</volume>
        <fpage>lqab024</fpage>
        <pub-id pub-id-type="doi">10.1093/nargab/lqab024</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Omar</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Guterman-Ram</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Berger</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Levaot</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Schlafen2 mutation in mice causes an osteopetrotic phenotype due to a decrease in the number of osteoclast progenitors</article-title>
        <source>Sci Rep</source>
        <year>2018</year>
        <volume>8</volume>
        <fpage>13005</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-018-31428-z</pub-id>
        <?supplied-pmid 30158544?>
        <pub-id pub-id-type="pmid">30158544</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Arkadir</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lossos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Abu Snineh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Schueler-Furman</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Nitschke</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MYORG is associated with recessive primary familial brain calcification</article-title>
        <source>Ann Clin Transl Neurol</source>
        <year>2019</year>
        <volume>6</volume>
        <fpage>106</fpage>
        <lpage>113</lpage>
        <pub-id pub-id-type="doi">10.1002/acn3.684</pub-id>
        <?supplied-pmid 30656188?>
        <pub-id pub-id-type="pmid">30656188</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Date</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Marcotte</surname>
            <given-names>EM</given-names>
          </name>
        </person-group>
        <article-title>Discovery of uncharacterized cellular systems by genome-wide analysis of functional linkages</article-title>
        <source>Nat Biotechnol</source>
        <year>2003</year>
        <volume>21</volume>
        <fpage>1055</fpage>
        <lpage>1062</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt861</pub-id>
        <?supplied-pmid 12923548?>
        <pub-id pub-id-type="pmid">12923548</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Allen-Vercoe</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Beiko</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic clustering of genes reveals shared evolutionary trajectories and putative gene functions</article-title>
        <source>Genome Biol Evol</source>
        <year>2018</year>
        <volume>10</volume>
        <fpage>2255</fpage>
        <lpage>2265</lpage>
        <pub-id pub-id-type="doi">10.1093/gbe/evy178</pub-id>
        <?supplied-pmid 30137329?>
        <pub-id pub-id-type="pmid">30137329</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sherill-Rofe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Findlay</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mellul</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Guberman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Braun</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes</article-title>
        <source>Genome Res</source>
        <year>2019</year>
        <volume>29</volume>
        <fpage>439</fpage>
        <lpage>448</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.241414.118</pub-id>
        <?supplied-pmid 30718334?>
        <pub-id pub-id-type="pmid">30718334</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Zitnik</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zuk</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Co-evolution based machine-learning for predicting functional interactions between human genes</article-title>
        <source>Nat Commun</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>6454</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-021-26792-w</pub-id>
        <?supplied-pmid 34753957?>
        <pub-id pub-id-type="pmid">34753957</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Unterman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Cazacu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kazimirsky</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ben-Zeev</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Berman</surname>
            <given-names>BP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome</article-title>
        <source>eLife</source>
        <year>2021</year>
        <volume>10</volume>
        <fpage>e67085</fpage>
        <pub-id pub-id-type="doi">10.7554/eLife.67085</pub-id>
        <?supplied-pmid 34355696?>
        <pub-id pub-id-type="pmid">34355696</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Braun</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Unterman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shtern</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Benenson</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ACE2 co-evolutionary pattern suggests targets for pharmaceutical intervention in the COVID-19 pandemic</article-title>
        <source>iScience</source>
        <year>2020</year>
        <volume>23</volume>
        <fpage>101384</fpage>
        <pub-id pub-id-type="doi">10.1016/j.isci.2020.101384</pub-id>
        <?supplied-pmid 32738617?>
        <pub-id pub-id-type="pmid">32738617</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gable</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Lyon</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Junge</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wyder</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Huerta-Cepas</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>STRING v11: proteinâprotein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title>
        <source>Nucleic Acids Res</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>D607</fpage>
        <lpage>D613</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id>
        <?supplied-pmid 30476243?>
        <pub-id pub-id-type="pmid">30476243</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yue</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Breschi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Vierstra</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Ryba</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A comparative encyclopedia of DNA elements in the mouse genome</article-title>
        <source>Nature</source>
        <year>2014</year>
        <volume>515</volume>
        <fpage>355</fpage>
        <lpage>364</lpage>
        <pub-id pub-id-type="doi">10.1038/nature13992</pub-id>
        <?supplied-pmid 25409824?>
        <pub-id pub-id-type="pmid">25409824</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Canavati</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Afawi</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Pendziwiat</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Abu Rayyan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kamal</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Inclusion of hemimegalencephaly into the phenotypic spectrum of NPRL3 pathogenic variants in familial focal epilepsy with variable foci</article-title>
        <source>Epilepsia</source>
        <year>2019</year>
        <volume>60</volume>
        <fpage>e67</fpage>
        <lpage>73</lpage>
        <pub-id pub-id-type="doi">10.1111/epi.15665</pub-id>
        <?supplied-pmid 31111464?>
        <pub-id pub-id-type="pmid">31111464</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kamal</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Pierce</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Canavati</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rayyan</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Jaraysa</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lobel</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities</article-title>
        <source>Cold Spring Harb Mol Case Stud</source>
        <year>2020</year>
        <volume>6</volume>
        <fpage>a005652</fpage>
        <pub-id pub-id-type="doi">10.1101/mcs.a005652</pub-id>
        <?supplied-pmid 33028645?>
        <pub-id pub-id-type="pmid">33028645</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Elson</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stein</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rabie</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Barnea-Zohar</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Winograd-Katz</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Reuven</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Sorting Nexin 10 as a key regulator of membrane trafficking in bone-resorbing osteoclasts: lessons learned from osteopetrosis</article-title>
        <source>Front Cell Dev Biol</source>
        <year>2021</year>
        <volume>9</volume>
        <fpage>671210</fpage>
        <pub-id pub-id-type="doi">10.3389/fcell.2021.671210</pub-id>
        <?supplied-pmid 34095139?>
        <pub-id pub-id-type="pmid">34095139</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Landrum</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Benson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Chao</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chitipiralla</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ClinVar: improving access to variant interpretations and supporting evidence</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1062</fpage>
        <lpage>D1067</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1153</pub-id>
        <?supplied-pmid 29165669?>
        <pub-id pub-id-type="pmid">29165669</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <mixed-citation publication-type="other">The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68â74.</mixed-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <mixed-citation publication-type="other">1000 Genomes Project. Data Release 20100804. <ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>. Accessed 23 Aug 2023.</mixed-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hakonarson</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>
        <source>Nucleic Acids Res</source>
        <year>2010</year>
        <volume>38</volume>
        <fpage>e164</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq603</pub-id>
        <?supplied-pmid 20601685?>
        <pub-id pub-id-type="pmid">20601685</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <mixed-citation publication-type="other">Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genome-wide mutational constraint map quantified from variation in 76,156 human genomes. Genetics. 2022. Available from: <ext-link ext-link-type="uri" xlink:href="http://biorxiv.org/lookup/doi/10.1101/2022.03.20.485034">http://biorxiv.org/lookup/doi/10.1101/2022.03.20.485034</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jian</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Boerwinkle</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>In silico prediction of splice-altering single nucleotide variants in the human genome</article-title>
        <source>Nucleic Acids Res</source>
        <year>2014</year>
        <volume>42</volume>
        <fpage>13534</fpage>
        <lpage>13544</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku1206</pub-id>
        <?supplied-pmid 25416802?>
        <pub-id pub-id-type="pmid">25416802</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jaganathan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Panagiotopoulou</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>McRae</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Darbandi</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Knowles</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>YI</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Predicting splicing from primary sequence with deep learning</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>176</volume>
        <fpage>535</fpage>
        <lpage>548.e24</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2018.12.015</pub-id>
        <?supplied-pmid 30661751?>
        <pub-id pub-id-type="pmid">30661751</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ng</surname>
            <given-names>PC</given-names>
          </name>
          <name>
            <surname>Henikoff</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>SIFT: predicting amino acid changes that affect protein function</article-title>
        <source>Nucleic Acids Res</source>
        <year>2003</year>
        <volume>31</volume>
        <fpage>3812</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkg509</pub-id>
        <?supplied-pmid 12824425?>
        <pub-id pub-id-type="pmid">12824425</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gargano</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Matentzoglu</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Carmody</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Lewis-Smith</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Vasilevsky</surname>
            <given-names>NA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The human phenotype ontology in 2021</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D1207</fpage>
        <lpage>D1217</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1043</pub-id>
        <?supplied-pmid 33264411?>
        <pub-id pub-id-type="pmid">33264411</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <mixed-citation publication-type="other">Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1303.3997">http://arxiv.org/abs/1303.3997</ext-link>. Cited 2022 Sep 15.</mixed-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McKenna</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hanna</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Banks</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sivachenko</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cibulskis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kernytsky</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>
        <source>Genome Res</source>
        <year>2010</year>
        <volume>20</volume>
        <fpage>1297</fpage>
        <lpage>1303</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id>
        <?supplied-pmid 20644199?>
        <pub-id pub-id-type="pmid">20644199</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>FADO</given-names>
          </name>
          <name>
            <surname>de Andrade</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Palmero</surname>
            <given-names>EI</given-names>
          </name>
        </person-group>
        <article-title>Insights on variant analysis in silico tools for pathogenicity prediction</article-title>
        <source>Front Genet</source>
        <year>2022</year>
        <volume>13</volume>
        <fpage>1010327</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2022.1010327</pub-id>
        <?supplied-pmid 36568376?>
        <pub-id pub-id-type="pmid">36568376</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fromer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Purcell</surname>
            <given-names>SM</given-names>
          </name>
        </person-group>
        <article-title>Using XHMM software to detect copy number variation in whole-exome sequencing data</article-title>
        <source>Curr Protoc Hum Genet Editor Board Jonathan Haines Al</source>
        <year>2014</year>
        <volume>81</volume>
        <fpage>7.23.1</fpage>
        <lpage>7.23.21</lpage>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Greene</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Turro</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>ontologyX: a suite of R packages for working with ontological data</article-title>
        <source>Bioinformatics</source>
        <year>2017</year>
        <volume>33</volume>
        <fpage>1104</fpage>
        <lpage>1106</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btw763</pub-id>
        <?supplied-pmid 28062448?>
        <pub-id pub-id-type="pmid">28062448</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>SchrÃ¶er</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Trenkler</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Exact and randomization distributions of Kolmogorov-Smirnov tests two or three samples</article-title>
        <source>Comput Stat Data Anal</source>
        <year>1995</year>
        <volume>20</volume>
        <fpage>185</fpage>
        <lpage>202</lpage>
        <pub-id pub-id-type="doi">10.1016/0167-9473(94)00040-P</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>R Core Team</collab>
        </person-group>
        <source>R: a language and environment for statistical computing</source>
        <year>2022</year>
        <publisher-loc>Vienna</publisher-loc>
        <publisher-name>R Foundation for Statistical Computing</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Fisher</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <source>Statistical methods for research workers</source>
        <year>1925</year>
        <publisher-loc>Edinburgh</publisher-loc>
        <publisher-name>Oliver and Boyd</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mosteller</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Fisher</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Questions and answers</article-title>
        <source>Am Stat</source>
        <year>1948</year>
        <volume>2</volume>
        <fpage>30</fpage>
        <lpage>31</lpage>
        <pub-id pub-id-type="doi">10.1080/00031305.1948.10483415</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>SchrÃ¶der</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Culhane</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Quackenbush</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Haibe-Kains</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>survcomp: an R/Bioconductor package for performance assessment and comparison of survival models</article-title>
        <source>Bioinformatics</source>
        <year>2011</year>
        <volume>27</volume>
        <fpage>3206</fpage>
        <lpage>3208</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btr511</pub-id>
        <?supplied-pmid 21903630?>
        <pub-id pub-id-type="pmid">21903630</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Blake</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Baldarelli</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kadin</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Bult</surname>
            <given-names>CJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mouse Genome Database (MGD): knowledgebase for mouse-human comparative biology</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D981</fpage>
        <lpage>D987</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1083</pub-id>
        <?supplied-pmid 33231642?>
        <pub-id pub-id-type="pmid">33231642</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <mixed-citation publication-type="other">OBO Phenotype Ontology. HPO to MP best matches. 2023. <ext-link ext-link-type="uri" xlink:href="https://github.com/obophenotype/upheno/blob/master/mappings/hp-to-mp-bestmatches.tsv">https://github.com/obophenotype/upheno/blob/master/mappings/hp-to-mp-bestmatches.tsv</ext-link>. Accessed 15 Feb 2023.</mixed-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Phenolyzer: phenotype-based prioritization of candidate genes for human diseases</article-title>
        <source>Nat Methods</source>
        <year>2015</year>
        <volume>12</volume>
        <fpage>841</fpage>
        <lpage>843</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth.3484</pub-id>
        <?supplied-pmid 26192085?>
        <pub-id pub-id-type="pmid">26192085</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Booth</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Azaiez</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kahrizi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Frees</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Exonic mutations and exon skipping: lessons learned from DFNA5</article-title>
        <source>Hum Mutat</source>
        <year>2018</year>
        <volume>39</volume>
        <fpage>433</fpage>
        <lpage>440</lpage>
        <pub-id pub-id-type="doi">10.1002/humu.23384</pub-id>
        <?supplied-pmid 29266521?>
        <pub-id pub-id-type="pmid">29266521</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hirsch</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tangshewinsirikul</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Booth</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Azaiez</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Yefet</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Quint</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A synonymous variant in MYO15A enriched in the Ashkenazi Jewish population causes autosomal recessive hearing loss due to abnormal splicing</article-title>
        <source>Eur J Hum Genet</source>
        <year>2021</year>
        <volume>29</volume>
        <fpage>988</fpage>
        <lpage>997</lpage>
        <pub-id pub-id-type="doi">10.1038/s41431-020-00790-w</pub-id>
        <?supplied-pmid 33398081?>
        <pub-id pub-id-type="pmid">33398081</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <mixed-citation publication-type="other">Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, Allen J, et al. shiny: web application framework for R. R package version 1.8.0.9000. 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://github.com/rstudio/shiny">https://github.com/rstudio/shiny</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://shiny.posit.co/">https://shiny.posit.co/</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shannon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Markiel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ozier</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Baliga</surname>
            <given-names>NS</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Ramage</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>
        <source>Genome Res</source>
        <year>2003</year>
        <volume>13</volume>
        <fpage>2498</fpage>
        <lpage>2504</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
        <?supplied-pmid 14597658?>
        <pub-id pub-id-type="pmid">14597658</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Franceschini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Frankild</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kuhn</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Simonovic</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Roth</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>STRING v9.1: protein-protein interaction networks, with increased coverage and integration</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>D808</fpage>
        <lpage>15</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks1094</pub-id>
        <?supplied-pmid 23203871?>
        <pub-id pub-id-type="pmid">23203871</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <mixed-citation publication-type="other">Canavati C. EvoRanker: a phylogenetic profiling-based algorithm for prioritizing candidate genes. 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Findlay</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Heath</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>VM</given-names>
          </name>
          <name>
            <surname>Malina</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Morin</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Coulombe</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice</article-title>
        <source>EMBO J</source>
        <year>2018</year>
        <volume>37</volume>
        <fpage>e100158</fpage>
        <pub-id pub-id-type="doi">10.15252/embj.2018100158</pub-id>
        <?supplied-pmid 30154076?>
        <pub-id pub-id-type="pmid">30154076</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rasmussen</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Rasmussen</surname>
            <given-names>HB</given-names>
          </name>
          <name>
            <surname>Silahtaroglu</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>The DLGAP family: neuronal expression, function and role in brain disorders</article-title>
        <source>Mol Brain</source>
        <year>2017</year>
        <volume>10</volume>
        <fpage>43</fpage>
        <pub-id pub-id-type="doi">10.1186/s13041-017-0324-9</pub-id>
        <?supplied-pmid 28870203?>
        <pub-id pub-id-type="pmid">28870203</pub-id>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Norris</surname>
            <given-names>RH</given-names>
          </name>
          <name>
            <surname>Gordon</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Nithianantharajah</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Neurodevelopmental synaptopathies: Insights from behaviour in rodent models of synapse gene mutations</article-title>
        <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
        <year>2018</year>
        <volume>84</volume>
        <fpage>424</fpage>
        <lpage>439</lpage>
        <pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.12.001</pub-id>
        <?supplied-pmid 29217145?>
        <pub-id pub-id-type="pmid">29217145</pub-id>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Catusi</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Garzo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Capra</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Briuglia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Baldo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Canevini</surname>
            <given-names>MP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>8p23.2-pter microdeletions: seven new cases narrowing the candidate region and review of the literature</article-title>
        <source>Genes</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>652</fpage>
        <pub-id pub-id-type="doi">10.3390/genes12050652</pub-id>
        <?supplied-pmid 33925474?>
        <pub-id pub-id-type="pmid">33925474</pub-id>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <mixed-citation publication-type="other">Rong X, Wang B, Dunham MM, Hedde PN, Wong JS, Gratton E, et al. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. eLife. 2015;4:e06557.</mixed-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ferrara</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Verkerke</surname>
            <given-names>ARP</given-names>
          </name>
          <name>
            <surname>Maschek</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Shahtout</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Siripoksup</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Eshima</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Low lysophosphatidylcholine induces skeletal muscle myopathy that is aggravated by high-fat diet feeding</article-title>
        <source>FASEB J Off Publ Fed Am Soc Exp Biol</source>
        <year>2021</year>
        <volume>35</volume>
        <fpage>e21867</fpage>
      </element-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Genome Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">Genome Med</journal-id>
    <journal-title-group>
      <journal-title>Genome Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1756-994X</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10765705</article-id>
    <article-id pub-id-type="publisher-id">1276</article-id>
    <article-id pub-id-type="doi">10.1186/s13073-023-01276-2</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Using multi-scale genomics to associate poorly annotated genes with rare diseases</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Canavati</surname>
          <given-names>Christina</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Sherill-Rofe</surname>
          <given-names>Dana</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Kamal</surname>
          <given-names>Lara</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bloch</surname>
          <given-names>Idit</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zahdeh</surname>
          <given-names>Fouad</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sharon</surname>
          <given-names>Elad</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Terespolsky</surname>
          <given-names>Batel</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Allan</surname>
          <given-names>Islam Abu</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rabie</surname>
          <given-names>Grace</given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kawas</surname>
          <given-names>Mariana</given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kassem</surname>
          <given-names>Hanin</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Avraham</surname>
          <given-names>Karen B.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Renbaum</surname>
          <given-names>Paul</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Levy-Lahad</surname>
          <given-names>Ephrat</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Kanaan</surname>
          <given-names>Moien</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9521-3217</contrib-id>
        <name>
          <surname>Tabach</surname>
          <given-names>Yuval</given-names>
        </name>
        <address>
          <email>yuval.tabach@mail.huji.ac.il</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qxff017</institution-id><institution-id institution-id-type="GRID">grid.9619.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0538</institution-id><institution>Department of Developmental Biology and Cancer Research, </institution><institution>Institute of Medical Research - Israel-Canada, The Hebrew University of Jerusalem, </institution></institution-wrap>Jerusalem, 9112102 Israel </aff>
      <aff id="Aff2"><label>2</label>Molecular Genetics Lab, Istishari Arab Hospital, Ramallah, Palestine </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04mhzgx49</institution-id><institution-id institution-id-type="GRID">grid.12136.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0546</institution-id><institution>Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine and Sagol School of Neuroscience, </institution><institution>Tel Aviv University, </institution></institution-wrap>Tel Aviv, 6997801 Israel </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03zpnb459</institution-id><institution-id institution-id-type="GRID">grid.414505.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0631 3825</institution-id><institution>Medical Genetics Institute, Shaare Zedek Medical Center, </institution></institution-wrap>Jerusalem, 91031 Israel </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qxff017</institution-id><institution-id institution-id-type="GRID">grid.9619.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0538</institution-id><institution>Faculty of Medicine, </institution><institution>The Hebrew University of Jerusalem, </institution></institution-wrap>Jerusalem, 9112102 Israel </aff>
      <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047cjg072</institution-id><institution-id institution-id-type="GRID">grid.440580.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 1016 7793</institution-id><institution>Hereditary Research Laboratory and Department of Life Sciences, </institution><institution>Bethlehem University, </institution></institution-wrap>Bethlehem, 72372 Palestine </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>4</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>4</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2024</year>
    </pub-date>
    <volume>16</volume>
    <elocation-id>4</elocation-id>
    <history>
      <date date-type="received">
        <day>29</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>12</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© The Author(s) 2023</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Next-generation sequencing (NGS) has significantly transformed the landscape of identifying disease-causing genes associated with genetic disorders. However, a substantial portion of sequenced patients remains undiagnosed. This may be attributed not only to the challenges posed by harder-to-detect variants, such as non-coding and structural variations but also to the existence of variants in genes not previously associated with the patientâs clinical phenotype. This study introduces EvORanker, an algorithm that integrates unbiased data from 1,028 eukaryotic genomes to link mutated genes to clinical phenotypes.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p id="Par2">EvORanker utilizes clinical data, multi-scale phylogenetic profiling, and other omics data to prioritize disease-associated genes. It was evaluated on solved exomes and simulated genomes, compared with existing methods, and applied to 6260 knockout genes with mouse phenotypes lacking human associations. Additionally, EvORanker was made accessible as a user-friendly web tool.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par3">In the analyzed exomic cohort, EvORanker accurately identified the âtrueâ disease gene as the top candidate in 69% of cases and within the top 5 candidates in 95% of cases, consistent with results from the simulated dataset. Notably, EvORanker outperformed existing methods, particularly for poorly annotated genes. In the case of the 6260 knockout genes with mouse phenotypes, EvORanker linked 41% of these genes to observed human disease phenotypes. Furthermore, in two unsolved cases, EvORanker successfully identified <italic>DLGAP2</italic> and <italic>LPCAT3</italic> as disease candidates for previously uncharacterized genetic syndromes.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p id="Par4">We highlight clade-based phylogenetic profiling as a powerful systematic approach for prioritizing potential disease genes. Our study showcases the efficacy of EvORanker in associating poorly annotated genes to disease phenotypes observed in patients. The EvORanker server is freely available at <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>.</p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1186/s13073-023-01276-2.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>EvORanker</kwd>
      <kwd>Gene-based prioritization</kwd>
      <kwd>
        <italic>DLGAP2</italic>
      </kwd>
      <kwd>
        <italic>LPCAT3</italic>
      </kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id>
            <institution>Israel Science Foundation</institution>
          </institution-wrap>
        </funding-source>
        <award-id>3797/21</award-id>
        <principal-award-recipient>
          <name>
            <surname>Tabach</surname>
            <given-names>Yuval</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Koum Foundation</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution> National Institutes of Health/NIDCD</institution>
        </funding-source>
        <award-id>R01DC011835</award-id>
        <principal-award-recipient>
          <name>
            <surname>Kanaan</surname>
            <given-names>Moien</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>Â© BioMed Central Ltd., part of Springer Nature 2024</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par5">The study of Mendelian disorders remains a gold standard for understanding gene function and linking a gene to a particular phenotype [<xref ref-type="bibr" rid="CR1">1</xref>]. Next-generation sequencing technologies (NGS) have revolutionized disease-gene discovery; however, most human genes are yet to be associated with a specific phenotype: Out of ~20,000 human genes, only 4900 genes have an associated phenotype in Online Mendelian Inheritance in Man (OMIM) (as of January 22, 2023) [<xref ref-type="bibr" rid="CR2">2</xref>]. Analyses of evolutionary constraints of human genes and models from mouse genetics suggest that the genetic basis of at least 10,000 Mendelian disorders awaits discovery [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p id="Par6">A typical human whole-exome sequencing (WES) or whole-genome sequencing (WGS) study yields thousands of single nucleotide variants, indels, and copy number variants [<xref ref-type="bibr" rid="CR3">3</xref>]. After filtering out frequent variants, a handful of in silico methods are used to estimate the pathogenicity of the variants. These estimates are based on evolutionary conservation, genomic position, structural features, and predicted function (e.g., impact on regulatory, splicing, or protein level) [<xref ref-type="bibr" rid="CR4">4</xref>â<xref ref-type="bibr" rid="CR7">7</xref>]. However, prioritizing variants solely based on predicted pathogenicity and rarity may not lead to identifying the underlying disease-causing gene. Hence, numerous gene-based computational methods have been developed to prioritize candidate genes contributing to the patientâs disease phenotypes. These methods incorporate patientsâ phenotypic information and omics datasets such as protein-protein interaction, co-expression analysis, cross-species phenotypic similarity analysis, and primary literature in order to provide users with further hints about genes that merit further investigation [<xref ref-type="bibr" rid="CR8">8</xref>â<xref ref-type="bibr" rid="CR12">12</xref>]. Recent approaches incorporate artificial intelligence for candidate gene diagnosis [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Nevertheless, the majority of these approaches depend on existing data and as such work well on studied genes (i.e., the rich get richer phenomenon). However, for poorly annotated genes, their performance may decline. Within the scope of this research, poorly annotated genes are defined as those lacking associations with specific phenotypes in the OMIM database [<xref ref-type="bibr" rid="CR2">2</xref>]. This absence of phenotype correlations underscores a scarcity of available data pertaining to their characteristics, ontology, and interactions [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p id="Par7">One unbiased approach that can infer novel gene function is phylogenetic profiling (PP) [<xref ref-type="bibr" rid="CR15">15</xref>]. PP identifies functionally related genes and protein-protein interactions using comparative genomics [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The phylogenetic profile of a gene describes the pattern of conservation of its orthologs in a set of genomes [<xref ref-type="bibr" rid="CR15">15</xref>]. Those patterns of conservation of protein sequences along evolution reflect protein function [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], interaction with other proteins [<xref ref-type="bibr" rid="CR17">17</xref>], and the crosstalk between the organism and the environment [<xref ref-type="bibr" rid="CR20">20</xref>]. PP relies on the well-established hypothesis that if two or more genes share a similar phylogenetic profile, then they may be functionally related [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>â<xref ref-type="bibr" rid="CR23">23</xref>]. This can further be implemented to annotate uncharacterized genes to a putative function based on the similarity of their PP with those of well-annotated genes [<xref ref-type="bibr" rid="CR24">24</xref>]. Previous studies using PP have succeeded in identifying new functional gene associations, novel disease-causing genes, and new pathway components [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p>
    <p id="Par8">The phylogenetic profile of a gene was originally described as a binary representation of the presence or absence of its orthologs across eukaryotic species [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. However, applying a binary representation to eukaryotes might not fully address the intricacy of eukaryotic protein evolution. Across the tree of life, the sequence similarity between two orthologs is a complex function of their evolutionary distance and the variable selective pressures forced upon them. Therefore, several methods such as normalized phylogenetic profiling (NPP) have been developed [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. NPP uses a continuous metric of conservation, offering an alternative to the binary scoring system. NPP has successfully revealed novel genes in various pathways and human genetic diseases including cancer [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Recently, we found that functionally-related genes can show a strong signal of correlated evolution within specific clades (e.g., animals, mammals, plants, fungi) or segments of the tree of life. These local co-evolution signals better reflect the complexity of pathways and protein evolution. Analyzing correlated evolution among genes both across and in part of the tree of life hence improves our ability to reveal the function of genes in different pathways [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. This âclade-wiseâ NPP approach was used to identify novel DNA repair genes [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and to map potential drugs for <italic>MECP2</italic> [<xref ref-type="bibr" rid="CR31">31</xref>] and <italic>ACE2</italic>-associated disorders [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
    <p id="Par9">In this study, we introduce a gene-prioritization tool, EvORanker (Ev: Evolution, O: Omics) (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). EvORanker integrates clade-wise NPP with omics data (e.g., protein-protein interaction, and co-expression data) obtained from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>] to associate a gene variant present in a patient with the patientâs phenotypes. Our primary objective is to establish an unbiased framework to resolve unsolved exomes/genomes by linking genes and especially poorly annotated genes to the disease phenotype observed in patients. Furthermore, we aimed to assess EvORankerâs efficacy in identifying candidate disease genes that lack human annotation.<fig id="Fig1"><label>Fig.Â 1</label><caption><p>Graphical abstract of the EvORanker pipeline. Starting from a list of annotated variants obtained from a patientâs exome/genome sequencing data and following variant filtering, a list of predicted <italic>patient candidate genes</italic> harboring putatively pathogenic variants are input to EvORanker. The second input is the HPO terms corresponding to the patientâs phenotypes. The first step of the pipeline is to rank the genes listed in the HPO database according to the input HPO terms using the OntologySimilarity tool. If any of the patient candidate genes is a known disease-causing gene or ranked high using <italic>OntologySimilarity</italic>, then a genetic diagnosis is achieved. If not, then each patient candidate gene in addition to the ranked HPO gene list is input into a co-evolution and STRING-based algorithm. The algorithm analyzes two lists of genes, the co-evolving and STRING-interacting genes with each patient candidate gene. A one-sided Kolmogorov-Smirnov (K-S) test is then used to test if the co-evolving and interacting genes rank significantly high within the patientâs <italic>phenotype-related genes</italic>. The <italic>p</italic>-values obtained from running the K-S test using each dataset are combined using Fisherâs combined test. The output is a list of patient candidate genes ranked based on Fisherâs combined test <italic>p</italic>-values (from more significant to less significant). A disease-causing candidate is identified among the patient genes where a significant number of co-evolving and/or interacting genes are enriched towards the genes highly related to the patientâs input phenotypes relative to the genes that are unrelated</p></caption><graphic xlink:href="13073_2023_1276_Fig1_HTML" id="MO1"/></fig></p>
    <p id="Par10">Mouse knockout data serves as a valuable resource for comprehending gene function [<xref ref-type="bibr" rid="CR34">34</xref>]. We, therefore, concentrated on genes with knockout phenotypes in mice that lack corresponding human annotation and demonstrate EvOrankerâs ability to identify disease candidates with limited information. The results of our analysis showed that EvORanker was able to identify disease genes that were ranked low by other gene-based methods, demonstrating the complementarity of EvORanker to those of other gene-based tools. Moreover, we employed EvORanker to investigate two patients with unresolved genetic syndromes. Our analysis revealed <italic>DLGAP2</italic> and <italic>LPCAT3</italic> as potential candidates for disease-causing genes. Notably, only clade-based NPP analysis was able to detect <italic>LPCAT3</italic> as a disease candidate. To enhance its practical utility, we designed EvORanker as a user-friendly gene-prioritization web tool that can be used by researchers and clinicians studying genetic disorders.</p>
  </sec>
  <sec id="Sec2">
    <title>Methods</title>
    <sec id="Sec3">
      <title>The patient exome database</title>
      <p id="Par11">For the purpose of benchmarking EvORanker, we gathered sequencing data of patients who sought clinical whole-exome sequencing at Istishari Arab Hospital in Ramallah for diagnostic purposes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). Each participant presented with a distinct clinical anomaly and was referred to Istishari Hospital by their respective physicians from various Palestinian regions to undergo exome sequencing for the identification of genetic causes. We established a database of 109 patient exomes who had received a known molecular diagnosis, some of which have been published [<xref ref-type="bibr" rid="CR35">35</xref>â<xref ref-type="bibr" rid="CR37">37</xref>]. All of the variants identified to be disease-causing in those patients had been reported as pathogenic/likely pathogenic in the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>]. The patients in this cohort exhibit diverse phenotypes (e.g., skeletal, immunological, neurological, and metabolic) (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>A). The majority of the patients were born to consanguineous parents. Each patient had been clinically diagnosed with a different rare Mendelian disease (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1), of which 91 followed an autosomal or X-linked recessive and 18 followed an autosomal or X-linked dominant mode of inheritance. Familial segregation analysis had been performed for each of the patientsâ families further confirming the diagnosis. In addition to the 109 exomes, we applied EvORanker on two exomes of patients (II-3, Fig. <xref rid="Fig10" ref-type="fig">10</xref>A, II-4, Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A) that had not received a molecular diagnosis. Written informed consent was obtained from all participants, or their parents, before their inclusion in the study. All the study participants, or their parents, provided permission to access their medical records.<fig id="Fig2"><label>Fig.Â 2</label><caption><p>Phenotypic diversity in <bold>A</bold> a cohort of 109 patients from the exome database and <bold>B</bold> a simulated dataset of 300 individuals with 300 pathogenic variants from ClinVar inserted into their genomes. The patients exhibit a wide range of phenotypes. Notably, various shared phenotypes, especially related to metabolic and neurological diseases, are observed among the patients. Key: ID, intellectual disability; GI, gastrointestinal disorders</p></caption><graphic xlink:href="13073_2023_1276_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec4">
      <title>Simulation of cases with disease-causing gene variants</title>
      <p id="Par12">We assessed our approach and compared it to other methods by simulating scenarios where mutations in disease-causing genes exist within a genome. VCF files of 300 individual genomes were downloaded from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>], providing a diverse representation of human populations (<ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>) [<xref ref-type="bibr" rid="CR40">40</xref>]. Variant annotation was performed using ANNOVAR [<xref ref-type="bibr" rid="CR41">41</xref>], and our variant filtering pipeline was applied (see TableÂ <xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>TableÂ 1</label><caption><p>Routine variant filtering criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left"><bold>Autosomal and X-linked recessive mode</bold></th><th align="left"><bold>Autosomal and X-linked dominant mode</bold></th></tr><tr><th align="left"><bold>Filtering criteria</bold></th><th align="left"><bold>Filtering criteria</bold></th></tr></thead><tbody><tr><td align="left" colspan="3"><bold>1. Variant frequency</bold></td></tr><tr><td align="left">âgnomAD [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left">âAF_popmax [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left">âIn-house exome database</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left" colspan="3"><bold>2. Splicing and synonymous variants</bold></td></tr><tr><td align="left">âdbscSNV_RF_SCORE and dbscSNV_ADA_SCORE [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" rowspan="2">dbscSNV_RF_SCOREâ&gt;=â0.5 or dbscSNV_ADA_SCOREâ&gt;=â0.5 or SpliceAIâ&gt;=â0.5</td><td align="left" rowspan="2">dbscSNV_RF_SCOREâ&gt;=â0.5 or dbscSNV_ADA_SCOREâ&gt;=â0.5 or SpliceAIâ&gt;=â0.5</td></tr><tr><td align="left">âSpliceAI [<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left" colspan="3"><bold>3. Nonsynonymous variants</bold></td></tr><tr><td align="left">âPolyphen2_HDIV_score [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td align="left" rowspan="3">Polyphen2_HDIV_scoreâ&gt;=â0.5 or REVEL scoreâ&gt;=â0.5 or SIFT scoreâ&lt;=â0.5</td><td align="left" rowspan="3">Polyphen2_HDIV_scoreâ&gt;=â0.5 or REVEL scoreâ&gt;=â0.5 or SIFT scoreâ&lt;=â0.5</td></tr><tr><td align="left">âREVEL score [<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr><td align="left">âSIFT score [<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr></tbody></table></table-wrap></p>
      <p id="Par13">For each of the 300 genomes, we introduced exonic or splicing pathogenic/likely pathogenic variants from the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>], excluding disease genes already found in the 109-real exome patient dataset. These 300 ClinVar variants were randomly selected from genes associated with diverse disease phenotypes, including complex neoplastic disorders (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>B). Among these variants, 181 followed an autosomal or X-linked recessive mode of inheritance, while 119 variants followed a dominant inheritance pattern. In instances where the mode of inheritance for a ClinVar pathogenic variant was uncertain, or if it could be attributed to both inheritance modes, or if it was not reported in affected patients, we randomly assigned the mode of inheritance. Subsequently, we randomly integrated these 300 sampled variants into the 300 annotated genomes. This process was permutated three times, each time spiking each variant of the set of 300 ClinVar variants into different genomes out of the 300. The outcome is a simulation of 900 artificial patients with 300 unique âgenetic diseasesâ (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2), each with a single mutation in one of 300 genes. This ensured that each disease appeared three times in three different genomes.</p>
      <p id="Par14">Phenotypic information for each spiked ClinVar gene variant was retrieved from the HPO (Human Phenotype Ontology) database [<xref ref-type="bibr" rid="CR46">46</xref>]. Additionally, to evaluate the robustness of EvORanker, we conducted validation through three independent spike shuffles (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S7).</p>
    </sec>
    <sec id="Sec5">
      <title>Genomics and variant-based prioritization of the patientsâ exome to map the patient candidate genes</title>
      <p id="Par15">Whole-exome sequencing was performed on the patients described in this study using the Truseq Capture Exome Kit (IlluminaÂ®). The captured and the amplified libraries were sequenced on the Illumina Nextseq500 platform according to the manufacturerâs protocol. Briefly, paired-end sequences were obtained at a read length of 150 bps. Sequence reads were then aligned to the reference human genome (hg19) using BWA aligner [<xref ref-type="bibr" rid="CR47">47</xref>]. Alignments then underwent preprocessing steps by PCR duplicate removal, base quality recalibration, and realignment around indels. The variants were finally called by GATK (Genome Analysis Toolkit) [<xref ref-type="bibr" rid="CR48">48</xref>] and annotated by ANNOVAR [<xref ref-type="bibr" rid="CR41">41</xref>]. For both the patient exomes and simulated genomes, we excluded intronic, untranslated region (UTR), and ncRNA variants. Nonsense, frameshift, nonsynonymous, and splice-site variants were prioritized by excluding frequent variants based on their minor allele frequency in gnomAD and AF_popmax [<xref ref-type="bibr" rid="CR42">42</xref>] and Istishari hospitalâs in-house exome database (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). In addition, variants predicted to be benign by variant effect predictor tools such as PolyPhen-2 [<xref ref-type="bibr" rid="CR5">5</xref>] and REVEL [<xref ref-type="bibr" rid="CR6">6</xref>] were excluded from the analysis (TableÂ <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR49">49</xref>]. For the patient exomes, copy number variations were called from the exome data using XHMM software [<xref ref-type="bibr" rid="CR50">50</xref>]. In this study, the genes that passed the variant filtering criteria are referred to as the <italic>patient candidate genes</italic>. Co-segregation analysis was performed by Sanger sequencing on an ABI 3130 Genetic Analyzer (Applied Biosystems). Primers used for validation and family segregation of the <italic>DLGAP2</italic> variant are as follows: Forward: CGGTAGAGACTGGGAGGATG and Reverse: ACTTACCTGACAAAACACACACA. Primers used for validation and family segregation of the <italic>LPCAT3</italic> variant are as follows: Forward<italic>:</italic> CGCATAGGGGTGACATGGTA and Reverse<italic>:</italic> TATGCATTTTGACGGGCCTG.</p>
    </sec>
    <sec id="Sec6">
      <title>Ranking the patient candidate genes according to their association with each patientâs disease-phenotypes</title>
      <p id="Par16">In order to retrieve a list of genes already reported to be associated with each patientâs clinical condition, we encoded the abnormalities reported in each patientâs medical report (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) to standard HPO terms [<xref ref-type="bibr" rid="CR46">46</xref>]. The combination of the patient HPO terms was then input into the OntologySimilarity package in R, a semantic similarity-based tool [<xref ref-type="bibr" rid="CR51">51</xref>], and used to identify and rank the genes listed in the HPO database based on their associations with the queried HPO terms. According to the recommended parameters in the toolâs documentation [<xref ref-type="bibr" rid="CR51">51</xref>], the semantic similarity score was calculated using Linâs definition of semantic similarity in combination with the âbest-match-averageâ approach. Additional semantic similarity measures, such as the product measure based on Resnikâs similarity expression, were also evaluated, yielding results that were nearly identical (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1). The output is a ranked list of the 4900 genes listed in the HPO database (as of January 2023) scored between zero and one (termed HPO-ranked genes). This score is based on the degree of similarity between the patientâs set HPO terms and the HPO terms annotated to each gene in the HPO database. The higher-scoring genes, referred to as <italic>phenotype-related genes</italic> in this study, are defined as genes that exhibit stronger associations with the queried phenotypes.</p>
      <p id="Par17">Defining an exact threshold for the output of OntologySimilarity [<xref ref-type="bibr" rid="CR51">51</xref>] is challenging. In most cases, it is hard to point to a clear threshold that above which the genes are âphenotype-related.â Furthermore, such a potential threshold is highly dependent on the user-defined HPO terms as HPOs are variable in their level of complexity and how well they are defined or studied. As such in our analysis, the genes were ranked and ordered based on their association with the set of input phenotypes, ranging from highly associated to not associated (top to bottom). We utilized a one-sided Kolmogorov-Smirnov test to assess the significance of a skewed distribution of co-evolved (or interacting genes) towards the upper end of the ranked genes (see below).</p>
    </sec>
    <sec id="Sec7">
      <title>Building the EvORanker algorithm</title>
      <p id="Par18">The main goal of EvORanker is to establish a link between the <italic>patient candidate genes</italic> and the patientâs phenotype. This link was evaluated based on two different sources of data on known and predicted gene functional interactions:, clade-wise phylogenetic profiling, and the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. Our working hypothesis is that of the <italic>patient candidate genes</italic>, the disease-causing gene would be functionally linked to the genes that cause similar phenotypes to those of the patient (e.g., the disease-causing gene in a patient with ciliopathy would show significant co-evolution/co-expression/interaction with cilia genes). We used the 109-patient exome and 900-simulated datasets to tune the parameters of the algorithm using exclusively phylogenetic profiling (PP). Subsequently, we compared and eventually integrated the PP-based analysis with the STRING-based analysis to maximize the performance of EvORanker.</p>
    </sec>
    <sec id="Sec8">
      <title>Clade-based phylogenetic profiling</title>
      <p id="Par19">The normalized phylogenetic profiling (NPP) matrix was constructed as previously described [<xref ref-type="bibr" rid="CR24">24</xref>]. Briefly, a matrix of BLASTP scores for all human genes against the genomes of 1,028 eukaryotic species was constructed. First, the bitscore of each best BLAST hit was normalized by the bitscore of the query protein self-hit. Then log2 transformation of the normalized bitscore was applied. Finally, to avoid any biases due to phylogenetic distance, the conservation score was scaled for each species to their overall distribution by transforming the values in the column (corresponding to a species) into <italic>z</italic>-scores.</p>
      <sec id="Sec9">
        <title>Clade-based analysis</title>
        <p id="Par20">To have a comprehensive mapping of protein-correlated evolution, we used 16 representative clades spanning the eukaryotic tree as previously described [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In addition to including all eukaryotes, the following clades were used: <italic>Chordata</italic>, <italic>Ecdysozoa</italic>, <italic>Platyhelminthes</italic>, <italic>Alveolates</italic>, <italic>Stramenopiles</italic>, <italic>Fungi</italic>, <italic>Viridiplantae</italic>, <italic>Mammalia</italic>, <italic>Archelosuria</italic>, <italic>Arthropoda</italic>, <italic>Nematoda</italic>, <italic>Basidiomycota</italic>, <italic>Ascomycota</italic>, <italic>Fungi incertae sedis</italic>, <italic>Liliopsida</italic>, and <italic>Eudicotyledons</italic> [<xref ref-type="bibr" rid="CR24">24</xref>]. These 16 representative clades spanning the eukaryotic tree show wide coverage (span most of the eukaryotic tree), mutual exclusivity (preferring non-nested clades), and uniformness (similar depth in the tree) in clade types (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2) [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
      </sec>
      <sec id="Sec10">
        <title>Retrieving coevolving genes for each patient candidate gene</title>
        <p id="Par21">The degree of co-evolution between two genes was evaluated using the Pearson correlation coefficient between their respective rows in the NPP matrix. As we demonstrated before [<xref ref-type="bibr" rid="CR24">24</xref>], for each <italic>patient candidate gene</italic>, we selected the genes with the top 100 correlation coefficients in each clade and ranked them from 1 to 100 according to the correlation coefficient in each clade where the gene is found to have an ortholog.</p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Using the Kolmogorov-Smirnov test to prioritize patient candidate genes based on phylogenetic profiling</title>
      <p id="Par22">Per patient exome/simulated genome, we analyzed each of the <italic>patient candidate genes</italic> separately. For each of these genes, we determined whether the genes that co-evolve with it were associated with the patientâs phenotype (i.e., the co-evolved genes were significantly enriched towards the <italic>phenotype-related genes</italic>). For that, we examined the ranking of the coevolving genes in the list of the <italic>HPO-ranked genes</italic> using a one-tailed, two-sample Kolmogorov-Smirnov (K-S) test [<xref ref-type="bibr" rid="CR52">52</xref>].</p>
      <p id="Par23">The K-S test is used to test whether two samples come from the same distribution. The K-S <bold><italic>D</italic></bold> statistic quantifies the distance between the empirical cumulative distribution function (ECDF) of the sample and the cumulative distribution function of the reference distribution. Let <italic>i</italic> denote the co-evolving genes and <italic>j</italic> denote the <italic>ranked HPO genes</italic>.</p>
      <p id="Par24">The null hypothesis: H0:<italic>Fi(x)</italic>ââ¥â<italic>Fj(x)</italic></p>
      <p id="Par25">The alternative hypothesis: H1:<italic>Fi(x)</italic>â&lt;â<italic>Fj(x)</italic></p>
      <p id="Par26">The D statistic: <bold><italic>D-</italic></bold>â=âmax<sub><italic>x</italic></sub>{<italic>Fj</italic>(<italic>x</italic>)-<italic>Fi</italic>(<italic>x</italic>)} where <italic>Fj</italic> is the ECDF of <italic>j</italic> and similarity for <italic>Fi</italic></p>
      <p id="Par27">The H1 hypothesis for the one-sided K-S test is that the cumulative distribution function of the ranking of the coevolving genes is enriched within the higher-scoring side of <italic>HPO-ranked genes (the phenotype-related genes)</italic>. A <italic>p</italic>-value was computed using the ks.test function in the stats package in R [<xref ref-type="bibr" rid="CR53">53</xref>]. The <italic>patient candidate genes</italic> were finally ranked by the resulting K-S test <italic>p</italic>-value (from more significant to less significant).</p>
    </sec>
    <sec id="Sec12">
      <title>Tuning the parameters of the EvORanker phylogenetic profiling-based analysis</title>
      <p id="Par28">We evaluated the performance phylogenetic profiling-based analysis to identify the âtrueâ disease-causing gene using the 109-patient exome and the 900-simulated databases.Â We examined different parameters and cutoff values using phylogenetic profiling. We compared different cutoff values of the ranked coevolving genes (top 10, 25, 50, 75, 100) with each <italic>patient candidate gene</italic>. In both datasets, a threshold of the top 50 coevolved genes yielded slightly better accuracy in ranking the âtrueâ gene in comparison to the other patient candidate genes (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S3), which we used for the rest of the analysis.</p>
    </sec>
    <sec id="Sec13">
      <title>Applying the Kolmogorov-Smirnov test using STRING-interacting genes</title>
      <p id="Par29">In addition to phylogenetic profiling, other known and predicted functionally associated genes (protein-protein interactions, text mining, and co-expression) were retrieved from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. STRING uses a scoring system that reflects the evidence of predicted interactions. We included interactions with a combined score of at least 0.5, which corresponds to a medium-confidence network. For each patient exome/simulated genome in the datasets, we applied the K-S test. The analysis was done for each <italic>patient candidate gene</italic>, with the STRING-interacting genes similarly as described above. We examined whether a substantial portion of string-interacting genes were also linked to phenotypes resembling those found in the patient.</p>
    </sec>
    <sec id="Sec14">
      <title>The final EvORanker gene prediction scoring system</title>
      <p id="Par30">The two <italic>p</italic>-values obtained from each K-S test using phylogenetic profiling and STRING were finally combined by Fisherâs combined probability test [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>] (Eq.Â <xref rid="Equ1" ref-type="disp-formula">1</xref>) which is the final EvORanker scoring system. Additionally, we assessed Simesâ method for combining the <italic>p</italic>-values, which produced similar results (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1). The Fisherâs combined probability test was computed using the combine.test function in the survcomp package in R [<xref ref-type="bibr" rid="CR56">56</xref>].<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${X}_{2k}^{2}\sim -2\sum_{i=1}^{k}{\text{log}}\left({p}_{i}\right)$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>â¼</mml:mo><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:munderover><mml:mo>â</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>k</mml:mi></mml:munderover><mml:mtext>log</mml:mtext><mml:mfenced close=")" open="("><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="13073_2023_1276_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p>
    </sec>
    <sec id="Sec15">
      <title>Applying EvORanker on genes with knockout phenotypes in mice that lack corresponding human annotation</title>
      <p id="Par31">A list of 6395 human genes with mouse knockout phenotypes but not yet associated with a phenotype in humans was compiled from Jackson laboratoryâs Mouse Genome Informatics (MGI) [<xref ref-type="bibr" rid="CR57">57</xref>], (downloaded, March 1, 2023). The knockout mouse gene phenotype terms were then mapped to human HPO terms using uPheno ontology inter-ontology closest matches obtained from the OBO Phenotype Ontology Github repository [<xref ref-type="bibr" rid="CR58">58</xref>] ending up with 6260 genes with mapped HPO terms. Then, for each gene, the corresponding HPO terms and a list of randomly sampled genes were input to EvORanker. The same data was input to Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>] for comparison. We were unable to compare to other tools (e.g., ExomeWalker or PHIVE) due to the impracticability of simulating 6,260âÃâ100 variants in 6,260.vcf files as input.</p>
    </sec>
    <sec id="Sec16">
      <title>Tool comparison</title>
      <p id="Par32">We compared EvORanker to the gene prioritization stage (second stage) of ExomeWalker and PHIVE algorithms [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. We used the 109-patient exome and 900-simulated benchmarking datasets to compare the tools with the same input HPO terms and <italic>patient candidate genes</italic>. We omitted one exome from the exome dataset where a large deletion was identified containing the <italic>NPRL3</italic> gene, leaving us with 108 exomes. We used.vcf files for each of the 108 patient exomes and the 900 genomes as input for Exomiser which includes ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>]. Additionally, we created.yml files containing the same HPO terms as input for each patient exome and simulated genome.</p>
    </sec>
    <sec id="Sec17">
      <title>In vitro splicing analysis</title>
      <p id="Par33">In vitro splicing, minigene assays were carried out as previously described [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Briefly, the genomic sequence at chr8:1626251-1627026 (hg19) which includes exon 9 (417Â bp) plus 128 and 231 nucleotides from the 5â² and 3â² flanking sequences, respectively, of <italic>DLGAP2</italic> (NM_001346810) was PCR amplified from a DNA sample homozygous (II-3, Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A) and wildtype (II-2, Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A) for the c.2702 Aâ&gt;âT variant using gene-specific primers designed with embedded XhoI and BamHI restriction enzyme recognition sites. After digestion, the PCR fragments were ligated into a pre-constructed pET01 Exontrap vector (MoBiTec, Goettingen, Germany). Selected colonies were then sequenced to confirm the proper orientation of the cloned fragment and identify both wild-type and variant colonies. Subsequently, the variant and wild-type minigenes were transfected into HEK293 cells in triplicate, followed by total RNA extraction 48Â h post-transfection, using the Quick-RNA MiniPrep Plus kit (ZYMO Research). cDNA was then synthesized using the qScript Flex cDNA synthesis kit (Quanta Biosciences) with a specific primer to the 3â² native exon of the pET01 Exontrap vector. Following PCR amplification, the products were then visualized on a 1.5% agarose gel and were later extracted and then Sanger sequenced. The primer sequences used for the PCR amplification (XhoIâ+âBamHI) are Forward: AAA-<underline>CTCGAG</underline>-AACACTACCTGCCCTTGAGC, and Reverse: AAA-<underline>GGATCC</underline>-ACTTACCTGACAAAACACACACA.</p>
    </sec>
    <sec id="Sec18">
      <title>Data analysis and figure creation</title>
      <p id="Par34">All data in this study were analyzed using R software [<xref ref-type="bibr" rid="CR53">53</xref>]. The EvORanker web interface was created using the R Shiny package [<xref ref-type="bibr" rid="CR62">62</xref>]. The majority of the figures were created using R software. FiguresÂ <xref rid="Fig9" ref-type="fig">9</xref>D and <xref rid="Fig10" ref-type="fig">10</xref>D were created using Cytoscape v3.9.1 [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
    </sec>
  </sec>
  <sec id="Sec19">
    <title>Results</title>
    <sec id="Sec20">
      <title>Overview</title>
      <p id="Par35">In this work, we developed EvORanker, a phylogenetic profiling-based algorithm, to identify disease-causing genes. To optimize and evaluate the performance of EvORanker, we employed three different approaches: (1) analyzing a private cohort of well phenotypically characterized patients with rare diseases; (2) simulating a dataset of 900 patients with 300 unique âgenetic diseasesââby spiking disease-causing mutations into real genomes; (3) evaluating EvORankerâs ability to identify human disease candidate genes using genes with knockout phenotypes in mice that lack corresponding human annotation. We demonstrate the contribution of clade-based phylogenetic profiling (PP) to the improved prediction of the disease-causing gene. This unbiased approach was compared and integrated with gene interaction data obtained from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. To evaluate the potential for bias in disease-gene prediction, we compared well-annotated genes to recently published ones. Finally, EvORanker was compared to other gene-based prioritization tools and applied to two unresolved exomes to demonstrate its efficacy in disease gene discovery.</p>
    </sec>
    <sec id="Sec21">
      <title>Benchmarking EvORanker using an exome-patient dataset</title>
      <p id="Par36">We analyzed an in-house database of 109 patient exomes with a genetic diagnosis. The patients suffer from various rare hereditary diseases, exhibiting diverse phenotype groups (e.g., skeletal, immunological, neurological, and metabolic diseases) (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>A). The dataset included 91 recessive and 18 dominant gene variants that explained the patientsâ phenotype (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). All these variants are reported to be pathogenic/likely pathogenic in the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>] and co-segregated with the phenotype in each corresponding family. The dataset includes 108 unique known disease genes (the <italic>CLCN1</italic> gene appears twice, once as autosomal recessive and once as autosomal dominant). For each patient in the exome dataset, we encoded each of the clinical abnormalities found in the patientâs medical record into Human Phenotype Ontology (HPO) [<xref ref-type="bibr" rid="CR46">46</xref>] terms (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p>
    </sec>
    <sec id="Sec22">
      <title>Benchmarking EvORanker using a simulated dataset</title>
      <p id="Par37">Next, we aimed to assess our ability to identify disease-causing mutations in simulated data. Simulating genetic diseases can be achieved by introducing pathogenic mutations into genomic data from an unaffected individual. To accomplish this, we utilized 300 unaffected genomes sourced from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>] as a benchmark for our evaluations. To introduce pathogenicity, we randomly integrated 300 distinct pathogenic/likely pathogenic variants from the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>] into the annotated genomes. These ClinVar variants are associated with genes showcasing diverse phenotypes including complex neoplastic disorders (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>B). Of these variants, 181 followed an autosomal or X-linked recessive mode of inheritance, while 119 variants followed a dominant inheritance pattern (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). Phenotypic information for each spiked ClinVar gene variant was obtained from the HPO database (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) and was assigned to the respective âpatient.â We conducted this process thrice, simulating a total of 900 artificial patients with 300 different genetic diseases. Each pathogenic mutation was inserted into three distinct genomes.</p>
      <sec id="Sec23">
        <title>Ranking genes based on each patientâs set of phenotypes</title>
        <p id="Par38">Using each set of patient HPO terms, we calculated the semantic similarity score [<xref ref-type="bibr" rid="CR51">51</xref>] (see the â<xref rid="Sec2" ref-type="sec">Methods</xref>â section) for each gene in the HPO database [<xref ref-type="bibr" rid="CR46">46</xref>]. The output is a list of genes scored from lower association to higher association with the patientâs set of HPO terms (which we term the phenotype-related genes).</p>
      </sec>
      <sec id="Sec24">
        <title>Retrieving the patientâs candidate genes</title>
        <p id="Par39">We applied our routine variant filtering criteria [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] to the annotated variants for each of the 109 exomes and simulated genomes (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). After variant filtering, each exome/genome contained gene variants that are considered to be pathogenic and predicted to affect protein function (we term the genes in which these variants were observed as <italic>patient candidate genes</italic>). In autosomal and X-linked recessive cases, each patient harbored 11â80 homozygous/hemizygous or compound heterozygous deleterious variants, while 80â170 heterozygous/hemizygous deleterious variants were observed in autosomal and X-linked dominant cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S4). We confirmed that all the âtrueâ causative variants passed the filtering criteria and remained within the gene variant list for each patient exome.</p>
      </sec>
      <sec id="Sec25">
        <title>Using multi-clade phylogenetic profiling to rank the patientâs candidate genes according to the patientâs phenotype</title>
        <p id="Par40">Our working hypothesis is that out of all the patient candidate genes, the one responsible for the disease will be associated (e.g., co-evolved) with other genes that are known to be associated with the disease (phenotype-related gene). For each <italic>patient candidate gene</italic>, we obtained a list of 50 co-evolved genes that exhibit a strong correlation based on global and local co-evolution signatures across 1028 eukaryotic species (details in the â<xref rid="Sec2" ref-type="sec">Methods</xref>â section) [<xref ref-type="bibr" rid="CR24">24</xref>]. For each <italic>patient candidate gene</italic>, we retrieved the top co-evolving genes in 16 clades (<italic>Chordata</italic>, <italic>Ecdysozoa</italic>, <italic>Platyhelminthes</italic>, <italic>Alveolates</italic>, <italic>Stramenopiles</italic>, <italic>Fungi</italic>, <italic>Viridiplantae</italic>, <italic>Mammalia</italic>, <italic>Archelosuria</italic>, <italic>Arthropoda</italic>, <italic>Nematoda</italic>, <italic>Basidiomycota</italic>, <italic>Ascomycota</italic>, <italic>Fungi incertae sedis</italic>, <italic>Liliopsida</italic>, and <italic>Eudicotyledons</italic>) (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2). The output per <italic>patient candidate gene</italic> is a table of genes that are strongly co-evolved with it in each clade in addition to all Eukaryotes.</p>
        <p id="Par41">To determine which of the <italic>patient candidate genes</italic> is most likely linked to the patientâs disease phenotype, we evaluated the intersection between the co-evolved genes and the phenotype-ranked genes using a one-sided <italic>Kolmogorov-Smirnov</italic> (K-S) test (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). A significant <italic>p</italic>-value is obtained if the co-evolving genes rank high within the <italic>phenotype-related genes</italic>. For each patient exome/simulated genome in our dataset, we ranked the <italic>patient candidate genes</italic> based on the resulting <italic>p</italic>-value, with the most significant <italic>p</italic>-value ranked first. By analyzing the co-evolved genes across the 16 clades in addition to all Eukaryotes, the âtrueâ disease-causing gene was ranked as the top gene in 46% of the autosomal and X-linked recessive cases and within the top 5 in 72% (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>). In autosomal and X-linked dominant cases, the âtrueâ gene was ranked as the top gene in 50% of the cases and within the top 10 genes in 78%. These results surpass those obtained from using only the co-evolving genes across Eukaryotes or within the Animalia clades (<italic>Chordata</italic>, <italic>Mammalia</italic>, <italic>Archelosauria</italic>, <italic>Ecdysozoa</italic>, <italic>Nematoda</italic>, <italic>Arthropoda</italic>, and <italic>Platyhelminthes</italic>) (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>). This indicates the added value of incorporating all 16 clades in the analysis. The same analysis was applied on the simulated genomes, yielding results consistent with those obtained from the real exome dataset (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.Â 3</label><caption><p>Using clades improves the performance of EvORanker phylogenetic profiling-based analysis. For each patient candidate gene list in the 109-patient exome and the 900-simulated genomes datasets (300 unique genetic disorders), we compared the accuracy of the phylogenetic profiling-based algorithm by retrieving the top 50 coevolved genes with each <italic>patient candidate gene</italic> across all Eukaryotes versus: (1) using all 16 clades where the query gene has an ortholog in addition to Eukaryotes. (2) Across only Animalia clades (<italic>Chordata</italic>, <italic>Mammalia</italic>, <italic>Archelosauria</italic>, <italic>Ecdysozoa</italic>, <italic>Nematoda</italic>, <italic>Arthropoda</italic>, and <italic>Platyhelminthes</italic>). Performance was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other patient candidate genes. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right). The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested clades, and the <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top or within the top 3 or top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage is for the âtrueâ gene being ranked at the top or within the top 10 genes. Overall, the best performance of ranking the âtrueâ causative gene was achieved by merging together the co-evolving genes within all clades (the 16 clades in addition to all Eukaryota) in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig3_HTML" id="MO6"/></fig></p>
      </sec>
      <sec id="Sec26">
        <title>Phylogenetic profiling analysis in different evolutionary scales improves the prediction of the disease-causing gene</title>
        <p id="Par42">We then aimed to assess the contribution of each of the 16 clades, in addition to all <italic>Eukaryota</italic>, towards the prediction of the âtrueâ disease-causing gene. Using the 109 patient exomes, this was accomplished by focusing on the genes that obtained a significant <italic>p</italic>-value (&lt;â0.05) through co-evolution analysis totaling 71 identified genes. We applied the K-S test to these 71 genes using the co-evolving genes within each clade. Results showed that each clade outperformed others in at least one case, thus highlighting the importance of combining information from different clades to enhance the performance of EvORanker (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>). Interestingly, the <italic>Fungi Incertae Sedis</italic> clade outperformed other clades in 14% (10/71) of the cases, followed by <italic>Chordata</italic>, <italic>Ascomycota</italic>, <italic>Arthropoda</italic>, and <italic>Eukaryota</italic>, each outperforming others in 10% of the cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S5). Taken together, these results emphasize that clades differentially specialize in detecting functional interactions in different pathways [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].<fig id="Fig4"><label>Fig.Â 4</label><caption><p>Each of the 16 clades in addition to <italic>Eukaryota</italic> contributes to the correct identification of the disease-causing gene. Each column in the heatmap represents a clade while each row represents the âtrueâ disease-causing gene in a patient exome from the 109-exome patient dataset. Only the genes that achieved an overall significant K-S test <italic>p</italic>-value (&lt;â0.05) using the co-evolution analysis are displayed (71 cases). Each entry in the heatmap is colored by the -log 10 of the K-S test <italic>p</italic>-value that was run on each clade separately. The entries colored in red represent the significant <italic>p</italic>-values (&gt;â-log10(0.05)). Light grey entries indicate non-significant <italic>p</italic>-values. Entries, where the gene is not found to have an ortholog in a certain clade, are colored off-white. The rows are clustered according to the <italic>p</italic>-values. The column on the left indicates the combined -log10 of the <italic>p</italic>-value obtained by running the K-S test after merging together the coevolving genes across the clades. In four cases (<italic>HUWE1</italic>, <italic>COL3A1</italic>, <italic>MYO7A</italic>, and <italic>CYP21A2</italic>), a significant <italic>p</italic>-value was obtained by none of the clades, but a significant combined <italic>p</italic>-value was still achieved by merging the co-evolving genes from all the clades</p></caption><graphic xlink:href="13073_2023_1276_Fig4_HTML" id="MO7"/></fig></p>
      </sec>
      <sec id="Sec27">
        <title>Phylogenetic profiling is complementary to other existing omics datasets</title>
        <p id="Par43">NPP represents an unbiased approach that can annotate gene function independently of the literature. We sought to evaluate whether clade-wise NPP could identify disease-associated genes that are overlooked by other existing omics. For that, we chose to use the STRING database since it integrates information on protein associations from multiple sources, including interaction experiments, known complexes and pathways, scientific literature, co-expression studies, and conserved genomic context [<xref ref-type="bibr" rid="CR33">33</xref>]. We conducted a comparison between the NPP and STRING-based analysis [<xref ref-type="bibr" rid="CR33">33</xref>] using both the patient exome and simulated datasets (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). NPP outperformed STRING in 29/109 (27%) of the cases, whereas STRING outperformed NPP in 50/109 (46%) of the cases (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6).<fig id="Fig5"><label>Fig.Â 5</label><caption><p>Comparative performance of NPP, STRING, and EvORanker using the 109-patient exome and the simulated datasets. The performance of each dataset was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other genes in each exome/genome in both datasets. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right), The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested datasets: NPP (using the top 50 coevolved genes), STRING versions 9.1, 11.5, and EvORanker (combining NPP and the newer version of STRING). The <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top, or within the top 3 or top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage is for the âtrueâ gene being ranked at the top or within the top 10 genes. Overall, the best performance was achieved using the combined approach (EvORanker) in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig5_HTML" id="MO8"/></fig></p>
        <p id="Par44">Considering the presence of complementarity of co-evolution and the STRING-based analysis, we integrated the two datasets by combining their respective <italic>p</italic>-values using Fisherâs combined probability test [<xref ref-type="bibr" rid="CR54">54</xref>]. This combined scoring system, which we termed EvORanker, yielded the highest accuracy in comparison to each dataset alone (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). Using the exome dataset, we showed that integrating NPP and STRING improved the results by 43% compared to NPP alone and by 30% compared to STRING alone (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6). Overall, in autosomal and X-linked recessive cases, EvORanker ranked the âtrueâ disease-causing gene as the top gene in 63/91 (69%) and within the top 5 genes in 86/91 (95%) cases (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). In autosomal and X-linked dominant cases, the âtrueâ gene was ranked as the top gene in 12/18 (67%) cases and among the top 10 genes in 17/18 (95%) (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). On the other hand, the âtrueâ disease genes did not achieve high scores in a total of 6/109 (5.5%) of the exomes (within the top 5 for recessive diseases and within the top 10 for dominant diseases); 5/91 recessive cases, and 1/18 dominant cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6).</p>
        <p id="Par45">We observed similar trends when analyzing the simulated dataset, providing further validation and affirming the consistency of our findings (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). In autosomal and X-linked recessive cases within the simulated dataset, EvORanker ranked the âtrueâ disease-causing gene as the top gene in 75% of cases and within the top 5 in 96% of cases. Conversely, for autosomal and X-linked dominant cases, the âtrueâ gene held the top position in 55% of cases and was within the top 10 in 85% of cases. This parallel in results strongly underscores the robustness of EvORanker across both real and simulated datasets. Furthermore, to validate the stability of our method, we conducted three independent spike shuffles, consistently yielding coherent and reliable results (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S7).</p>
      </sec>
    </sec>
    <sec id="Sec28">
      <title>Performance of phylogenetic profiling versus STRING on new gene entries (2020â2022)</title>
      <p id="Par46">As STRING is based on publicly available data, it is suited to identify well-researched genes. We hypothesized that STRING performance would be better the more information it has accrued over time and that our unbiased PP approach would have a particular advantage for genes that have not been extensively characterized. To test this hypothesis, we compared the performance of STRING version v.11.5 [<xref ref-type="bibr" rid="CR33">33</xref>] with that of the older version STRING v.9.1 [<xref ref-type="bibr" rid="CR64">64</xref>] (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). We found that the performance of the newer version was indeed better than that of the older version. Furthermore, the performance of STRING v11.5 decreased dramatically for genes that only recently became associated with disease. For example, the performance of STRING in ranking the âtrueâ disease gene within the top 5 is around 85% for genes identified by the end of 2015 compared to 29% for genes identifiedÂ between 2016â2020 (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S8).<fig id="Fig6"><label>Fig.Â 6</label><caption><p>The effect of years elapsed on the performance of NPP versus STRING, using the 109-patient exome dataset. The <italic>x</italic>-axis indicates the calendar years (divided into 5-year windows) in which a gene was described to be associated with a disease phenotype. The <italic>y</italic>-axis indicates the percentage of âtrueâ disease genes that ranked at the top (top 1) relative to the other <italic>patient candidate</italic> using NPP (red bars) or STRING (blue bars)</p></caption><graphic xlink:href="13073_2023_1276_Fig6_HTML" id="MO9"/></fig></p>
      <p id="Par47">We then evaluated the performance of NPP and STRING on newly discovered or recently published genes. We retrieved a list of 94 new gene entries that were added to the most recent version of the HPO database (2022) compared to an older version (2020) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3). We then applied the K-S test separately using NPP and STRING and the HPO terms associated with each gene as input. We found that for those genes newly associated with human phenotypes, the K-S test yielded significant <italic>p</italic>-values using NPP in 45% of the genes compared to 38% using STRING (Fig. <xref rid="Fig7" ref-type="fig">7</xref>A, B). These results emphasize the success of phylogenetic profiling in predicting the phenotype associations of newly discovered or less studied genes and highlight the complementarity observed when comparing these two datasets.<fig id="Fig7"><label>Fig.Â 7</label><caption><p>Comparison of NPP versus STRING for genes with recent (2020â2022) annotation. <bold>A</bold> The <italic>x</italic>-axis indicates -log(10) <italic>p</italic>-values obtained from running the K-S test using NPP. The <italic>y</italic>-axis indicates -log(10) <italic>p</italic>-values obtained from running the K-S test using the STRING dataset. The red dots represent the genes where NPP performed better than STRING, while the blue dots indicate the opposite. The marginal histogram indicates the distribution of the -log(10) <italic>p</italic>-values of both datasets. The correlation score between the two datasets is 0.046, suggesting that the two datasets exhibit a complex relationship, where a subset of the data displays complementarity, while another subset shows correlation. <bold>B</bold> Density distribution of the -log(10) <italic>p</italic>-values obtained from the K-S test using the NPP, STRING, and both (combined). Significance was calculated using the Wilcoxon test (*<italic>p</italic>-valueâ&lt;â0.05, **<italic>p</italic>-valueâ&lt;â0.01; ns, nonsignificant). Combining NPP and STRING achieved significantly more significant results that either approach alone</p></caption><graphic xlink:href="13073_2023_1276_Fig7_HTML" id="MO10"/></fig></p>
    </sec>
    <sec id="Sec29">
      <title>Performance of EvORanker on genes with knockout phenotypes in mice that lack corresponding human annotation</title>
      <p id="Par48">We aimed to assess EvORankerâs capability to identify disease candidate genes that lack a known phenotype association in humans but possess mouse orthologs linked to phenotypes. Specifically, we aimed to identify human genes without established phenotype links, yet having a corresponding mouse ortholog with a phenotype association. These genes were considered as the âtrueâ disease gene candidates for the purpose of this evaluation. We compiled a list of 6260 human ortholog genes with mouse knockout phenotypes, yet not associated with a phenotype in humans. For each of these genes, we input a set of HPOs mapped from the respective mouse knockout phenotypes. The goal was to evaluate EvORankerâs ability to correctly pinpoint the âtrueâ disease gene candidate in comparison to 100 randomly sampled human genes. The same dataset was used as input for Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>] for comparative analysis.</p>
      <p id="Par49">EvORanker yielded significant <italic>p</italic>-values for 41% of the tested genes (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>A). Moreover, both EvORanker and Phenolyzer ranked the âtrue geneâ among the top 10 in 16% of the cases (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>B). Notably, EvORanker identified genes that Phenolyzer failed to identify, and vice versa, highlighting the complementarity of the tools (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S9).<fig id="Fig8"><label>Fig.Â 8</label><caption><p>EvORankerâs performance in identifying candidate disease genes using mouse knockout genes without corresponding human annotation. <bold>A</bold> The graph shows the percentage of genes with mouse knockout phenotypes that were tested for significant <italic>p</italic>-values using EvORanker. Out of 6260 genes, 41% showed significant <italic>p</italic>-values. <bold>B</bold> Comparison of EvORanker and Phenolyzer [<xref ref-type="bibr" rid="CR49">49</xref>] in identifying true disease gene candidates. The graph shows the count of genes with mouse knockout phenotypes and their respective ranking, each in comparison to 100 randomly sampled genes by EvORanker and Phenolyzer. Among the tested genes, 16% were ranked in the top 10 by both tools</p></caption><graphic xlink:href="13073_2023_1276_Fig8_HTML" id="MO11"/></fig></p>
    </sec>
    <sec id="Sec30">
      <title>Tool comparison</title>
      <p id="Par50">Using the 109-exome and simulated datasets, we compared the performance of EvORanker to the gene-prioritization stage of ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>]. ExomeWalker prioritizes genes based on protein-protein interaction, while PHIVE uses mouse phenotypic data. To ensure a fair comparison, we chose to compare to ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] because both adopt a similar strategy to EvORanker. Unlike Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>], these methods do not rely on pre-existing knowledge about known disease genes. The comparison was performed using the exome and simulated datasets with the same input HPO terms. However, since ExomeWalker and PHIVE are not well-suited for CNV analysis, we omitted from this analysis one exome where the causative variant was a large deletion encompassing the <italic>NPRL3</italic> gene. The results of the 108-exome dataset showed that EvORanker outperformed either one or both ExomeWalker and PHIVE in 74% (80/108) of the cases and outperformed both tools in 30% (32/108) of the cases (Fig.Â <xref rid="Fig9" ref-type="fig">9</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S10). On the other hand, either one or both of the other tools outperformed EvORanker in 20% (22/108) of the cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S10). For the simulated dataset, EvORanker outperformed both ExomeWalker and PHIVE (Fig.Â <xref rid="Fig9" ref-type="fig">9</xref>).<fig id="Fig9"><label>Fig.Â 9</label><caption><p>EvORanker outperforms two other algorithms (ExomeWalker and PHIVE). The performance of each algorithm in the 108-exome dataset and the simulated dataset (shuffled three times) was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other patient genes. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right). The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested algorithms, and the <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top or within the top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage indicates whether the âtrueâ gene was ranked at the top or within the top 10 genes. EvORanker outperformed ExomeWalker and PHIVE in both recessive and dominant diseases in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig9_HTML" id="MO5"/></fig></p>
    </sec>
    <sec id="Sec31">
      <title>Solving the unsolved: candidate genes in reanalysis of patient exomes</title>
      <p id="Par51">We then initiated the application of EvORanker to identify novel disease-causing candidate genes in families with negative clinical exome results. To illustrate its effectiveness, we present two cases where we successfully resolved previously unsolved exomes.</p>
      <sec id="Sec32">
        <title>Family 1</title>
        <p id="Par52">We utilized EvORanker to analyze the exome data of a patient with an undiagnosed neurodevelopmental disorder for which no disease-causing variant was identified. The patient and one of her siblings displayed symptoms of global psychomotor delay, dysphasia, and attention-deficit hyperactivity disorder (ADHD) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A). By employing the previously described analysis steps and inputting the HPO terms HP:0001263, HP:0002357, HP:0000752, and HP:0000736, EvORanker prioritized <italic>DLGAP2</italic> as the top candidate gene (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>B). Further analysis revealed a strong correlation between <italic>DLGAP2</italic> and several genes related to similar phenotypes to that of the patient, such as <italic>GRIN2A</italic>, <italic>NLGN1</italic>, <italic>CNTNAP2</italic>, <italic>SRPX2</italic>, <italic>SYNGAP1</italic>, <italic>GABRA5</italic>, <italic>DLG3</italic>, <italic>SATB1</italic>, <italic>PTCHD1</italic>, <italic>ARHGEF6</italic>, and <italic>NLGN4X</italic> (Fig. <xref rid="Fig10" ref-type="fig">10</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S11). These âphenotype-relatedâ genes were significantly enriched within the top co-evolving and STRING-interacting genes with <italic>DLGAP2</italic> (combined Fisher <italic>p</italic>-valueâ=â1.65âÃâ10<sup>â6</sup>) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S11). Additionally, <italic>DLGAP2</italic> was ranked as the top gene by both PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] and ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] but ranked 10th by Phenolyzer tool [<xref ref-type="bibr" rid="CR59">59</xref>].<fig id="Fig10"><label>Fig.Â 10</label><caption><p>EvORanker identifies <italic>DLGAP2</italic> as a novel gene underlying a neurodevelopmental phenotype. <bold>A</bold> Pedigree: In a consanguineous family affected children have psychomotor delay and dysphasia, hyperactivity, and poor attention span. Shown is the segregation of the <italic>DLGAP2</italic> NM_001346810:c.A2702T, p.Glu901Val variant. N, normal allele; V, variant allele. <bold>B</bold> EvORanker results: <italic>DLGAP2</italic> is ranked as the top candidate relative to the other patient candidates. The <italic>x</italic>-axis indicates the proband (patient II-3), and the <italic>y</italic>-axis indicates the EvORanker -log(10) <italic>p</italic>-value obtained from running the K-S test using the co-evolved and STRING-interacting genes with each patient gene. Red dots indicate significant <italic>p</italic>-values, and dark blue dots indicate non-significant <italic>p</italic>-values. <italic>DLGAP2</italic> was the only gene that co-segregated with the phenotype in family 1. <bold>C</bold> One-sided, two-sample KolmogorovâSmirnov model. The <italic>x</italic>-axis indicates the semantic similarity score obtained by the <italic>OntologySimilarity</italic> tool in relation to the patientâs (II-3, family 1) phenotypes (HP:0001263, HP:0002357, HP:0000752, HP:0000736). The <italic>y</italic>-axis indicates the cumulative distribution. The orange line corresponds to the empirical distribution of all genes listed in the HPO database, ranked according to semantic similarity. The red line represents the empirical distribution of the genes coevolved with <italic>DLGAP2</italic>, and the blue line represents the empirical distribution of the genes interacting with <italic>DLGAP2</italic> based on STRING. The red dashed line indicates the D statistic representing the maximum vertical distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes coevolved with <italic>DLGAP2</italic>. The blue dashed line indicates the D statistic measured by the distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes interacting with <italic>DLGAP2</italic> based on STRING. Both coevolution and STRING-based analysis yielded significant <italic>p</italic>-values corresponding to the D statistic. <bold>D</bold> Coevolution and STRING-based subnetwork showing the patientâs phenotype-related genes coevolving with the <italic>DLGAP2</italic> gene. The dark grey node in the network indicates <italic>DLGAP2</italic> and the light grey nodes represent the phenotype-related genes. The black edges represent STRING interactions, and the colored edges represent the clade where two genes co-evolve. The network exhibits a group of phenotype-related correlated genes that have not been identified by the STRING database (<italic>EHMT1</italic>, <italic>IL1RAPL1</italic>, <italic>SATB2</italic>, <italic>GABRA5</italic>, <italic>SRPX2</italic>, <italic>SEMA3E</italic>, <italic>CACNG2</italic>)</p></caption><graphic xlink:href="13073_2023_1276_Fig10_HTML" id="MO3"/></fig></p>
        <p id="Par53">The high ranking of <italic>DLGAP2</italic> by EvORanker prompted us to further research the <italic>DLGAP2</italic> variant. The <italic>DLGAP2</italic> variant (NM_001346810:c.A2702T, p.Glu901Val) is strongly conserved and not found in the gnomAD population frequency database [<xref ref-type="bibr" rid="CR42">42</xref>] nor in our in-house database. Both affected siblings were homozygous for the variant, and it was the only variant that co-segregated with the phenotype in the family (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A). The variant is positioned on the third nucleotide preceding the splice donor site within exon 9 (out of 12 exons) of the <italic>DLGAP2</italic> gene. It is predicted to alter gene splicing by different prediction tools (e.g., SpliceAI [<xref ref-type="bibr" rid="CR44">44</xref>]). Since the <italic>DLGAP2</italic> gene is minimally expressed in whole blood, a minigene splicing assay was performed to assess the effect of the c.A2702T variant on gene splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). The minigene assay results showed that the variant led to the activation of a cryptic splice site and aberrant splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). Sequencing of the RT-PCR product of the mutant construct showed a 4-bp deletion (GAAA del) (Chr8:1,626,792â1,626,795), resulting in a frameshift and premature termination after 59 codons (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12).</p>
      </sec>
      <sec id="Sec33">
        <title>Family 2</title>
        <p id="Par54">We applied EvORanker to the exome data of a patient diagnosed with a multisystem disease including failure to thrive, recurring abdominal pain, chronic diarrhea, skeletal muscle wasting, elevated liver enzymes, and high levels of creatine kinase (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). The patient is of consanguineous parentage and is the sole affected individual in the family (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). Using HPO terms corresponding to the patientâs phenotype (HP:0001508, HP:0002910, HP:0002574, HP:0002028, HP:0003236, HP:0003202), EvORanker prioritized <italic>LPCAT3</italic> as the top patient candidate gene (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>B). <italic>LPCAT3</italic> demonstrated strong coevolution signals with genes related to the patientâs phenotype (<italic>PYGL</italic>, <italic>DLD</italic>, <italic>TXNRD2</italic>, <italic>COG8</italic>, <italic>SUCLG1</italic>, <italic>MVK</italic>, <italic>SMAD4</italic>, <italic>CPT1A</italic>) in the plant (<italic>Viridiplantae</italic> and <italic>Eudicotyledons</italic>), <italic>Mammalia</italic>, and <italic>Fungi</italic> kingdoms (Fig. <xref rid="Fig11" ref-type="fig">11</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figs. S13, S14 and S15). The genes that showed the strongest coevolution with <italic>LPCAT3</italic> were significantly enriched within the <italic>phenotype-related genes</italic> (<italic>p</italic>-valueâ=â7.93âÃâ10<sup>â15</sup>) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). Conversely, the genes that interacted with <italic>LPCAT3</italic> through STRING did not exhibit significant enrichment within the <italic>phenotype-related genes</italic> (<italic>p</italic>-valueâ=â0.53) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). Despite this, <italic>LPCAT3</italic> still had the most significant <italic>p</italic>-value among all candidates based on the combined EvORanker score (Fisher combined <italic>p</italic>-valueâ=â1.42âÃâ10<sup>â13</sup>). <italic>LPCAT3</italic> was ranked third by ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>], excluded by PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] and ranked 8th by Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>]. The proband (II-4) was homozygous for a truncating variant in exon 9 of the <italic>LPCAT3</italic> gene (NM_005768:c.G939A, p.W313X) (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). This variant was not found in the gnomAD population frequency database [<xref ref-type="bibr" rid="CR42">42</xref>] nor in our in-house database. The <italic>LPCAT3</italic> variant was the only variant among the <italic>patient candidate genes</italic> that co-segregated with the phenotype in the family (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A).<fig id="Fig11"><label>Fig.Â 11</label><caption><p>EvORanker identifies <italic>LPCAT3</italic> as a novel gene underlying a multisystem disorder. <bold>A</bold> Pedigree of a consanguineous family. The affected son has failure to thrive, chronic diarrhea with recurrent abdominal pain, muscle atrophy, elevated liver enzymes, and high creatine kinase levels. Shown is the segregation of the <italic>LPCAT3</italic> NM_005768:c.G939A, p.Trp313Ter variant. N, normal allele; V, variant allele. <bold>B</bold> EvORanker results: <italic>LPCAT3</italic> is ranked as the top candidate relative to other candidate genes. The <italic>x</italic>-axis indicates the proband (patient II-4), and the <italic>y</italic>-axis indicates the combined -log10 <italic>p</italic>-value obtained from running the K-S test using the co-evolved and STRING-interacting genes with each patient gene. Red dots indicate significant <italic>p</italic>-values, and dark blue dots indicate non-significant <italic>p</italic>-values. <italic>LPCAT3</italic> was the only gene that co-segregated with the phenotype in family 2. <bold>C</bold> One-sided, two-sample KolmogorovâSmirnov model. The <italic>x</italic>-axis indicates the semantic similarity score obtained by the OntologySimilarity tool in relation to the patientâs (II-4, family 2) phenotypes (HP:0001508, HP:0002910, HP:0002574, HP:0002028, HP:0003236, HP:0003202). The <italic>y</italic>-axis indicates the cumulative distribution. The orange line corresponds to the empirical distribution of all genes listed in the HPO database, ranked according to semantic similarity. The red line indicates the empirical distribution of the genes coevolved with <italic>LPCAT3</italic>, and the blue line indicates the empirical distribution of the genes interacting with <italic>LPCAT3</italic> based on STRING. The red dashed line indicates the D statistic representing the maximum vertical distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes coevolved with <italic>LPCAT3</italic>. The blue dashed line indicates the D statistic measured by the distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes interacting with <italic>LPCAT3</italic> based on STRING. Only coevolution-based analysis yielded significant <italic>p</italic>-values corresponding to the D statistic. <bold>D</bold> Coevolution and STRING-based subnetwork showing the patientâs phenotype-related genes coevolving with the <italic>LPCAT3</italic> gene. The yellow node in the network indicates <italic>LPCAT3</italic> and the light grey nodes represent the phenotype-related genes. The black edges represent STRING interactions, and the colored edges represent the clade where two genes co-evolve. We demonstrate that our clade-wise NPP approach uncovered correlations between <italic>LPCAT3</italic> and <italic>phenotype-related genes</italic> that were not captured by STRING</p></caption><graphic xlink:href="13073_2023_1276_Fig11_HTML" id="MO4"/></fig></p>
        <p id="Par55">Complete knockout of <italic>LPCAT3</italic> in mice results in premature death. However, tissue-specific knockouts in the liver and intestines have been documented, with the latter causing impaired growth and abnormal enterocyte morphology along with enterocyte lipid accumulation (Rong et al., 2015). Liver-specific knockouts in mice display a decrease in plasma triglycerides and an occurrence of hepatosteatosis (Rong et al., 2015). The patient from family 2 demonstrated anomalies in both the intestine and liver. Duodenal biopsies showed nodular lesions in the duodenal bulb and the descending portion of the duodenum with atrophic mucosa suggestive of severe enteropathy. Fragments of duodenal mucosa showed partial villous blunting with a mild increase of lamina propria lymphoplasmacytic cell infiltrate. Liver enzymes revealed a reduced ratio of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, suggesting fatty liver disease, along with reduced plasma triglycerides (34Â mg/dL) and HDL levels (27.1Â mg/dL). These findings suggest <italic>LPCAT3</italic> as a potential causative gene for the disease in the proband of this family.</p>
      </sec>
    </sec>
    <sec id="Sec34">
      <title>EvORanker web tool</title>
      <p id="Par56">The EvORanker web tool (<ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>) is an easy-to-use and user-friendly decision support tool built for geneticists and researchers in the NGS field (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S16). The user submits a set of HPO terms describing the patientâs medical condition and the patientâs candidate genes, preferably genes that survived variant filtering. The algorithm then performs the aforementioned analyses and returns the outputs in two stages:<list list-type="order"><list-item><p id="Par57">Step 1: If the queried gene is already listed in the HPO database, a semantic similarity score (ranging from 0 to 1) reflecting the similarity of the geneâs associated HPO terms to the userâs input HPO terms is calculated using the OntologySimilarity package [<xref ref-type="bibr" rid="CR51">51</xref>] and is indicated in a table output in the âStep 1: Semantic Similarity-based Prioritizationâ tab.</p></list-item><list-item><p id="Par58">Step 2: In the case where none of the queried genes are listed in the HPO dataset or where none had a high or sufficient semantic similarity score (i.e., a non-diagnostic case), the user can navigate to co-evolution and STRING-based gene prioritization. The output is a table containing each queried gene and the corresponding EvORanker <italic>p</italic>-value. The EvORanker <italic>p</italic>-value is the result of Fisherâs combined test obtained by integration of multi-clade phylogenetic profiling and STRING-based analysis as described above.</p></list-item></list></p>
      <p id="Par59">EvORanker also provides useful visualizations of the results, including a bar plot of the ranked genes by EvORanker, and a co-evolution and STRING subnetwork generated upon click of any queried gene in the âStep 2â results table. The network highlights the HPO-related genes co-evolving with the query gene in addition to edges representing STRING interactions. Additionally, the user can retrieve more detailed co-evolutionary information including the clade where every two genes co-evolve, the co-evolutionary rank of the HPO-related genes with each query gene, and can inspect gene enrichment results of the coevolving genes and STRING-interacting genes with each query gene. The web interface is available at the following link: <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>. Recognizing the need to analyze a larger number of genes than recommended for the web tool due to memory constraints, we have established a GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>) [<xref ref-type="bibr" rid="CR65">65</xref>]. This repository allows users to access the tool and input an expanded number of genes, accommodating their requirements.</p>
    </sec>
  </sec>
  <sec id="Sec35">
    <title>Discussion</title>
    <p id="Par60">Clinical elucidation of genetic variants in connection to a patientâs phenotype is a time-consuming and costly element in the genomic diagnosis of rare genetic diseases. To address this issue, several computational algorithms have been developed over the years to prioritize candidate genes based on the patientâs phenotype using different sources of information, such as protein-protein interactions, data mining, and gene expression [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>â<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>â<xref ref-type="bibr" rid="CR14">14</xref>]. Nevertheless, although PP was successfully used to identify novel disease genes [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR66">66</xref>], we are not aware of any tool that systematically utilizes clade-based phylogenetic profiling to prioritize patient candidate genes. Herein, we described EvORanker, an algorithm that employs multi-scale phylogenetic profiling and gene interaction data from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>] to analyze âunsolvedâ WES/WGS cases in search of novel genetic causes of disease. This algorithm integrates unbiased comparative genomic analysis with publicly available gene data, including function and interactions.</p>
    <p id="Par61">Multi-scale phylogenetic profiling is particularly valuable for identifying disease associations for poorly annotated genes. The ability to conduct analysis of every gene independently of existing knowledge expands the scope of disease-gene discovery. This is particularly important in light of the ârich get richerâ phenomenon, where genes that have already been studied receive disproportionate attention, while poorly annotated genes are often overlooked. Among the 6260 tested knockout genes that exhibit a phenotype in mice and have an ortholog in humans, EvORanker was able to link 41% of these genes to the disease phenotype observed in mice (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: S9). This highlights the potential of EvORanker to discover new disease genes and expand our understanding of disease mechanisms.</p>
    <p id="Par62">Furthermore, our study demonstrates the power of our multi-clade concept in capturing co-evolution, as shown by our ability to more effectively identify the âtrueâ disease-causing genes across multiple clades, beyond just Eukaryota or Animalia clades (Figs. <xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S5). This is aligned with the notion that multi-clade phylogenetic profiling-based methods more effectively capture co-evolution [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Importantly, our clade-wise NPP approach revealed correlations between genes that could not be anticipated using other omics (Fig. <xref rid="Fig11" ref-type="fig">11</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). The integration of NPP with STRING leads to increased efficiency of EvORanker (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>), especially for newly annotated genes, and highlights the complementarity of these two datasets. In future studies, we may contemplate incorporating additional datasets into the algorithm, such as mouse and zebrafish knockout data, and other sources for protein-protein interaction networks, by utilizing similar concepts.</p>
    <p id="Par63">We benchmarked our tool using both real patient exome data, in addition to simulated data. The utilization of actual patient data enhances the translational potential of our findings and underscores the clinical relevance of our tool. EvORanker ranked the âtrueâ gene within the top 5 in 95% of the patient-exome dataset. On the other hand, failed to rank the âtrueâ gene within the top 5 for recessive diseases and within the top 10 for dominant diseases in 6/109 exomes. Further investigation revealed that in 3 of those cases (<italic>TBL1XR1</italic>, <italic>NHLRC2</italic>, <italic>ADGRG1</italic>), the HPO terms used as input into the algorithm were both insufficient and non-specific (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). This highlights the importance of precise selection of HPO terms to achieve accurate results. Notably, our results remained consistent across both the real-patient and simulation datasets, further validating the practical utility and effectiveness of our tool in real-world applications.</p>
    <p id="Par64">We applied EvORanker on two unresolved exomes in which previous clinical whole exome sequencing (WES) did not identify a known genetic cause. In the first case (family 1), the <italic>DLGAP2</italic> gene was ranked as the top candidate for a proband with a neurodevelopmental disorder (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>B). <italic>DLGAP2</italic> plays a role in the molecular organization of neuronal synapses and neuronal cell signaling [<xref ref-type="bibr" rid="CR67">67</xref>]. The pathogenicity of the NM_001346810:c.A2702T, p.Glu901Val variant observed in <italic>DLGAP2</italic> was validated by demonstrating its effect on splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). Homozygous knockout mice for <italic>DLGAP2</italic> exhibit novelty-induced hyperactivity, increased aggression, impaired reverse learning, decreased dendritic spine density, and synaptopathy [<xref ref-type="bibr" rid="CR68">68</xref>] providing further support for the association of <italic>DLGAP2</italic> with the patientâs phenotype. Furthermore, <italic>DLGAP2</italic> was hypothesized to be a strong candidate for neurodevelopmental and behavioral phenotypes observed in patients harboring 8p23.2-pter microdeletions including <italic>DLGAP2</italic> and four other genes [<xref ref-type="bibr" rid="CR69">69</xref>]. Notably, our analysis using NPP revealed a group of <italic>DLGAP2</italic>-associated genes not detected by STRING (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>D), providing new avenues for investigating the role of <italic>DLGAP2</italic> in the nervous system.</p>
    <p id="Par65">In the second âunsolvedâ exome, only NPP ranked the <italic>LPCAT3</italic> gene as the top candidate (family 2, Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). This ranking of <italic>LPCAT3</italic> was achieved by the detection of novel functional associations with <italic>phenotype-related genes</italic> based on co-evolution (<italic>PYGL</italic>, <italic>DLD</italic>, <italic>TXNRD2</italic>, <italic>COG8</italic>, <italic>SUCLG1</italic>, <italic>MVK</italic>, <italic>SMAD4</italic>, <italic>CPT1A</italic>) (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>D). These <italic>phenotype-related genes</italic> showed significant coevolution with <italic>LPCAT3</italic> in the clades of <italic>Viridiplantae</italic>, <italic>Eudicotyledons</italic>, <italic>Mammalia</italic>, and <italic>Fungi</italic> (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figs. S11 and S14), pointing towards novel associations not captured by STRING [<xref ref-type="bibr" rid="CR33">33</xref>]. These findings are supported by phenotypic similarities between the patient and liver and intestinal knockout mice [<xref ref-type="bibr" rid="CR70">70</xref>], including failure to thrive, enteropathy, and low levels of triglycerides and high-density lipoprotein. <italic>LPCAT3</italic> nullizygous mice exhibit postnatal death [<xref ref-type="bibr" rid="CR70">70</xref>], making it difficult to study the global effects of <italic>LPCAT3</italic> knockdown. Although a recent report linked <italic>LPCAT3</italic> overexpression to skeletal muscle myopathy [<xref ref-type="bibr" rid="CR71">71</xref>], further research is needed to understand the role and mechanism of <italic>LPCAT3</italic> in this condition. Taken together, these results underscore the potential of clade-based NPP to predict functional associations with phenotype-relevant genes. Further validation in additional patients with variants in these genes is warranted to confirm their roles as novel disease-associated genes. Subsequent functional validation studies are crucial to better understand the mechanisms of disease pathogenesis.</p>
    <p id="Par66">EvORanker is entirely gene-based, making it adaptable to various sequencing experiments and accessible for users with minimal computational knowledge. In addition to providing a ranked gene list, EvORanker offers the ability to explore evolutionary and STRING-based gene networks across multiple clades. A recommended strategy for users is to first examine the ranking of genes based on the OntologySimilarity semantic similarity score [<xref ref-type="bibr" rid="CR51">51</xref>], in the event that one of the candidate genes is already listed in the HPO database. If not, the user can then evaluate the ranking of genes based on the EvORanker score, where a novel association between the gene and input phenotypes may be discovered. The EvORanker server is freely available at <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>, which will be updated on a regular basis. We also created a GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>) [<xref ref-type="bibr" rid="CR65">65</xref>] which allows users to access the tool and input an expanded number of genes.</p>
  </sec>
  <sec id="Sec36">
    <title>Conclusions</title>
    <p id="Par67">In summary, our work introduces EvORanker as a powerful tool in the genomic diagnostic landscape. By integrating multi-scale phylogenetic profiling and STRING-based gene interaction data, EvORanker offers a unique and effective approach to prioritize candidate genes in âunsolvedâ cases identified through whole-exome and whole-genome sequencing. Our validation using real patient exome data and simulation data demonstrates EvORankerâs robust capability to consistently prioritize the âtrueâ gene, showcasing its reliability and translational potential in research applications.</p>
    <p id="Par68">The effectiveness of EvORanker in identifying candidate disease genes, as demonstrated by the identification of <italic>DLGAP2</italic> and <italic>LPCAT3</italic> in previously unresolved cases, highlights its potential to contribute to our understanding of disease mechanisms. Moreover, its adaptability, user-friendly interface, and accessibility without extensive computational expertise make EvORanker a valuable asset for researchers. As we navigate the intricate landscape of rare genetic diseases, EvORanker stands as a promising tool, offering not only a ranked gene list but also insights into STRING-based and evolutionary gene networks across multiple clades. We believe that the adoption of EvORanker will contribute significantly to advancing genomic diagnostics in the pursuit of unraveling the genetic mysteries underlying rare diseases.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <sec id="Sec37">
      <title>Supplementary Information</title>
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="13073_2023_1276_MOESM1_ESM.xlsx">
            <caption>
              <p><bold>Additional file 1: Table S1.</bold> Clinical and Genetic Characteristics of the 109-Patient Exome Dataset. <bold>Table S2.</bold> ClinVar-Simulated Genetic Variants and Associated Phenotypes. <bold>Table S3.</bold> Newly added disease-gene entries in the Human Phenotype Ontology (HPO) database.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="13073_2023_1276_MOESM2_ESM.docx">
            <caption>
              <p><bold>Additional file 2: Figure S1.</bold> Parameter combinations and EvORanker performance. <bold>Figure S2.</bold> The 16 clades used in the phylogenetic profiling-based algorithm. <bold>Figure S3.</bold> Cutoff values and EvORanker performance. <bold>Figure S4.</bold> Distribution of the number of<italic> patient candidate genes</italic> that passed the variant filtering criteria in autosomal and x-linked recessive (red) and dominant (dark blue) cases in the (A) patient exome dataset and the (B) simulated dataset (shuffled three times). <bold>Figure S5.</bold> Contribution of each of the 16 clades to the overall performance of the EvORanker. <bold>Figure S6.</bold> Radar plot showing the ranking of the âtrueâ disease-causing gene (top 1, top 10, or NULL) using EvORanker (red), NPP (golden), and STRING (dark blue). <bold>Figure S7.</bold> Evaluating EvORanker Performance across three independent spike shuffles. <bold>Figure S8.</bold> Performance of NPP versus STRING using the 109-patient exome dataset across the years. <bold>Figure S9.</bold> Comparison of EvORanker and Phenolyzer in identifying true disease gene candidates. <bold>Figure S10.</bold> Radar plot showing the ranking of the âtrueâ disease-causing gene (top 1, top 10, or NULL) using EvORanker (red), PHIVE (golden), and ExomeWalker (blue). <bold>Figure S11.</bold> Distributions of the <italic>HPO-ranked genes</italic>, the co-evolved genes, and STRING-interacting genes with <italic>DLGAP2</italic>. <bold>Figure S12.</bold> Effect of <italic>DLGAP2</italic> p.E901V on splicing. <bold>Figure S13.</bold> Density distributions of the <italic>HPO-ranked genes</italic>, the co-evolved genes, and STRING-interacting genes with <italic>LPCAT3</italic>. <bold>Figure S14.</bold> Clades differentially predict the functional interaction between the <italic>phenotype-related genes</italic> and <italic>LPCAT3</italic>. <bold>Figure S15.</bold> The Phylogenetic profiles of <italic>LPCAT3</italic> and patient HPO-related genes across 1,028 eukaryotes. <bold>Figure S16.</bold> Homepage of the EvoRanker web interface.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisherâs Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Dana Sherill-Rofe and Lara Kamal contributed equally to this work.</p>
    </fn>
    <fn>
      <p>Ephrat Levy-Lahad, Moien Kanaan andÂ Yuval Tabach contributed equally to this work.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>We would like to acknowledge The Carole and Andrew Harper Diversity Program for their support in this research.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authorsâ contributions</title>
    <p>Conceptualization: CC, DSR, YT, MK, PR, and ELL. Algorithm development: CC, IB, DSR, ES, BT, and YT. Web-tool development: CC. Bioinformatics and data analysis: CC and FZ. Exome sequencing and subsequent data analysis for the benchmarking dataset comprising 109 cases, as well as the two âunsolvedâ cases, along with collaboration and communication with clinicians: CC, LK, GR, MK, HK, and MK. In vitro splicing assay: LK, KBA, and IAA. Supervision: YT, ELL, MK, and PR. Manuscript: CC wrote the manuscript with help from YT, DSR, and ELL. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This study was supported by the Israel Science Foundation (grant no. 3797/21) to Yuval Tabach, Ephrat Levy-Lahad, and Paul Renbaum; The Koum Foundation to Ephrat Levy-Lahad and Paul Renbaum; The National Institutes of Health/NIDCD (R01DC011835) to Karen B. Avraham and Moien Kanaan; The Ministry of Innovation, Science and Technology (grant no. 3-17417) to Yuval Tabach.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>All the algorithm-related data files on which the conclusions of the paper rely on are publicly available on GitHub at the following link: <ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link> [<xref ref-type="bibr" rid="CR65">65</xref>].</p>
    <p>The dataset comprising the exome sequencing data of 109 patients at Istishari Arab Hospital in Ramallah, Palestine, is available through Professor Moien Kanaan. It was employed for benchmarking purposes in the current study. However, due to licensing constraints, these data are not publicly accessible. Researchers interested in accessing the dataset may do so upon making a reasonable request. To initiate the request, individuals are required to contact Professor Moien Kanaan directly via email (moien.kanaan@iah.ps). Please note that the process of obtaining access involves a meeting with professor Moien Kanaan, during which the interested party will be required to provide details on how the data will be utilized, secured, and maintained to ensure the privacy and confidentiality of the patients. This may include a discussion on data security measures, protocols for restricting access to authorized personnel, and assurances that the data will not be made available to third parties. The timeline for granting access will be determined on a case-by-case basis, taking into consideration the nature of the request and the required ethical and legal approvals.</p>
    <p>The VCF files for the 300 genomes utilized in the simulation analysis were obtained from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>], accessible at (<ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>) [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par69">The studies involving human participants received ethical approval from the Institutional Review Board (IRB) of the Shaare Zedek Medical Center, Jerusalem, Israel (IRB no. 20/10). All procedures were conducted in accordance with the principles outlined in the Declaration of Helsinki. Prior to their inclusion in the study, written informed consent was obtained from all participants or their parents. Additionally, participants or their parents granted permission to access their medical records. The study was conducted with due consideration of ethical guidelines, ensuring the confidentiality and voluntary participation of all individuals involved.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par70">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par71">The authors declare that they have no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bamshad</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Nickerson</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Chong</surname>
            <given-names>JX</given-names>
          </name>
        </person-group>
        <article-title>Mendelian gene discovery: fast and furious with no end in sight</article-title>
        <source>Am J Hum Genet</source>
        <year>2019</year>
        <volume>105</volume>
        <fpage>448</fpage>
        <lpage>455</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2019.07.011</pub-id>
        <?supplied-pmid 31491408?>
        <pub-id pub-id-type="pmid">31491408</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <mixed-citation publication-type="other">Online Mendelian Inheritance in Man, OMIMÂ®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). 2023. <ext-link ext-link-type="uri" xlink:href="https://omim.org/">https://omim.org/</ext-link>. Accessed 18 Sept 2023.</mixed-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Oellrich</surname>
            <given-names>A</given-names>
          </name>
          <collab>Project SMG</collab>
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Mungall</surname>
            <given-names>CJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Improved exome prioritization of disease genes through cross-species phenotype comparison</article-title>
        <source>Genome Res</source>
        <year>2014</year>
        <volume>24</volume>
        <fpage>340</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.160325.113</pub-id>
        <?supplied-pmid 24162188?>
        <pub-id pub-id-type="pmid">24162188</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Davydov</surname>
            <given-names>EV</given-names>
          </name>
          <name>
            <surname>Goode</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Sirota</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cooper</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Sidow</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Batzoglou</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Identifying a high fraction of the human genome to be under selective constraint using GERP++</article-title>
        <source>PLoS Comput Biol</source>
        <year>2010</year>
        <volume>6</volume>
        <fpage>e1001025</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1001025</pub-id>
        <?supplied-pmid 21152010?>
        <pub-id pub-id-type="pmid">21152010</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Adzhubei</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Jordan</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Sunyaev</surname>
            <given-names>SR</given-names>
          </name>
        </person-group>
        <article-title>Predicting functional effect of human missense mutations using PolyPhen-2</article-title>
        <source>Curr Protoc Hum Genet</source>
        <year>2013</year>
        <volume>Chapter 7</volume>
        <fpage>Unit7.20</fpage>
        <?supplied-pmid 23315928?>
        <pub-id pub-id-type="pmid">23315928</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ioannidis</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Rothstein</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Pejaver</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Middha</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McDonnell</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Baheti</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>REVEL: an ensemble method for predicting the pathogenicity of rare missense variants</article-title>
        <source>Am J Hum Genet</source>
        <year>2016</year>
        <volume>99</volume>
        <fpage>877</fpage>
        <lpage>885</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.08.016</pub-id>
        <?supplied-pmid 27666373?>
        <pub-id pub-id-type="pmid">27666373</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Labes</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wagner</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Lotem</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lahad</surname>
            <given-names>EL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Machine-learning of complex evolutionary signals improves classification of SNVs</article-title>
        <source>NAR Genomics Bioinform</source>
        <year>2022</year>
        <volume>4</volume>
        <fpage>lqac025</fpage>
        <pub-id pub-id-type="doi">10.1093/nargab/lqac025</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Smedley</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Czeschik</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Amberger</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bocchini</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hamosh</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Walking the interactome for candidate prioritization in exome sequencing studies of Mendelian diseases</article-title>
        <source>Bioinformatics Oxf Engl</source>
        <year>2014</year>
        <volume>30</volume>
        <fpage>3215</fpage>
        <lpage>3222</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu508</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zemojtel</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mackenroth</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>JÃ¤ger</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hecht</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Krawitz</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome</article-title>
        <source>Sci Transl Med</source>
        <year>2014</year>
        <volume>6</volume>
        <fpage>252ra123</fpage>
        <pub-id pub-id-type="doi">10.1126/scitranslmed.3009262</pub-id>
        <?supplied-pmid 25186178?>
        <pub-id pub-id-type="pmid">25186178</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tranchevent</surname>
            <given-names>L-C</given-names>
          </name>
          <name>
            <surname>Ardeshirdavani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>ElShal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Alcaide</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Aerts</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Auboeuf</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Candidate gene prioritization with Endeavour</article-title>
        <source>Nucleic Acids Res</source>
        <year>2016</year>
        <volume>44</volume>
        <fpage>W117</fpage>
        <lpage>121</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkw365</pub-id>
        <?supplied-pmid 27131783?>
        <pub-id pub-id-type="pmid">27131783</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <mixed-citation publication-type="other">Zolotareva O, Kleine M. A Survey of gene prioritization tools for Mendelian and complex human diseases. J Integr Bioinform. 2019;16:/j/jib.2019.16.issue-4/jib-2018-0069/jib-2018-0069.xml.</mixed-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Birgmeier</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Haeussler</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Deisseroth</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Steinberg</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Jagadeesh</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Ratner</surname>
            <given-names>AJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>AMELIE speeds Mendelian diagnosis by matching patient phenotype and genotype to primary literature</article-title>
        <source>Sci Transl Med</source>
        <year>2020</year>
        <volume>12</volume>
        <fpage>eaau9113</fpage>
        <pub-id pub-id-type="doi">10.1126/scitranslmed.aau9113</pub-id>
        <?supplied-pmid 32434849?>
        <pub-id pub-id-type="pmid">32434849</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Torkamani</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Artificial intelligence in clinical and genomic diagnostics</article-title>
        <source>Genome Med</source>
        <year>2019</year>
        <volume>11</volume>
        <fpage>70</fpage>
        <pub-id pub-id-type="doi">10.1186/s13073-019-0689-8</pub-id>
        <?supplied-pmid 31744524?>
        <pub-id pub-id-type="pmid">31744524</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>De La Vega</surname>
            <given-names>FM</given-names>
          </name>
          <name>
            <surname>Chowdhury</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Frise</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>McCarthy</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hernandez</surname>
            <given-names>EJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases</article-title>
        <source>Genome Med</source>
        <year>2021</year>
        <volume>13</volume>
        <fpage>153</fpage>
        <pub-id pub-id-type="doi">10.1186/s13073-021-00965-0</pub-id>
        <?supplied-pmid 34645491?>
        <pub-id pub-id-type="pmid">34645491</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pellegrini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Marcotte</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Eisenberg</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Yeates</surname>
            <given-names>TO</given-names>
          </name>
        </person-group>
        <article-title>Assigning protein functions by comparative genome analysis: protein phylogenetic profiles</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>1999</year>
        <volume>96</volume>
        <fpage>4285</fpage>
        <lpage>4288</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.96.8.4285</pub-id>
        <?supplied-pmid 10200254?>
        <pub-id pub-id-type="pmid">10200254</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Enault</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Suhre</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Poirot</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Abergel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Claverie</surname>
            <given-names>J-M</given-names>
          </name>
        </person-group>
        <article-title>Phydbac2: improved inference of gene function using interactive phylogenomic profiling and chromosomal location analysis</article-title>
        <source>Nucleic Acids Res</source>
        <year>2004</year>
        <volume>32</volume>
        <fpage>W336</fpage>
        <lpage>339</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkh365</pub-id>
        <?supplied-pmid 15215406?>
        <pub-id pub-id-type="pmid">15215406</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Subramaniam</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Locally defined protein phylogenetic profiles reveal previously missed protein interactions and functional relationships</article-title>
        <source>Proteins</source>
        <year>2006</year>
        <volume>62</volume>
        <fpage>1115</fpage>
        <lpage>1124</lpage>
        <pub-id pub-id-type="doi">10.1002/prot.20830</pub-id>
        <?supplied-pmid 16385560?>
        <pub-id pub-id-type="pmid">16385560</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eisen</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic analysis and gene functional predictions: phylogenomics in action</article-title>
        <source>Theor Popul Biol</source>
        <year>2002</year>
        <volume>61</volume>
        <fpage>481</fpage>
        <lpage>487</lpage>
        <pub-id pub-id-type="doi">10.1006/tpbi.2002.1594</pub-id>
        <?supplied-pmid 12167367?>
        <pub-id pub-id-type="pmid">12167367</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Protein function predictions based on the phylogenetic profile method</article-title>
        <source>Crit Rev Biotechnol</source>
        <year>2008</year>
        <volume>28</volume>
        <fpage>233</fpage>
        <lpage>238</lpage>
        <pub-id pub-id-type="doi">10.1080/07388550802512633</pub-id>
        <?supplied-pmid 19051102?>
        <pub-id pub-id-type="pmid">19051102</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dey</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic profiling for probing the modular architecture of the human genome</article-title>
        <source>Cell Syst</source>
        <year>2015</year>
        <volume>1</volume>
        <fpage>106</fpage>
        <lpage>115</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cels.2015.08.006</pub-id>
        <?supplied-pmid 27135799?>
        <pub-id pub-id-type="pmid">27135799</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Billi</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Hayes</surname>
            <given-names>GD</given-names>
          </name>
          <name>
            <surname>Newman</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Zuk</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Gabel</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of small RNA pathway genes using patterns of phylogenetic conservation and divergence</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>493</volume>
        <fpage>694</fpage>
        <lpage>698</lpage>
        <pub-id pub-id-type="doi">10.1038/nature11779</pub-id>
        <?supplied-pmid 23364702?>
        <pub-id pub-id-type="pmid">23364702</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Golan</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>HernÃ¡ndez-HernÃ¡ndez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Messer</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Fukuda</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kouznetsova</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Human disease locus discovery and mapping to molecular pathways through phylogenetic profiling</article-title>
        <source>Mol Syst Biol</source>
        <year>2013</year>
        <volume>9</volume>
        <fpage>692</fpage>
        <pub-id pub-id-type="doi">10.1038/msb.2013.50</pub-id>
        <?supplied-pmid 24084807?>
        <pub-id pub-id-type="pmid">24084807</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dey</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Jaimovich</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Seki</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Systematic discovery of human gene function and principles of modular organization through phylogenetic profiling</article-title>
        <source>Cell Rep</source>
        <year>2015</year>
        <volume>10</volume>
        <fpage>993</fpage>
        <lpage>1006</lpage>
        <pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.025</pub-id>
        <?supplied-pmid 25683721?>
        <pub-id pub-id-type="pmid">25683721</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tsaban</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sherill-Rofe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Schueler-Furman</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CladeOScope: functional interactions through the prism of clade-wise co-evolution</article-title>
        <source>NAR Genomics Bioinform</source>
        <year>2021</year>
        <volume>3</volume>
        <fpage>lqab024</fpage>
        <pub-id pub-id-type="doi">10.1093/nargab/lqab024</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Omar</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Guterman-Ram</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Berger</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Levaot</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Schlafen2 mutation in mice causes an osteopetrotic phenotype due to a decrease in the number of osteoclast progenitors</article-title>
        <source>Sci Rep</source>
        <year>2018</year>
        <volume>8</volume>
        <fpage>13005</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-018-31428-z</pub-id>
        <?supplied-pmid 30158544?>
        <pub-id pub-id-type="pmid">30158544</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Arkadir</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lossos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Abu Snineh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Schueler-Furman</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Nitschke</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MYORG is associated with recessive primary familial brain calcification</article-title>
        <source>Ann Clin Transl Neurol</source>
        <year>2019</year>
        <volume>6</volume>
        <fpage>106</fpage>
        <lpage>113</lpage>
        <pub-id pub-id-type="doi">10.1002/acn3.684</pub-id>
        <?supplied-pmid 30656188?>
        <pub-id pub-id-type="pmid">30656188</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Date</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Marcotte</surname>
            <given-names>EM</given-names>
          </name>
        </person-group>
        <article-title>Discovery of uncharacterized cellular systems by genome-wide analysis of functional linkages</article-title>
        <source>Nat Biotechnol</source>
        <year>2003</year>
        <volume>21</volume>
        <fpage>1055</fpage>
        <lpage>1062</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt861</pub-id>
        <?supplied-pmid 12923548?>
        <pub-id pub-id-type="pmid">12923548</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Allen-Vercoe</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Beiko</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic clustering of genes reveals shared evolutionary trajectories and putative gene functions</article-title>
        <source>Genome Biol Evol</source>
        <year>2018</year>
        <volume>10</volume>
        <fpage>2255</fpage>
        <lpage>2265</lpage>
        <pub-id pub-id-type="doi">10.1093/gbe/evy178</pub-id>
        <?supplied-pmid 30137329?>
        <pub-id pub-id-type="pmid">30137329</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sherill-Rofe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Findlay</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mellul</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Guberman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Braun</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes</article-title>
        <source>Genome Res</source>
        <year>2019</year>
        <volume>29</volume>
        <fpage>439</fpage>
        <lpage>448</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.241414.118</pub-id>
        <?supplied-pmid 30718334?>
        <pub-id pub-id-type="pmid">30718334</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Zitnik</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zuk</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Co-evolution based machine-learning for predicting functional interactions between human genes</article-title>
        <source>Nat Commun</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>6454</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-021-26792-w</pub-id>
        <?supplied-pmid 34753957?>
        <pub-id pub-id-type="pmid">34753957</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Unterman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Cazacu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kazimirsky</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ben-Zeev</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Berman</surname>
            <given-names>BP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome</article-title>
        <source>eLife</source>
        <year>2021</year>
        <volume>10</volume>
        <fpage>e67085</fpage>
        <pub-id pub-id-type="doi">10.7554/eLife.67085</pub-id>
        <?supplied-pmid 34355696?>
        <pub-id pub-id-type="pmid">34355696</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Braun</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Unterman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shtern</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Benenson</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ACE2 co-evolutionary pattern suggests targets for pharmaceutical intervention in the COVID-19 pandemic</article-title>
        <source>iScience</source>
        <year>2020</year>
        <volume>23</volume>
        <fpage>101384</fpage>
        <pub-id pub-id-type="doi">10.1016/j.isci.2020.101384</pub-id>
        <?supplied-pmid 32738617?>
        <pub-id pub-id-type="pmid">32738617</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gable</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Lyon</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Junge</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wyder</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Huerta-Cepas</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>STRING v11: proteinâprotein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title>
        <source>Nucleic Acids Res</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>D607</fpage>
        <lpage>D613</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id>
        <?supplied-pmid 30476243?>
        <pub-id pub-id-type="pmid">30476243</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yue</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Breschi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Vierstra</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Ryba</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A comparative encyclopedia of DNA elements in the mouse genome</article-title>
        <source>Nature</source>
        <year>2014</year>
        <volume>515</volume>
        <fpage>355</fpage>
        <lpage>364</lpage>
        <pub-id pub-id-type="doi">10.1038/nature13992</pub-id>
        <?supplied-pmid 25409824?>
        <pub-id pub-id-type="pmid">25409824</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Canavati</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Afawi</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Pendziwiat</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Abu Rayyan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kamal</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Inclusion of hemimegalencephaly into the phenotypic spectrum of NPRL3 pathogenic variants in familial focal epilepsy with variable foci</article-title>
        <source>Epilepsia</source>
        <year>2019</year>
        <volume>60</volume>
        <fpage>e67</fpage>
        <lpage>73</lpage>
        <pub-id pub-id-type="doi">10.1111/epi.15665</pub-id>
        <?supplied-pmid 31111464?>
        <pub-id pub-id-type="pmid">31111464</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kamal</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Pierce</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Canavati</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rayyan</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Jaraysa</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lobel</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities</article-title>
        <source>Cold Spring Harb Mol Case Stud</source>
        <year>2020</year>
        <volume>6</volume>
        <fpage>a005652</fpage>
        <pub-id pub-id-type="doi">10.1101/mcs.a005652</pub-id>
        <?supplied-pmid 33028645?>
        <pub-id pub-id-type="pmid">33028645</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Elson</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stein</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rabie</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Barnea-Zohar</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Winograd-Katz</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Reuven</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Sorting Nexin 10 as a key regulator of membrane trafficking in bone-resorbing osteoclasts: lessons learned from osteopetrosis</article-title>
        <source>Front Cell Dev Biol</source>
        <year>2021</year>
        <volume>9</volume>
        <fpage>671210</fpage>
        <pub-id pub-id-type="doi">10.3389/fcell.2021.671210</pub-id>
        <?supplied-pmid 34095139?>
        <pub-id pub-id-type="pmid">34095139</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Landrum</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Benson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Chao</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chitipiralla</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ClinVar: improving access to variant interpretations and supporting evidence</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1062</fpage>
        <lpage>D1067</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1153</pub-id>
        <?supplied-pmid 29165669?>
        <pub-id pub-id-type="pmid">29165669</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <mixed-citation publication-type="other">The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68â74.</mixed-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <mixed-citation publication-type="other">1000 Genomes Project. Data Release 20100804. <ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>. Accessed 23 Aug 2023.</mixed-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hakonarson</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>
        <source>Nucleic Acids Res</source>
        <year>2010</year>
        <volume>38</volume>
        <fpage>e164</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq603</pub-id>
        <?supplied-pmid 20601685?>
        <pub-id pub-id-type="pmid">20601685</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <mixed-citation publication-type="other">Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genome-wide mutational constraint map quantified from variation in 76,156 human genomes. Genetics. 2022. Available from: <ext-link ext-link-type="uri" xlink:href="http://biorxiv.org/lookup/doi/10.1101/2022.03.20.485034">http://biorxiv.org/lookup/doi/10.1101/2022.03.20.485034</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jian</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Boerwinkle</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>In silico prediction of splice-altering single nucleotide variants in the human genome</article-title>
        <source>Nucleic Acids Res</source>
        <year>2014</year>
        <volume>42</volume>
        <fpage>13534</fpage>
        <lpage>13544</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku1206</pub-id>
        <?supplied-pmid 25416802?>
        <pub-id pub-id-type="pmid">25416802</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jaganathan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Panagiotopoulou</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>McRae</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Darbandi</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Knowles</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>YI</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Predicting splicing from primary sequence with deep learning</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>176</volume>
        <fpage>535</fpage>
        <lpage>548.e24</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2018.12.015</pub-id>
        <?supplied-pmid 30661751?>
        <pub-id pub-id-type="pmid">30661751</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ng</surname>
            <given-names>PC</given-names>
          </name>
          <name>
            <surname>Henikoff</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>SIFT: predicting amino acid changes that affect protein function</article-title>
        <source>Nucleic Acids Res</source>
        <year>2003</year>
        <volume>31</volume>
        <fpage>3812</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkg509</pub-id>
        <?supplied-pmid 12824425?>
        <pub-id pub-id-type="pmid">12824425</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gargano</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Matentzoglu</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Carmody</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Lewis-Smith</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Vasilevsky</surname>
            <given-names>NA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The human phenotype ontology in 2021</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D1207</fpage>
        <lpage>D1217</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1043</pub-id>
        <?supplied-pmid 33264411?>
        <pub-id pub-id-type="pmid">33264411</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <mixed-citation publication-type="other">Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1303.3997">http://arxiv.org/abs/1303.3997</ext-link>. Cited 2022 Sep 15.</mixed-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McKenna</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hanna</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Banks</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sivachenko</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cibulskis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kernytsky</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>
        <source>Genome Res</source>
        <year>2010</year>
        <volume>20</volume>
        <fpage>1297</fpage>
        <lpage>1303</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id>
        <?supplied-pmid 20644199?>
        <pub-id pub-id-type="pmid">20644199</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>FADO</given-names>
          </name>
          <name>
            <surname>de Andrade</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Palmero</surname>
            <given-names>EI</given-names>
          </name>
        </person-group>
        <article-title>Insights on variant analysis in silico tools for pathogenicity prediction</article-title>
        <source>Front Genet</source>
        <year>2022</year>
        <volume>13</volume>
        <fpage>1010327</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2022.1010327</pub-id>
        <?supplied-pmid 36568376?>
        <pub-id pub-id-type="pmid">36568376</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fromer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Purcell</surname>
            <given-names>SM</given-names>
          </name>
        </person-group>
        <article-title>Using XHMM software to detect copy number variation in whole-exome sequencing data</article-title>
        <source>Curr Protoc Hum Genet Editor Board Jonathan Haines Al</source>
        <year>2014</year>
        <volume>81</volume>
        <fpage>7.23.1</fpage>
        <lpage>7.23.21</lpage>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Greene</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Turro</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>ontologyX: a suite of R packages for working with ontological data</article-title>
        <source>Bioinformatics</source>
        <year>2017</year>
        <volume>33</volume>
        <fpage>1104</fpage>
        <lpage>1106</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btw763</pub-id>
        <?supplied-pmid 28062448?>
        <pub-id pub-id-type="pmid">28062448</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>SchrÃ¶er</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Trenkler</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Exact and randomization distributions of Kolmogorov-Smirnov tests two or three samples</article-title>
        <source>Comput Stat Data Anal</source>
        <year>1995</year>
        <volume>20</volume>
        <fpage>185</fpage>
        <lpage>202</lpage>
        <pub-id pub-id-type="doi">10.1016/0167-9473(94)00040-P</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>R Core Team</collab>
        </person-group>
        <source>R: a language and environment for statistical computing</source>
        <year>2022</year>
        <publisher-loc>Vienna</publisher-loc>
        <publisher-name>R Foundation for Statistical Computing</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Fisher</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <source>Statistical methods for research workers</source>
        <year>1925</year>
        <publisher-loc>Edinburgh</publisher-loc>
        <publisher-name>Oliver and Boyd</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mosteller</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Fisher</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Questions and answers</article-title>
        <source>Am Stat</source>
        <year>1948</year>
        <volume>2</volume>
        <fpage>30</fpage>
        <lpage>31</lpage>
        <pub-id pub-id-type="doi">10.1080/00031305.1948.10483415</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>SchrÃ¶der</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Culhane</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Quackenbush</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Haibe-Kains</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>survcomp: an R/Bioconductor package for performance assessment and comparison of survival models</article-title>
        <source>Bioinformatics</source>
        <year>2011</year>
        <volume>27</volume>
        <fpage>3206</fpage>
        <lpage>3208</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btr511</pub-id>
        <?supplied-pmid 21903630?>
        <pub-id pub-id-type="pmid">21903630</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Blake</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Baldarelli</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kadin</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Bult</surname>
            <given-names>CJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mouse Genome Database (MGD): knowledgebase for mouse-human comparative biology</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D981</fpage>
        <lpage>D987</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1083</pub-id>
        <?supplied-pmid 33231642?>
        <pub-id pub-id-type="pmid">33231642</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <mixed-citation publication-type="other">OBO Phenotype Ontology. HPO to MP best matches. 2023. <ext-link ext-link-type="uri" xlink:href="https://github.com/obophenotype/upheno/blob/master/mappings/hp-to-mp-bestmatches.tsv">https://github.com/obophenotype/upheno/blob/master/mappings/hp-to-mp-bestmatches.tsv</ext-link>. Accessed 15 Feb 2023.</mixed-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Phenolyzer: phenotype-based prioritization of candidate genes for human diseases</article-title>
        <source>Nat Methods</source>
        <year>2015</year>
        <volume>12</volume>
        <fpage>841</fpage>
        <lpage>843</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth.3484</pub-id>
        <?supplied-pmid 26192085?>
        <pub-id pub-id-type="pmid">26192085</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Booth</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Azaiez</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kahrizi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Frees</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Exonic mutations and exon skipping: lessons learned from DFNA5</article-title>
        <source>Hum Mutat</source>
        <year>2018</year>
        <volume>39</volume>
        <fpage>433</fpage>
        <lpage>440</lpage>
        <pub-id pub-id-type="doi">10.1002/humu.23384</pub-id>
        <?supplied-pmid 29266521?>
        <pub-id pub-id-type="pmid">29266521</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hirsch</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tangshewinsirikul</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Booth</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Azaiez</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Yefet</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Quint</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A synonymous variant in MYO15A enriched in the Ashkenazi Jewish population causes autosomal recessive hearing loss due to abnormal splicing</article-title>
        <source>Eur J Hum Genet</source>
        <year>2021</year>
        <volume>29</volume>
        <fpage>988</fpage>
        <lpage>997</lpage>
        <pub-id pub-id-type="doi">10.1038/s41431-020-00790-w</pub-id>
        <?supplied-pmid 33398081?>
        <pub-id pub-id-type="pmid">33398081</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <mixed-citation publication-type="other">Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, Allen J, et al. shiny: web application framework for R. R package version 1.8.0.9000. 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://github.com/rstudio/shiny">https://github.com/rstudio/shiny</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://shiny.posit.co/">https://shiny.posit.co/</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shannon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Markiel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ozier</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Baliga</surname>
            <given-names>NS</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Ramage</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>
        <source>Genome Res</source>
        <year>2003</year>
        <volume>13</volume>
        <fpage>2498</fpage>
        <lpage>2504</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
        <?supplied-pmid 14597658?>
        <pub-id pub-id-type="pmid">14597658</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Franceschini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Frankild</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kuhn</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Simonovic</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Roth</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>STRING v9.1: protein-protein interaction networks, with increased coverage and integration</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>D808</fpage>
        <lpage>15</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks1094</pub-id>
        <?supplied-pmid 23203871?>
        <pub-id pub-id-type="pmid">23203871</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <mixed-citation publication-type="other">Canavati C. EvoRanker: a phylogenetic profiling-based algorithm for prioritizing candidate genes. 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Findlay</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Heath</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>VM</given-names>
          </name>
          <name>
            <surname>Malina</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Morin</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Coulombe</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice</article-title>
        <source>EMBO J</source>
        <year>2018</year>
        <volume>37</volume>
        <fpage>e100158</fpage>
        <pub-id pub-id-type="doi">10.15252/embj.2018100158</pub-id>
        <?supplied-pmid 30154076?>
        <pub-id pub-id-type="pmid">30154076</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rasmussen</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Rasmussen</surname>
            <given-names>HB</given-names>
          </name>
          <name>
            <surname>Silahtaroglu</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>The DLGAP family: neuronal expression, function and role in brain disorders</article-title>
        <source>Mol Brain</source>
        <year>2017</year>
        <volume>10</volume>
        <fpage>43</fpage>
        <pub-id pub-id-type="doi">10.1186/s13041-017-0324-9</pub-id>
        <?supplied-pmid 28870203?>
        <pub-id pub-id-type="pmid">28870203</pub-id>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Norris</surname>
            <given-names>RH</given-names>
          </name>
          <name>
            <surname>Gordon</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Nithianantharajah</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Neurodevelopmental synaptopathies: Insights from behaviour in rodent models of synapse gene mutations</article-title>
        <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
        <year>2018</year>
        <volume>84</volume>
        <fpage>424</fpage>
        <lpage>439</lpage>
        <pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.12.001</pub-id>
        <?supplied-pmid 29217145?>
        <pub-id pub-id-type="pmid">29217145</pub-id>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Catusi</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Garzo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Capra</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Briuglia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Baldo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Canevini</surname>
            <given-names>MP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>8p23.2-pter microdeletions: seven new cases narrowing the candidate region and review of the literature</article-title>
        <source>Genes</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>652</fpage>
        <pub-id pub-id-type="doi">10.3390/genes12050652</pub-id>
        <?supplied-pmid 33925474?>
        <pub-id pub-id-type="pmid">33925474</pub-id>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <mixed-citation publication-type="other">Rong X, Wang B, Dunham MM, Hedde PN, Wong JS, Gratton E, et al. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. eLife. 2015;4:e06557.</mixed-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ferrara</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Verkerke</surname>
            <given-names>ARP</given-names>
          </name>
          <name>
            <surname>Maschek</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Shahtout</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Siripoksup</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Eshima</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Low lysophosphatidylcholine induces skeletal muscle myopathy that is aggravated by high-fat diet feeding</article-title>
        <source>FASEB J Off Publ Fed Am Soc Exp Biol</source>
        <year>2021</year>
        <volume>35</volume>
        <fpage>e21867</fpage>
      </element-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Genome Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">Genome Med</journal-id>
    <journal-title-group>
      <journal-title>Genome Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1756-994X</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10765705</article-id>
    <article-id pub-id-type="publisher-id">1276</article-id>
    <article-id pub-id-type="doi">10.1186/s13073-023-01276-2</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Using multi-scale genomics to associate poorly annotated genes with rare diseases</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Canavati</surname>
          <given-names>Christina</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Sherill-Rofe</surname>
          <given-names>Dana</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Kamal</surname>
          <given-names>Lara</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bloch</surname>
          <given-names>Idit</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zahdeh</surname>
          <given-names>Fouad</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sharon</surname>
          <given-names>Elad</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Terespolsky</surname>
          <given-names>Batel</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Allan</surname>
          <given-names>Islam Abu</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rabie</surname>
          <given-names>Grace</given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kawas</surname>
          <given-names>Mariana</given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kassem</surname>
          <given-names>Hanin</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Avraham</surname>
          <given-names>Karen B.</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Renbaum</surname>
          <given-names>Paul</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Levy-Lahad</surname>
          <given-names>Ephrat</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Kanaan</surname>
          <given-names>Moien</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9521-3217</contrib-id>
        <name>
          <surname>Tabach</surname>
          <given-names>Yuval</given-names>
        </name>
        <address>
          <email>yuval.tabach@mail.huji.ac.il</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qxff017</institution-id><institution-id institution-id-type="GRID">grid.9619.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0538</institution-id><institution>Department of Developmental Biology and Cancer Research, </institution><institution>Institute of Medical Research - Israel-Canada, The Hebrew University of Jerusalem, </institution></institution-wrap>Jerusalem, 9112102 Israel </aff>
      <aff id="Aff2"><label>2</label>Molecular Genetics Lab, Istishari Arab Hospital, Ramallah, Palestine </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04mhzgx49</institution-id><institution-id institution-id-type="GRID">grid.12136.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0546</institution-id><institution>Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine and Sagol School of Neuroscience, </institution><institution>Tel Aviv University, </institution></institution-wrap>Tel Aviv, 6997801 Israel </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03zpnb459</institution-id><institution-id institution-id-type="GRID">grid.414505.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0631 3825</institution-id><institution>Medical Genetics Institute, Shaare Zedek Medical Center, </institution></institution-wrap>Jerusalem, 91031 Israel </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qxff017</institution-id><institution-id institution-id-type="GRID">grid.9619.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0538</institution-id><institution>Faculty of Medicine, </institution><institution>The Hebrew University of Jerusalem, </institution></institution-wrap>Jerusalem, 9112102 Israel </aff>
      <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047cjg072</institution-id><institution-id institution-id-type="GRID">grid.440580.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 1016 7793</institution-id><institution>Hereditary Research Laboratory and Department of Life Sciences, </institution><institution>Bethlehem University, </institution></institution-wrap>Bethlehem, 72372 Palestine </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>4</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>4</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2024</year>
    </pub-date>
    <volume>16</volume>
    <elocation-id>4</elocation-id>
    <history>
      <date date-type="received">
        <day>29</day>
        <month>4</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>12</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© The Author(s) 2023</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Next-generation sequencing (NGS) has significantly transformed the landscape of identifying disease-causing genes associated with genetic disorders. However, a substantial portion of sequenced patients remains undiagnosed. This may be attributed not only to the challenges posed by harder-to-detect variants, such as non-coding and structural variations but also to the existence of variants in genes not previously associated with the patientâs clinical phenotype. This study introduces EvORanker, an algorithm that integrates unbiased data from 1,028 eukaryotic genomes to link mutated genes to clinical phenotypes.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p id="Par2">EvORanker utilizes clinical data, multi-scale phylogenetic profiling, and other omics data to prioritize disease-associated genes. It was evaluated on solved exomes and simulated genomes, compared with existing methods, and applied to 6260 knockout genes with mouse phenotypes lacking human associations. Additionally, EvORanker was made accessible as a user-friendly web tool.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par3">In the analyzed exomic cohort, EvORanker accurately identified the âtrueâ disease gene as the top candidate in 69% of cases and within the top 5 candidates in 95% of cases, consistent with results from the simulated dataset. Notably, EvORanker outperformed existing methods, particularly for poorly annotated genes. In the case of the 6260 knockout genes with mouse phenotypes, EvORanker linked 41% of these genes to observed human disease phenotypes. Furthermore, in two unsolved cases, EvORanker successfully identified <italic>DLGAP2</italic> and <italic>LPCAT3</italic> as disease candidates for previously uncharacterized genetic syndromes.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p id="Par4">We highlight clade-based phylogenetic profiling as a powerful systematic approach for prioritizing potential disease genes. Our study showcases the efficacy of EvORanker in associating poorly annotated genes to disease phenotypes observed in patients. The EvORanker server is freely available at <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>.</p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1186/s13073-023-01276-2.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>EvORanker</kwd>
      <kwd>Gene-based prioritization</kwd>
      <kwd>
        <italic>DLGAP2</italic>
      </kwd>
      <kwd>
        <italic>LPCAT3</italic>
      </kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id>
            <institution>Israel Science Foundation</institution>
          </institution-wrap>
        </funding-source>
        <award-id>3797/21</award-id>
        <principal-award-recipient>
          <name>
            <surname>Tabach</surname>
            <given-names>Yuval</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Koum Foundation</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution> National Institutes of Health/NIDCD</institution>
        </funding-source>
        <award-id>R01DC011835</award-id>
        <principal-award-recipient>
          <name>
            <surname>Kanaan</surname>
            <given-names>Moien</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>Â© BioMed Central Ltd., part of Springer Nature 2024</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par5">The study of Mendelian disorders remains a gold standard for understanding gene function and linking a gene to a particular phenotype [<xref ref-type="bibr" rid="CR1">1</xref>]. Next-generation sequencing technologies (NGS) have revolutionized disease-gene discovery; however, most human genes are yet to be associated with a specific phenotype: Out of ~20,000 human genes, only 4900 genes have an associated phenotype in Online Mendelian Inheritance in Man (OMIM) (as of January 22, 2023) [<xref ref-type="bibr" rid="CR2">2</xref>]. Analyses of evolutionary constraints of human genes and models from mouse genetics suggest that the genetic basis of at least 10,000 Mendelian disorders awaits discovery [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p id="Par6">A typical human whole-exome sequencing (WES) or whole-genome sequencing (WGS) study yields thousands of single nucleotide variants, indels, and copy number variants [<xref ref-type="bibr" rid="CR3">3</xref>]. After filtering out frequent variants, a handful of in silico methods are used to estimate the pathogenicity of the variants. These estimates are based on evolutionary conservation, genomic position, structural features, and predicted function (e.g., impact on regulatory, splicing, or protein level) [<xref ref-type="bibr" rid="CR4">4</xref>â<xref ref-type="bibr" rid="CR7">7</xref>]. However, prioritizing variants solely based on predicted pathogenicity and rarity may not lead to identifying the underlying disease-causing gene. Hence, numerous gene-based computational methods have been developed to prioritize candidate genes contributing to the patientâs disease phenotypes. These methods incorporate patientsâ phenotypic information and omics datasets such as protein-protein interaction, co-expression analysis, cross-species phenotypic similarity analysis, and primary literature in order to provide users with further hints about genes that merit further investigation [<xref ref-type="bibr" rid="CR8">8</xref>â<xref ref-type="bibr" rid="CR12">12</xref>]. Recent approaches incorporate artificial intelligence for candidate gene diagnosis [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Nevertheless, the majority of these approaches depend on existing data and as such work well on studied genes (i.e., the rich get richer phenomenon). However, for poorly annotated genes, their performance may decline. Within the scope of this research, poorly annotated genes are defined as those lacking associations with specific phenotypes in the OMIM database [<xref ref-type="bibr" rid="CR2">2</xref>]. This absence of phenotype correlations underscores a scarcity of available data pertaining to their characteristics, ontology, and interactions [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    <p id="Par7">One unbiased approach that can infer novel gene function is phylogenetic profiling (PP) [<xref ref-type="bibr" rid="CR15">15</xref>]. PP identifies functionally related genes and protein-protein interactions using comparative genomics [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The phylogenetic profile of a gene describes the pattern of conservation of its orthologs in a set of genomes [<xref ref-type="bibr" rid="CR15">15</xref>]. Those patterns of conservation of protein sequences along evolution reflect protein function [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], interaction with other proteins [<xref ref-type="bibr" rid="CR17">17</xref>], and the crosstalk between the organism and the environment [<xref ref-type="bibr" rid="CR20">20</xref>]. PP relies on the well-established hypothesis that if two or more genes share a similar phylogenetic profile, then they may be functionally related [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>â<xref ref-type="bibr" rid="CR23">23</xref>]. This can further be implemented to annotate uncharacterized genes to a putative function based on the similarity of their PP with those of well-annotated genes [<xref ref-type="bibr" rid="CR24">24</xref>]. Previous studies using PP have succeeded in identifying new functional gene associations, novel disease-causing genes, and new pathway components [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p>
    <p id="Par8">The phylogenetic profile of a gene was originally described as a binary representation of the presence or absence of its orthologs across eukaryotic species [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. However, applying a binary representation to eukaryotes might not fully address the intricacy of eukaryotic protein evolution. Across the tree of life, the sequence similarity between two orthologs is a complex function of their evolutionary distance and the variable selective pressures forced upon them. Therefore, several methods such as normalized phylogenetic profiling (NPP) have been developed [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. NPP uses a continuous metric of conservation, offering an alternative to the binary scoring system. NPP has successfully revealed novel genes in various pathways and human genetic diseases including cancer [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Recently, we found that functionally-related genes can show a strong signal of correlated evolution within specific clades (e.g., animals, mammals, plants, fungi) or segments of the tree of life. These local co-evolution signals better reflect the complexity of pathways and protein evolution. Analyzing correlated evolution among genes both across and in part of the tree of life hence improves our ability to reveal the function of genes in different pathways [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. This âclade-wiseâ NPP approach was used to identify novel DNA repair genes [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and to map potential drugs for <italic>MECP2</italic> [<xref ref-type="bibr" rid="CR31">31</xref>] and <italic>ACE2</italic>-associated disorders [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
    <p id="Par9">In this study, we introduce a gene-prioritization tool, EvORanker (Ev: Evolution, O: Omics) (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). EvORanker integrates clade-wise NPP with omics data (e.g., protein-protein interaction, and co-expression data) obtained from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>] to associate a gene variant present in a patient with the patientâs phenotypes. Our primary objective is to establish an unbiased framework to resolve unsolved exomes/genomes by linking genes and especially poorly annotated genes to the disease phenotype observed in patients. Furthermore, we aimed to assess EvORankerâs efficacy in identifying candidate disease genes that lack human annotation.<fig id="Fig1"><label>Fig.Â 1</label><caption><p>Graphical abstract of the EvORanker pipeline. Starting from a list of annotated variants obtained from a patientâs exome/genome sequencing data and following variant filtering, a list of predicted <italic>patient candidate genes</italic> harboring putatively pathogenic variants are input to EvORanker. The second input is the HPO terms corresponding to the patientâs phenotypes. The first step of the pipeline is to rank the genes listed in the HPO database according to the input HPO terms using the OntologySimilarity tool. If any of the patient candidate genes is a known disease-causing gene or ranked high using <italic>OntologySimilarity</italic>, then a genetic diagnosis is achieved. If not, then each patient candidate gene in addition to the ranked HPO gene list is input into a co-evolution and STRING-based algorithm. The algorithm analyzes two lists of genes, the co-evolving and STRING-interacting genes with each patient candidate gene. A one-sided Kolmogorov-Smirnov (K-S) test is then used to test if the co-evolving and interacting genes rank significantly high within the patientâs <italic>phenotype-related genes</italic>. The <italic>p</italic>-values obtained from running the K-S test using each dataset are combined using Fisherâs combined test. The output is a list of patient candidate genes ranked based on Fisherâs combined test <italic>p</italic>-values (from more significant to less significant). A disease-causing candidate is identified among the patient genes where a significant number of co-evolving and/or interacting genes are enriched towards the genes highly related to the patientâs input phenotypes relative to the genes that are unrelated</p></caption><graphic xlink:href="13073_2023_1276_Fig1_HTML" id="MO1"/></fig></p>
    <p id="Par10">Mouse knockout data serves as a valuable resource for comprehending gene function [<xref ref-type="bibr" rid="CR34">34</xref>]. We, therefore, concentrated on genes with knockout phenotypes in mice that lack corresponding human annotation and demonstrate EvOrankerâs ability to identify disease candidates with limited information. The results of our analysis showed that EvORanker was able to identify disease genes that were ranked low by other gene-based methods, demonstrating the complementarity of EvORanker to those of other gene-based tools. Moreover, we employed EvORanker to investigate two patients with unresolved genetic syndromes. Our analysis revealed <italic>DLGAP2</italic> and <italic>LPCAT3</italic> as potential candidates for disease-causing genes. Notably, only clade-based NPP analysis was able to detect <italic>LPCAT3</italic> as a disease candidate. To enhance its practical utility, we designed EvORanker as a user-friendly gene-prioritization web tool that can be used by researchers and clinicians studying genetic disorders.</p>
  </sec>
  <sec id="Sec2">
    <title>Methods</title>
    <sec id="Sec3">
      <title>The patient exome database</title>
      <p id="Par11">For the purpose of benchmarking EvORanker, we gathered sequencing data of patients who sought clinical whole-exome sequencing at Istishari Arab Hospital in Ramallah for diagnostic purposes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). Each participant presented with a distinct clinical anomaly and was referred to Istishari Hospital by their respective physicians from various Palestinian regions to undergo exome sequencing for the identification of genetic causes. We established a database of 109 patient exomes who had received a known molecular diagnosis, some of which have been published [<xref ref-type="bibr" rid="CR35">35</xref>â<xref ref-type="bibr" rid="CR37">37</xref>]. All of the variants identified to be disease-causing in those patients had been reported as pathogenic/likely pathogenic in the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>]. The patients in this cohort exhibit diverse phenotypes (e.g., skeletal, immunological, neurological, and metabolic) (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>A). The majority of the patients were born to consanguineous parents. Each patient had been clinically diagnosed with a different rare Mendelian disease (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1), of which 91 followed an autosomal or X-linked recessive and 18 followed an autosomal or X-linked dominant mode of inheritance. Familial segregation analysis had been performed for each of the patientsâ families further confirming the diagnosis. In addition to the 109 exomes, we applied EvORanker on two exomes of patients (II-3, Fig. <xref rid="Fig10" ref-type="fig">10</xref>A, II-4, Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A) that had not received a molecular diagnosis. Written informed consent was obtained from all participants, or their parents, before their inclusion in the study. All the study participants, or their parents, provided permission to access their medical records.<fig id="Fig2"><label>Fig.Â 2</label><caption><p>Phenotypic diversity in <bold>A</bold> a cohort of 109 patients from the exome database and <bold>B</bold> a simulated dataset of 300 individuals with 300 pathogenic variants from ClinVar inserted into their genomes. The patients exhibit a wide range of phenotypes. Notably, various shared phenotypes, especially related to metabolic and neurological diseases, are observed among the patients. Key: ID, intellectual disability; GI, gastrointestinal disorders</p></caption><graphic xlink:href="13073_2023_1276_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec4">
      <title>Simulation of cases with disease-causing gene variants</title>
      <p id="Par12">We assessed our approach and compared it to other methods by simulating scenarios where mutations in disease-causing genes exist within a genome. VCF files of 300 individual genomes were downloaded from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>], providing a diverse representation of human populations (<ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>) [<xref ref-type="bibr" rid="CR40">40</xref>]. Variant annotation was performed using ANNOVAR [<xref ref-type="bibr" rid="CR41">41</xref>], and our variant filtering pipeline was applied (see TableÂ <xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>TableÂ 1</label><caption><p>Routine variant filtering criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left"><bold>Autosomal and X-linked recessive mode</bold></th><th align="left"><bold>Autosomal and X-linked dominant mode</bold></th></tr><tr><th align="left"><bold>Filtering criteria</bold></th><th align="left"><bold>Filtering criteria</bold></th></tr></thead><tbody><tr><td align="left" colspan="3"><bold>1. Variant frequency</bold></td></tr><tr><td align="left">âgnomAD [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left">âAF_popmax [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left">âIn-house exome database</td><td align="left">&lt;=â0.02</td><td align="left">&lt;â0.001</td></tr><tr><td align="left" colspan="3"><bold>2. Splicing and synonymous variants</bold></td></tr><tr><td align="left">âdbscSNV_RF_SCORE and dbscSNV_ADA_SCORE [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" rowspan="2">dbscSNV_RF_SCOREâ&gt;=â0.5 or dbscSNV_ADA_SCOREâ&gt;=â0.5 or SpliceAIâ&gt;=â0.5</td><td align="left" rowspan="2">dbscSNV_RF_SCOREâ&gt;=â0.5 or dbscSNV_ADA_SCOREâ&gt;=â0.5 or SpliceAIâ&gt;=â0.5</td></tr><tr><td align="left">âSpliceAI [<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left" colspan="3"><bold>3. Nonsynonymous variants</bold></td></tr><tr><td align="left">âPolyphen2_HDIV_score [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td align="left" rowspan="3">Polyphen2_HDIV_scoreâ&gt;=â0.5 or REVEL scoreâ&gt;=â0.5 or SIFT scoreâ&lt;=â0.5</td><td align="left" rowspan="3">Polyphen2_HDIV_scoreâ&gt;=â0.5 or REVEL scoreâ&gt;=â0.5 or SIFT scoreâ&lt;=â0.5</td></tr><tr><td align="left">âREVEL score [<xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr><td align="left">âSIFT score [<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr></tbody></table></table-wrap></p>
      <p id="Par13">For each of the 300 genomes, we introduced exonic or splicing pathogenic/likely pathogenic variants from the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>], excluding disease genes already found in the 109-real exome patient dataset. These 300 ClinVar variants were randomly selected from genes associated with diverse disease phenotypes, including complex neoplastic disorders (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>B). Among these variants, 181 followed an autosomal or X-linked recessive mode of inheritance, while 119 variants followed a dominant inheritance pattern. In instances where the mode of inheritance for a ClinVar pathogenic variant was uncertain, or if it could be attributed to both inheritance modes, or if it was not reported in affected patients, we randomly assigned the mode of inheritance. Subsequently, we randomly integrated these 300 sampled variants into the 300 annotated genomes. This process was permutated three times, each time spiking each variant of the set of 300 ClinVar variants into different genomes out of the 300. The outcome is a simulation of 900 artificial patients with 300 unique âgenetic diseasesâ (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2), each with a single mutation in one of 300 genes. This ensured that each disease appeared three times in three different genomes.</p>
      <p id="Par14">Phenotypic information for each spiked ClinVar gene variant was retrieved from the HPO (Human Phenotype Ontology) database [<xref ref-type="bibr" rid="CR46">46</xref>]. Additionally, to evaluate the robustness of EvORanker, we conducted validation through three independent spike shuffles (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S7).</p>
    </sec>
    <sec id="Sec5">
      <title>Genomics and variant-based prioritization of the patientsâ exome to map the patient candidate genes</title>
      <p id="Par15">Whole-exome sequencing was performed on the patients described in this study using the Truseq Capture Exome Kit (IlluminaÂ®). The captured and the amplified libraries were sequenced on the Illumina Nextseq500 platform according to the manufacturerâs protocol. Briefly, paired-end sequences were obtained at a read length of 150 bps. Sequence reads were then aligned to the reference human genome (hg19) using BWA aligner [<xref ref-type="bibr" rid="CR47">47</xref>]. Alignments then underwent preprocessing steps by PCR duplicate removal, base quality recalibration, and realignment around indels. The variants were finally called by GATK (Genome Analysis Toolkit) [<xref ref-type="bibr" rid="CR48">48</xref>] and annotated by ANNOVAR [<xref ref-type="bibr" rid="CR41">41</xref>]. For both the patient exomes and simulated genomes, we excluded intronic, untranslated region (UTR), and ncRNA variants. Nonsense, frameshift, nonsynonymous, and splice-site variants were prioritized by excluding frequent variants based on their minor allele frequency in gnomAD and AF_popmax [<xref ref-type="bibr" rid="CR42">42</xref>] and Istishari hospitalâs in-house exome database (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). In addition, variants predicted to be benign by variant effect predictor tools such as PolyPhen-2 [<xref ref-type="bibr" rid="CR5">5</xref>] and REVEL [<xref ref-type="bibr" rid="CR6">6</xref>] were excluded from the analysis (TableÂ <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR49">49</xref>]. For the patient exomes, copy number variations were called from the exome data using XHMM software [<xref ref-type="bibr" rid="CR50">50</xref>]. In this study, the genes that passed the variant filtering criteria are referred to as the <italic>patient candidate genes</italic>. Co-segregation analysis was performed by Sanger sequencing on an ABI 3130 Genetic Analyzer (Applied Biosystems). Primers used for validation and family segregation of the <italic>DLGAP2</italic> variant are as follows: Forward: CGGTAGAGACTGGGAGGATG and Reverse: ACTTACCTGACAAAACACACACA. Primers used for validation and family segregation of the <italic>LPCAT3</italic> variant are as follows: Forward<italic>:</italic> CGCATAGGGGTGACATGGTA and Reverse<italic>:</italic> TATGCATTTTGACGGGCCTG.</p>
    </sec>
    <sec id="Sec6">
      <title>Ranking the patient candidate genes according to their association with each patientâs disease-phenotypes</title>
      <p id="Par16">In order to retrieve a list of genes already reported to be associated with each patientâs clinical condition, we encoded the abnormalities reported in each patientâs medical report (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) to standard HPO terms [<xref ref-type="bibr" rid="CR46">46</xref>]. The combination of the patient HPO terms was then input into the OntologySimilarity package in R, a semantic similarity-based tool [<xref ref-type="bibr" rid="CR51">51</xref>], and used to identify and rank the genes listed in the HPO database based on their associations with the queried HPO terms. According to the recommended parameters in the toolâs documentation [<xref ref-type="bibr" rid="CR51">51</xref>], the semantic similarity score was calculated using Linâs definition of semantic similarity in combination with the âbest-match-averageâ approach. Additional semantic similarity measures, such as the product measure based on Resnikâs similarity expression, were also evaluated, yielding results that were nearly identical (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1). The output is a ranked list of the 4900 genes listed in the HPO database (as of January 2023) scored between zero and one (termed HPO-ranked genes). This score is based on the degree of similarity between the patientâs set HPO terms and the HPO terms annotated to each gene in the HPO database. The higher-scoring genes, referred to as <italic>phenotype-related genes</italic> in this study, are defined as genes that exhibit stronger associations with the queried phenotypes.</p>
      <p id="Par17">Defining an exact threshold for the output of OntologySimilarity [<xref ref-type="bibr" rid="CR51">51</xref>] is challenging. In most cases, it is hard to point to a clear threshold that above which the genes are âphenotype-related.â Furthermore, such a potential threshold is highly dependent on the user-defined HPO terms as HPOs are variable in their level of complexity and how well they are defined or studied. As such in our analysis, the genes were ranked and ordered based on their association with the set of input phenotypes, ranging from highly associated to not associated (top to bottom). We utilized a one-sided Kolmogorov-Smirnov test to assess the significance of a skewed distribution of co-evolved (or interacting genes) towards the upper end of the ranked genes (see below).</p>
    </sec>
    <sec id="Sec7">
      <title>Building the EvORanker algorithm</title>
      <p id="Par18">The main goal of EvORanker is to establish a link between the <italic>patient candidate genes</italic> and the patientâs phenotype. This link was evaluated based on two different sources of data on known and predicted gene functional interactions:, clade-wise phylogenetic profiling, and the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. Our working hypothesis is that of the <italic>patient candidate genes</italic>, the disease-causing gene would be functionally linked to the genes that cause similar phenotypes to those of the patient (e.g., the disease-causing gene in a patient with ciliopathy would show significant co-evolution/co-expression/interaction with cilia genes). We used the 109-patient exome and 900-simulated datasets to tune the parameters of the algorithm using exclusively phylogenetic profiling (PP). Subsequently, we compared and eventually integrated the PP-based analysis with the STRING-based analysis to maximize the performance of EvORanker.</p>
    </sec>
    <sec id="Sec8">
      <title>Clade-based phylogenetic profiling</title>
      <p id="Par19">The normalized phylogenetic profiling (NPP) matrix was constructed as previously described [<xref ref-type="bibr" rid="CR24">24</xref>]. Briefly, a matrix of BLASTP scores for all human genes against the genomes of 1,028 eukaryotic species was constructed. First, the bitscore of each best BLAST hit was normalized by the bitscore of the query protein self-hit. Then log2 transformation of the normalized bitscore was applied. Finally, to avoid any biases due to phylogenetic distance, the conservation score was scaled for each species to their overall distribution by transforming the values in the column (corresponding to a species) into <italic>z</italic>-scores.</p>
      <sec id="Sec9">
        <title>Clade-based analysis</title>
        <p id="Par20">To have a comprehensive mapping of protein-correlated evolution, we used 16 representative clades spanning the eukaryotic tree as previously described [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In addition to including all eukaryotes, the following clades were used: <italic>Chordata</italic>, <italic>Ecdysozoa</italic>, <italic>Platyhelminthes</italic>, <italic>Alveolates</italic>, <italic>Stramenopiles</italic>, <italic>Fungi</italic>, <italic>Viridiplantae</italic>, <italic>Mammalia</italic>, <italic>Archelosuria</italic>, <italic>Arthropoda</italic>, <italic>Nematoda</italic>, <italic>Basidiomycota</italic>, <italic>Ascomycota</italic>, <italic>Fungi incertae sedis</italic>, <italic>Liliopsida</italic>, and <italic>Eudicotyledons</italic> [<xref ref-type="bibr" rid="CR24">24</xref>]. These 16 representative clades spanning the eukaryotic tree show wide coverage (span most of the eukaryotic tree), mutual exclusivity (preferring non-nested clades), and uniformness (similar depth in the tree) in clade types (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2) [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
      </sec>
      <sec id="Sec10">
        <title>Retrieving coevolving genes for each patient candidate gene</title>
        <p id="Par21">The degree of co-evolution between two genes was evaluated using the Pearson correlation coefficient between their respective rows in the NPP matrix. As we demonstrated before [<xref ref-type="bibr" rid="CR24">24</xref>], for each <italic>patient candidate gene</italic>, we selected the genes with the top 100 correlation coefficients in each clade and ranked them from 1 to 100 according to the correlation coefficient in each clade where the gene is found to have an ortholog.</p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Using the Kolmogorov-Smirnov test to prioritize patient candidate genes based on phylogenetic profiling</title>
      <p id="Par22">Per patient exome/simulated genome, we analyzed each of the <italic>patient candidate genes</italic> separately. For each of these genes, we determined whether the genes that co-evolve with it were associated with the patientâs phenotype (i.e., the co-evolved genes were significantly enriched towards the <italic>phenotype-related genes</italic>). For that, we examined the ranking of the coevolving genes in the list of the <italic>HPO-ranked genes</italic> using a one-tailed, two-sample Kolmogorov-Smirnov (K-S) test [<xref ref-type="bibr" rid="CR52">52</xref>].</p>
      <p id="Par23">The K-S test is used to test whether two samples come from the same distribution. The K-S <bold><italic>D</italic></bold> statistic quantifies the distance between the empirical cumulative distribution function (ECDF) of the sample and the cumulative distribution function of the reference distribution. Let <italic>i</italic> denote the co-evolving genes and <italic>j</italic> denote the <italic>ranked HPO genes</italic>.</p>
      <p id="Par24">The null hypothesis: H0:<italic>Fi(x)</italic>ââ¥â<italic>Fj(x)</italic></p>
      <p id="Par25">The alternative hypothesis: H1:<italic>Fi(x)</italic>â&lt;â<italic>Fj(x)</italic></p>
      <p id="Par26">The D statistic: <bold><italic>D-</italic></bold>â=âmax<sub><italic>x</italic></sub>{<italic>Fj</italic>(<italic>x</italic>)-<italic>Fi</italic>(<italic>x</italic>)} where <italic>Fj</italic> is the ECDF of <italic>j</italic> and similarity for <italic>Fi</italic></p>
      <p id="Par27">The H1 hypothesis for the one-sided K-S test is that the cumulative distribution function of the ranking of the coevolving genes is enriched within the higher-scoring side of <italic>HPO-ranked genes (the phenotype-related genes)</italic>. A <italic>p</italic>-value was computed using the ks.test function in the stats package in R [<xref ref-type="bibr" rid="CR53">53</xref>]. The <italic>patient candidate genes</italic> were finally ranked by the resulting K-S test <italic>p</italic>-value (from more significant to less significant).</p>
    </sec>
    <sec id="Sec12">
      <title>Tuning the parameters of the EvORanker phylogenetic profiling-based analysis</title>
      <p id="Par28">We evaluated the performance phylogenetic profiling-based analysis to identify the âtrueâ disease-causing gene using the 109-patient exome and the 900-simulated databases.Â We examined different parameters and cutoff values using phylogenetic profiling. We compared different cutoff values of the ranked coevolving genes (top 10, 25, 50, 75, 100) with each <italic>patient candidate gene</italic>. In both datasets, a threshold of the top 50 coevolved genes yielded slightly better accuracy in ranking the âtrueâ gene in comparison to the other patient candidate genes (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S3), which we used for the rest of the analysis.</p>
    </sec>
    <sec id="Sec13">
      <title>Applying the Kolmogorov-Smirnov test using STRING-interacting genes</title>
      <p id="Par29">In addition to phylogenetic profiling, other known and predicted functionally associated genes (protein-protein interactions, text mining, and co-expression) were retrieved from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. STRING uses a scoring system that reflects the evidence of predicted interactions. We included interactions with a combined score of at least 0.5, which corresponds to a medium-confidence network. For each patient exome/simulated genome in the datasets, we applied the K-S test. The analysis was done for each <italic>patient candidate gene</italic>, with the STRING-interacting genes similarly as described above. We examined whether a substantial portion of string-interacting genes were also linked to phenotypes resembling those found in the patient.</p>
    </sec>
    <sec id="Sec14">
      <title>The final EvORanker gene prediction scoring system</title>
      <p id="Par30">The two <italic>p</italic>-values obtained from each K-S test using phylogenetic profiling and STRING were finally combined by Fisherâs combined probability test [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>] (Eq.Â <xref rid="Equ1" ref-type="disp-formula">1</xref>) which is the final EvORanker scoring system. Additionally, we assessed Simesâ method for combining the <italic>p</italic>-values, which produced similar results (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1). The Fisherâs combined probability test was computed using the combine.test function in the survcomp package in R [<xref ref-type="bibr" rid="CR56">56</xref>].<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${X}_{2k}^{2}\sim -2\sum_{i=1}^{k}{\text{log}}\left({p}_{i}\right)$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>â¼</mml:mo><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:munderover><mml:mo>â</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>k</mml:mi></mml:munderover><mml:mtext>log</mml:mtext><mml:mfenced close=")" open="("><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="13073_2023_1276_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p>
    </sec>
    <sec id="Sec15">
      <title>Applying EvORanker on genes with knockout phenotypes in mice that lack corresponding human annotation</title>
      <p id="Par31">A list of 6395 human genes with mouse knockout phenotypes but not yet associated with a phenotype in humans was compiled from Jackson laboratoryâs Mouse Genome Informatics (MGI) [<xref ref-type="bibr" rid="CR57">57</xref>], (downloaded, March 1, 2023). The knockout mouse gene phenotype terms were then mapped to human HPO terms using uPheno ontology inter-ontology closest matches obtained from the OBO Phenotype Ontology Github repository [<xref ref-type="bibr" rid="CR58">58</xref>] ending up with 6260 genes with mapped HPO terms. Then, for each gene, the corresponding HPO terms and a list of randomly sampled genes were input to EvORanker. The same data was input to Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>] for comparison. We were unable to compare to other tools (e.g., ExomeWalker or PHIVE) due to the impracticability of simulating 6,260âÃâ100 variants in 6,260.vcf files as input.</p>
    </sec>
    <sec id="Sec16">
      <title>Tool comparison</title>
      <p id="Par32">We compared EvORanker to the gene prioritization stage (second stage) of ExomeWalker and PHIVE algorithms [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. We used the 109-patient exome and 900-simulated benchmarking datasets to compare the tools with the same input HPO terms and <italic>patient candidate genes</italic>. We omitted one exome from the exome dataset where a large deletion was identified containing the <italic>NPRL3</italic> gene, leaving us with 108 exomes. We used.vcf files for each of the 108 patient exomes and the 900 genomes as input for Exomiser which includes ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>]. Additionally, we created.yml files containing the same HPO terms as input for each patient exome and simulated genome.</p>
    </sec>
    <sec id="Sec17">
      <title>In vitro splicing analysis</title>
      <p id="Par33">In vitro splicing, minigene assays were carried out as previously described [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Briefly, the genomic sequence at chr8:1626251-1627026 (hg19) which includes exon 9 (417Â bp) plus 128 and 231 nucleotides from the 5â² and 3â² flanking sequences, respectively, of <italic>DLGAP2</italic> (NM_001346810) was PCR amplified from a DNA sample homozygous (II-3, Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A) and wildtype (II-2, Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A) for the c.2702 Aâ&gt;âT variant using gene-specific primers designed with embedded XhoI and BamHI restriction enzyme recognition sites. After digestion, the PCR fragments were ligated into a pre-constructed pET01 Exontrap vector (MoBiTec, Goettingen, Germany). Selected colonies were then sequenced to confirm the proper orientation of the cloned fragment and identify both wild-type and variant colonies. Subsequently, the variant and wild-type minigenes were transfected into HEK293 cells in triplicate, followed by total RNA extraction 48Â h post-transfection, using the Quick-RNA MiniPrep Plus kit (ZYMO Research). cDNA was then synthesized using the qScript Flex cDNA synthesis kit (Quanta Biosciences) with a specific primer to the 3â² native exon of the pET01 Exontrap vector. Following PCR amplification, the products were then visualized on a 1.5% agarose gel and were later extracted and then Sanger sequenced. The primer sequences used for the PCR amplification (XhoIâ+âBamHI) are Forward: AAA-<underline>CTCGAG</underline>-AACACTACCTGCCCTTGAGC, and Reverse: AAA-<underline>GGATCC</underline>-ACTTACCTGACAAAACACACACA.</p>
    </sec>
    <sec id="Sec18">
      <title>Data analysis and figure creation</title>
      <p id="Par34">All data in this study were analyzed using R software [<xref ref-type="bibr" rid="CR53">53</xref>]. The EvORanker web interface was created using the R Shiny package [<xref ref-type="bibr" rid="CR62">62</xref>]. The majority of the figures were created using R software. FiguresÂ <xref rid="Fig9" ref-type="fig">9</xref>D and <xref rid="Fig10" ref-type="fig">10</xref>D were created using Cytoscape v3.9.1 [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
    </sec>
  </sec>
  <sec id="Sec19">
    <title>Results</title>
    <sec id="Sec20">
      <title>Overview</title>
      <p id="Par35">In this work, we developed EvORanker, a phylogenetic profiling-based algorithm, to identify disease-causing genes. To optimize and evaluate the performance of EvORanker, we employed three different approaches: (1) analyzing a private cohort of well phenotypically characterized patients with rare diseases; (2) simulating a dataset of 900 patients with 300 unique âgenetic diseasesââby spiking disease-causing mutations into real genomes; (3) evaluating EvORankerâs ability to identify human disease candidate genes using genes with knockout phenotypes in mice that lack corresponding human annotation. We demonstrate the contribution of clade-based phylogenetic profiling (PP) to the improved prediction of the disease-causing gene. This unbiased approach was compared and integrated with gene interaction data obtained from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>]. To evaluate the potential for bias in disease-gene prediction, we compared well-annotated genes to recently published ones. Finally, EvORanker was compared to other gene-based prioritization tools and applied to two unresolved exomes to demonstrate its efficacy in disease gene discovery.</p>
    </sec>
    <sec id="Sec21">
      <title>Benchmarking EvORanker using an exome-patient dataset</title>
      <p id="Par36">We analyzed an in-house database of 109 patient exomes with a genetic diagnosis. The patients suffer from various rare hereditary diseases, exhibiting diverse phenotype groups (e.g., skeletal, immunological, neurological, and metabolic diseases) (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>A). The dataset included 91 recessive and 18 dominant gene variants that explained the patientsâ phenotype (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). All these variants are reported to be pathogenic/likely pathogenic in the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>] and co-segregated with the phenotype in each corresponding family. The dataset includes 108 unique known disease genes (the <italic>CLCN1</italic> gene appears twice, once as autosomal recessive and once as autosomal dominant). For each patient in the exome dataset, we encoded each of the clinical abnormalities found in the patientâs medical record into Human Phenotype Ontology (HPO) [<xref ref-type="bibr" rid="CR46">46</xref>] terms (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).</p>
    </sec>
    <sec id="Sec22">
      <title>Benchmarking EvORanker using a simulated dataset</title>
      <p id="Par37">Next, we aimed to assess our ability to identify disease-causing mutations in simulated data. Simulating genetic diseases can be achieved by introducing pathogenic mutations into genomic data from an unaffected individual. To accomplish this, we utilized 300 unaffected genomes sourced from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>] as a benchmark for our evaluations. To introduce pathogenicity, we randomly integrated 300 distinct pathogenic/likely pathogenic variants from the ClinVar database [<xref ref-type="bibr" rid="CR38">38</xref>] into the annotated genomes. These ClinVar variants are associated with genes showcasing diverse phenotypes including complex neoplastic disorders (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>B). Of these variants, 181 followed an autosomal or X-linked recessive mode of inheritance, while 119 variants followed a dominant inheritance pattern (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). Phenotypic information for each spiked ClinVar gene variant was obtained from the HPO database (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) and was assigned to the respective âpatient.â We conducted this process thrice, simulating a total of 900 artificial patients with 300 different genetic diseases. Each pathogenic mutation was inserted into three distinct genomes.</p>
      <sec id="Sec23">
        <title>Ranking genes based on each patientâs set of phenotypes</title>
        <p id="Par38">Using each set of patient HPO terms, we calculated the semantic similarity score [<xref ref-type="bibr" rid="CR51">51</xref>] (see the â<xref rid="Sec2" ref-type="sec">Methods</xref>â section) for each gene in the HPO database [<xref ref-type="bibr" rid="CR46">46</xref>]. The output is a list of genes scored from lower association to higher association with the patientâs set of HPO terms (which we term the phenotype-related genes).</p>
      </sec>
      <sec id="Sec24">
        <title>Retrieving the patientâs candidate genes</title>
        <p id="Par39">We applied our routine variant filtering criteria [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] to the annotated variants for each of the 109 exomes and simulated genomes (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). After variant filtering, each exome/genome contained gene variants that are considered to be pathogenic and predicted to affect protein function (we term the genes in which these variants were observed as <italic>patient candidate genes</italic>). In autosomal and X-linked recessive cases, each patient harbored 11â80 homozygous/hemizygous or compound heterozygous deleterious variants, while 80â170 heterozygous/hemizygous deleterious variants were observed in autosomal and X-linked dominant cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S4). We confirmed that all the âtrueâ causative variants passed the filtering criteria and remained within the gene variant list for each patient exome.</p>
      </sec>
      <sec id="Sec25">
        <title>Using multi-clade phylogenetic profiling to rank the patientâs candidate genes according to the patientâs phenotype</title>
        <p id="Par40">Our working hypothesis is that out of all the patient candidate genes, the one responsible for the disease will be associated (e.g., co-evolved) with other genes that are known to be associated with the disease (phenotype-related gene). For each <italic>patient candidate gene</italic>, we obtained a list of 50 co-evolved genes that exhibit a strong correlation based on global and local co-evolution signatures across 1028 eukaryotic species (details in the â<xref rid="Sec2" ref-type="sec">Methods</xref>â section) [<xref ref-type="bibr" rid="CR24">24</xref>]. For each <italic>patient candidate gene</italic>, we retrieved the top co-evolving genes in 16 clades (<italic>Chordata</italic>, <italic>Ecdysozoa</italic>, <italic>Platyhelminthes</italic>, <italic>Alveolates</italic>, <italic>Stramenopiles</italic>, <italic>Fungi</italic>, <italic>Viridiplantae</italic>, <italic>Mammalia</italic>, <italic>Archelosuria</italic>, <italic>Arthropoda</italic>, <italic>Nematoda</italic>, <italic>Basidiomycota</italic>, <italic>Ascomycota</italic>, <italic>Fungi incertae sedis</italic>, <italic>Liliopsida</italic>, and <italic>Eudicotyledons</italic>) (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2). The output per <italic>patient candidate gene</italic> is a table of genes that are strongly co-evolved with it in each clade in addition to all Eukaryotes.</p>
        <p id="Par41">To determine which of the <italic>patient candidate genes</italic> is most likely linked to the patientâs disease phenotype, we evaluated the intersection between the co-evolved genes and the phenotype-ranked genes using a one-sided <italic>Kolmogorov-Smirnov</italic> (K-S) test (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). A significant <italic>p</italic>-value is obtained if the co-evolving genes rank high within the <italic>phenotype-related genes</italic>. For each patient exome/simulated genome in our dataset, we ranked the <italic>patient candidate genes</italic> based on the resulting <italic>p</italic>-value, with the most significant <italic>p</italic>-value ranked first. By analyzing the co-evolved genes across the 16 clades in addition to all Eukaryotes, the âtrueâ disease-causing gene was ranked as the top gene in 46% of the autosomal and X-linked recessive cases and within the top 5 in 72% (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>). In autosomal and X-linked dominant cases, the âtrueâ gene was ranked as the top gene in 50% of the cases and within the top 10 genes in 78%. These results surpass those obtained from using only the co-evolving genes across Eukaryotes or within the Animalia clades (<italic>Chordata</italic>, <italic>Mammalia</italic>, <italic>Archelosauria</italic>, <italic>Ecdysozoa</italic>, <italic>Nematoda</italic>, <italic>Arthropoda</italic>, and <italic>Platyhelminthes</italic>) (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>). This indicates the added value of incorporating all 16 clades in the analysis. The same analysis was applied on the simulated genomes, yielding results consistent with those obtained from the real exome dataset (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.Â 3</label><caption><p>Using clades improves the performance of EvORanker phylogenetic profiling-based analysis. For each patient candidate gene list in the 109-patient exome and the 900-simulated genomes datasets (300 unique genetic disorders), we compared the accuracy of the phylogenetic profiling-based algorithm by retrieving the top 50 coevolved genes with each <italic>patient candidate gene</italic> across all Eukaryotes versus: (1) using all 16 clades where the query gene has an ortholog in addition to Eukaryotes. (2) Across only Animalia clades (<italic>Chordata</italic>, <italic>Mammalia</italic>, <italic>Archelosauria</italic>, <italic>Ecdysozoa</italic>, <italic>Nematoda</italic>, <italic>Arthropoda</italic>, and <italic>Platyhelminthes</italic>). Performance was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other patient candidate genes. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right). The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested clades, and the <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top or within the top 3 or top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage is for the âtrueâ gene being ranked at the top or within the top 10 genes. Overall, the best performance of ranking the âtrueâ causative gene was achieved by merging together the co-evolving genes within all clades (the 16 clades in addition to all Eukaryota) in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig3_HTML" id="MO6"/></fig></p>
      </sec>
      <sec id="Sec26">
        <title>Phylogenetic profiling analysis in different evolutionary scales improves the prediction of the disease-causing gene</title>
        <p id="Par42">We then aimed to assess the contribution of each of the 16 clades, in addition to all <italic>Eukaryota</italic>, towards the prediction of the âtrueâ disease-causing gene. Using the 109 patient exomes, this was accomplished by focusing on the genes that obtained a significant <italic>p</italic>-value (&lt;â0.05) through co-evolution analysis totaling 71 identified genes. We applied the K-S test to these 71 genes using the co-evolving genes within each clade. Results showed that each clade outperformed others in at least one case, thus highlighting the importance of combining information from different clades to enhance the performance of EvORanker (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>). Interestingly, the <italic>Fungi Incertae Sedis</italic> clade outperformed other clades in 14% (10/71) of the cases, followed by <italic>Chordata</italic>, <italic>Ascomycota</italic>, <italic>Arthropoda</italic>, and <italic>Eukaryota</italic>, each outperforming others in 10% of the cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S5). Taken together, these results emphasize that clades differentially specialize in detecting functional interactions in different pathways [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].<fig id="Fig4"><label>Fig.Â 4</label><caption><p>Each of the 16 clades in addition to <italic>Eukaryota</italic> contributes to the correct identification of the disease-causing gene. Each column in the heatmap represents a clade while each row represents the âtrueâ disease-causing gene in a patient exome from the 109-exome patient dataset. Only the genes that achieved an overall significant K-S test <italic>p</italic>-value (&lt;â0.05) using the co-evolution analysis are displayed (71 cases). Each entry in the heatmap is colored by the -log 10 of the K-S test <italic>p</italic>-value that was run on each clade separately. The entries colored in red represent the significant <italic>p</italic>-values (&gt;â-log10(0.05)). Light grey entries indicate non-significant <italic>p</italic>-values. Entries, where the gene is not found to have an ortholog in a certain clade, are colored off-white. The rows are clustered according to the <italic>p</italic>-values. The column on the left indicates the combined -log10 of the <italic>p</italic>-value obtained by running the K-S test after merging together the coevolving genes across the clades. In four cases (<italic>HUWE1</italic>, <italic>COL3A1</italic>, <italic>MYO7A</italic>, and <italic>CYP21A2</italic>), a significant <italic>p</italic>-value was obtained by none of the clades, but a significant combined <italic>p</italic>-value was still achieved by merging the co-evolving genes from all the clades</p></caption><graphic xlink:href="13073_2023_1276_Fig4_HTML" id="MO7"/></fig></p>
      </sec>
      <sec id="Sec27">
        <title>Phylogenetic profiling is complementary to other existing omics datasets</title>
        <p id="Par43">NPP represents an unbiased approach that can annotate gene function independently of the literature. We sought to evaluate whether clade-wise NPP could identify disease-associated genes that are overlooked by other existing omics. For that, we chose to use the STRING database since it integrates information on protein associations from multiple sources, including interaction experiments, known complexes and pathways, scientific literature, co-expression studies, and conserved genomic context [<xref ref-type="bibr" rid="CR33">33</xref>]. We conducted a comparison between the NPP and STRING-based analysis [<xref ref-type="bibr" rid="CR33">33</xref>] using both the patient exome and simulated datasets (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). NPP outperformed STRING in 29/109 (27%) of the cases, whereas STRING outperformed NPP in 50/109 (46%) of the cases (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6).<fig id="Fig5"><label>Fig.Â 5</label><caption><p>Comparative performance of NPP, STRING, and EvORanker using the 109-patient exome and the simulated datasets. The performance of each dataset was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other genes in each exome/genome in both datasets. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right), The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested datasets: NPP (using the top 50 coevolved genes), STRING versions 9.1, 11.5, and EvORanker (combining NPP and the newer version of STRING). The <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top, or within the top 3 or top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage is for the âtrueâ gene being ranked at the top or within the top 10 genes. Overall, the best performance was achieved using the combined approach (EvORanker) in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig5_HTML" id="MO8"/></fig></p>
        <p id="Par44">Considering the presence of complementarity of co-evolution and the STRING-based analysis, we integrated the two datasets by combining their respective <italic>p</italic>-values using Fisherâs combined probability test [<xref ref-type="bibr" rid="CR54">54</xref>]. This combined scoring system, which we termed EvORanker, yielded the highest accuracy in comparison to each dataset alone (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). Using the exome dataset, we showed that integrating NPP and STRING improved the results by 43% compared to NPP alone and by 30% compared to STRING alone (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6). Overall, in autosomal and X-linked recessive cases, EvORanker ranked the âtrueâ disease-causing gene as the top gene in 63/91 (69%) and within the top 5 genes in 86/91 (95%) cases (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). In autosomal and X-linked dominant cases, the âtrueâ gene was ranked as the top gene in 12/18 (67%) cases and among the top 10 genes in 17/18 (95%) (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). On the other hand, the âtrueâ disease genes did not achieve high scores in a total of 6/109 (5.5%) of the exomes (within the top 5 for recessive diseases and within the top 10 for dominant diseases); 5/91 recessive cases, and 1/18 dominant cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6).</p>
        <p id="Par45">We observed similar trends when analyzing the simulated dataset, providing further validation and affirming the consistency of our findings (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). In autosomal and X-linked recessive cases within the simulated dataset, EvORanker ranked the âtrueâ disease-causing gene as the top gene in 75% of cases and within the top 5 in 96% of cases. Conversely, for autosomal and X-linked dominant cases, the âtrueâ gene held the top position in 55% of cases and was within the top 10 in 85% of cases. This parallel in results strongly underscores the robustness of EvORanker across both real and simulated datasets. Furthermore, to validate the stability of our method, we conducted three independent spike shuffles, consistently yielding coherent and reliable results (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S7).</p>
      </sec>
    </sec>
    <sec id="Sec28">
      <title>Performance of phylogenetic profiling versus STRING on new gene entries (2020â2022)</title>
      <p id="Par46">As STRING is based on publicly available data, it is suited to identify well-researched genes. We hypothesized that STRING performance would be better the more information it has accrued over time and that our unbiased PP approach would have a particular advantage for genes that have not been extensively characterized. To test this hypothesis, we compared the performance of STRING version v.11.5 [<xref ref-type="bibr" rid="CR33">33</xref>] with that of the older version STRING v.9.1 [<xref ref-type="bibr" rid="CR64">64</xref>] (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). We found that the performance of the newer version was indeed better than that of the older version. Furthermore, the performance of STRING v11.5 decreased dramatically for genes that only recently became associated with disease. For example, the performance of STRING in ranking the âtrueâ disease gene within the top 5 is around 85% for genes identified by the end of 2015 compared to 29% for genes identifiedÂ between 2016â2020 (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S8).<fig id="Fig6"><label>Fig.Â 6</label><caption><p>The effect of years elapsed on the performance of NPP versus STRING, using the 109-patient exome dataset. The <italic>x</italic>-axis indicates the calendar years (divided into 5-year windows) in which a gene was described to be associated with a disease phenotype. The <italic>y</italic>-axis indicates the percentage of âtrueâ disease genes that ranked at the top (top 1) relative to the other <italic>patient candidate</italic> using NPP (red bars) or STRING (blue bars)</p></caption><graphic xlink:href="13073_2023_1276_Fig6_HTML" id="MO9"/></fig></p>
      <p id="Par47">We then evaluated the performance of NPP and STRING on newly discovered or recently published genes. We retrieved a list of 94 new gene entries that were added to the most recent version of the HPO database (2022) compared to an older version (2020) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3). We then applied the K-S test separately using NPP and STRING and the HPO terms associated with each gene as input. We found that for those genes newly associated with human phenotypes, the K-S test yielded significant <italic>p</italic>-values using NPP in 45% of the genes compared to 38% using STRING (Fig. <xref rid="Fig7" ref-type="fig">7</xref>A, B). These results emphasize the success of phylogenetic profiling in predicting the phenotype associations of newly discovered or less studied genes and highlight the complementarity observed when comparing these two datasets.<fig id="Fig7"><label>Fig.Â 7</label><caption><p>Comparison of NPP versus STRING for genes with recent (2020â2022) annotation. <bold>A</bold> The <italic>x</italic>-axis indicates -log(10) <italic>p</italic>-values obtained from running the K-S test using NPP. The <italic>y</italic>-axis indicates -log(10) <italic>p</italic>-values obtained from running the K-S test using the STRING dataset. The red dots represent the genes where NPP performed better than STRING, while the blue dots indicate the opposite. The marginal histogram indicates the distribution of the -log(10) <italic>p</italic>-values of both datasets. The correlation score between the two datasets is 0.046, suggesting that the two datasets exhibit a complex relationship, where a subset of the data displays complementarity, while another subset shows correlation. <bold>B</bold> Density distribution of the -log(10) <italic>p</italic>-values obtained from the K-S test using the NPP, STRING, and both (combined). Significance was calculated using the Wilcoxon test (*<italic>p</italic>-valueâ&lt;â0.05, **<italic>p</italic>-valueâ&lt;â0.01; ns, nonsignificant). Combining NPP and STRING achieved significantly more significant results that either approach alone</p></caption><graphic xlink:href="13073_2023_1276_Fig7_HTML" id="MO10"/></fig></p>
    </sec>
    <sec id="Sec29">
      <title>Performance of EvORanker on genes with knockout phenotypes in mice that lack corresponding human annotation</title>
      <p id="Par48">We aimed to assess EvORankerâs capability to identify disease candidate genes that lack a known phenotype association in humans but possess mouse orthologs linked to phenotypes. Specifically, we aimed to identify human genes without established phenotype links, yet having a corresponding mouse ortholog with a phenotype association. These genes were considered as the âtrueâ disease gene candidates for the purpose of this evaluation. We compiled a list of 6260 human ortholog genes with mouse knockout phenotypes, yet not associated with a phenotype in humans. For each of these genes, we input a set of HPOs mapped from the respective mouse knockout phenotypes. The goal was to evaluate EvORankerâs ability to correctly pinpoint the âtrueâ disease gene candidate in comparison to 100 randomly sampled human genes. The same dataset was used as input for Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>] for comparative analysis.</p>
      <p id="Par49">EvORanker yielded significant <italic>p</italic>-values for 41% of the tested genes (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>A). Moreover, both EvORanker and Phenolyzer ranked the âtrue geneâ among the top 10 in 16% of the cases (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>B). Notably, EvORanker identified genes that Phenolyzer failed to identify, and vice versa, highlighting the complementarity of the tools (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S9).<fig id="Fig8"><label>Fig.Â 8</label><caption><p>EvORankerâs performance in identifying candidate disease genes using mouse knockout genes without corresponding human annotation. <bold>A</bold> The graph shows the percentage of genes with mouse knockout phenotypes that were tested for significant <italic>p</italic>-values using EvORanker. Out of 6260 genes, 41% showed significant <italic>p</italic>-values. <bold>B</bold> Comparison of EvORanker and Phenolyzer [<xref ref-type="bibr" rid="CR49">49</xref>] in identifying true disease gene candidates. The graph shows the count of genes with mouse knockout phenotypes and their respective ranking, each in comparison to 100 randomly sampled genes by EvORanker and Phenolyzer. Among the tested genes, 16% were ranked in the top 10 by both tools</p></caption><graphic xlink:href="13073_2023_1276_Fig8_HTML" id="MO11"/></fig></p>
    </sec>
    <sec id="Sec30">
      <title>Tool comparison</title>
      <p id="Par50">Using the 109-exome and simulated datasets, we compared the performance of EvORanker to the gene-prioritization stage of ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>]. ExomeWalker prioritizes genes based on protein-protein interaction, while PHIVE uses mouse phenotypic data. To ensure a fair comparison, we chose to compare to ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] and PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] because both adopt a similar strategy to EvORanker. Unlike Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>], these methods do not rely on pre-existing knowledge about known disease genes. The comparison was performed using the exome and simulated datasets with the same input HPO terms. However, since ExomeWalker and PHIVE are not well-suited for CNV analysis, we omitted from this analysis one exome where the causative variant was a large deletion encompassing the <italic>NPRL3</italic> gene. The results of the 108-exome dataset showed that EvORanker outperformed either one or both ExomeWalker and PHIVE in 74% (80/108) of the cases and outperformed both tools in 30% (32/108) of the cases (Fig.Â <xref rid="Fig9" ref-type="fig">9</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S10). On the other hand, either one or both of the other tools outperformed EvORanker in 20% (22/108) of the cases (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S10). For the simulated dataset, EvORanker outperformed both ExomeWalker and PHIVE (Fig.Â <xref rid="Fig9" ref-type="fig">9</xref>).<fig id="Fig9"><label>Fig.Â 9</label><caption><p>EvORanker outperforms two other algorithms (ExomeWalker and PHIVE). The performance of each algorithm in the 108-exome dataset and the simulated dataset (shuffled three times) was measured by examining the ranking of the âtrueâ disease-causing gene relative to the other patient genes. The upper bar plot shows results for the autosomal and X-linked recessive cases for the real-exome dataset (left) and the simulated dataset (right). The simulated dataset contains 181 unique recessive cases and 119 unique dominant cases. The results present a compilation of three separate independent shuffles totaling 900 simulations. The lower bar plot shows results for the autosomal and X-linked dominant cases. The <italic>y</italic>-axis indicates the tested algorithms, and the <italic>x</italic>-axis indicates the percentage of cases where the âtrueâ disease gene was ranked at the top or within the top 5 genes relative to the other candidate genes in recessive cases. In dominant cases, the percentage indicates whether the âtrueâ gene was ranked at the top or within the top 10 genes. EvORanker outperformed ExomeWalker and PHIVE in both recessive and dominant diseases in both datasets</p></caption><graphic xlink:href="13073_2023_1276_Fig9_HTML" id="MO5"/></fig></p>
    </sec>
    <sec id="Sec31">
      <title>Solving the unsolved: candidate genes in reanalysis of patient exomes</title>
      <p id="Par51">We then initiated the application of EvORanker to identify novel disease-causing candidate genes in families with negative clinical exome results. To illustrate its effectiveness, we present two cases where we successfully resolved previously unsolved exomes.</p>
      <sec id="Sec32">
        <title>Family 1</title>
        <p id="Par52">We utilized EvORanker to analyze the exome data of a patient with an undiagnosed neurodevelopmental disorder for which no disease-causing variant was identified. The patient and one of her siblings displayed symptoms of global psychomotor delay, dysphasia, and attention-deficit hyperactivity disorder (ADHD) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A). By employing the previously described analysis steps and inputting the HPO terms HP:0001263, HP:0002357, HP:0000752, and HP:0000736, EvORanker prioritized <italic>DLGAP2</italic> as the top candidate gene (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>B). Further analysis revealed a strong correlation between <italic>DLGAP2</italic> and several genes related to similar phenotypes to that of the patient, such as <italic>GRIN2A</italic>, <italic>NLGN1</italic>, <italic>CNTNAP2</italic>, <italic>SRPX2</italic>, <italic>SYNGAP1</italic>, <italic>GABRA5</italic>, <italic>DLG3</italic>, <italic>SATB1</italic>, <italic>PTCHD1</italic>, <italic>ARHGEF6</italic>, and <italic>NLGN4X</italic> (Fig. <xref rid="Fig10" ref-type="fig">10</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S11). These âphenotype-relatedâ genes were significantly enriched within the top co-evolving and STRING-interacting genes with <italic>DLGAP2</italic> (combined Fisher <italic>p</italic>-valueâ=â1.65âÃâ10<sup>â6</sup>) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S11). Additionally, <italic>DLGAP2</italic> was ranked as the top gene by both PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] and ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>] but ranked 10th by Phenolyzer tool [<xref ref-type="bibr" rid="CR59">59</xref>].<fig id="Fig10"><label>Fig.Â 10</label><caption><p>EvORanker identifies <italic>DLGAP2</italic> as a novel gene underlying a neurodevelopmental phenotype. <bold>A</bold> Pedigree: In a consanguineous family affected children have psychomotor delay and dysphasia, hyperactivity, and poor attention span. Shown is the segregation of the <italic>DLGAP2</italic> NM_001346810:c.A2702T, p.Glu901Val variant. N, normal allele; V, variant allele. <bold>B</bold> EvORanker results: <italic>DLGAP2</italic> is ranked as the top candidate relative to the other patient candidates. The <italic>x</italic>-axis indicates the proband (patient II-3), and the <italic>y</italic>-axis indicates the EvORanker -log(10) <italic>p</italic>-value obtained from running the K-S test using the co-evolved and STRING-interacting genes with each patient gene. Red dots indicate significant <italic>p</italic>-values, and dark blue dots indicate non-significant <italic>p</italic>-values. <italic>DLGAP2</italic> was the only gene that co-segregated with the phenotype in family 1. <bold>C</bold> One-sided, two-sample KolmogorovâSmirnov model. The <italic>x</italic>-axis indicates the semantic similarity score obtained by the <italic>OntologySimilarity</italic> tool in relation to the patientâs (II-3, family 1) phenotypes (HP:0001263, HP:0002357, HP:0000752, HP:0000736). The <italic>y</italic>-axis indicates the cumulative distribution. The orange line corresponds to the empirical distribution of all genes listed in the HPO database, ranked according to semantic similarity. The red line represents the empirical distribution of the genes coevolved with <italic>DLGAP2</italic>, and the blue line represents the empirical distribution of the genes interacting with <italic>DLGAP2</italic> based on STRING. The red dashed line indicates the D statistic representing the maximum vertical distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes coevolved with <italic>DLGAP2</italic>. The blue dashed line indicates the D statistic measured by the distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes interacting with <italic>DLGAP2</italic> based on STRING. Both coevolution and STRING-based analysis yielded significant <italic>p</italic>-values corresponding to the D statistic. <bold>D</bold> Coevolution and STRING-based subnetwork showing the patientâs phenotype-related genes coevolving with the <italic>DLGAP2</italic> gene. The dark grey node in the network indicates <italic>DLGAP2</italic> and the light grey nodes represent the phenotype-related genes. The black edges represent STRING interactions, and the colored edges represent the clade where two genes co-evolve. The network exhibits a group of phenotype-related correlated genes that have not been identified by the STRING database (<italic>EHMT1</italic>, <italic>IL1RAPL1</italic>, <italic>SATB2</italic>, <italic>GABRA5</italic>, <italic>SRPX2</italic>, <italic>SEMA3E</italic>, <italic>CACNG2</italic>)</p></caption><graphic xlink:href="13073_2023_1276_Fig10_HTML" id="MO3"/></fig></p>
        <p id="Par53">The high ranking of <italic>DLGAP2</italic> by EvORanker prompted us to further research the <italic>DLGAP2</italic> variant. The <italic>DLGAP2</italic> variant (NM_001346810:c.A2702T, p.Glu901Val) is strongly conserved and not found in the gnomAD population frequency database [<xref ref-type="bibr" rid="CR42">42</xref>] nor in our in-house database. Both affected siblings were homozygous for the variant, and it was the only variant that co-segregated with the phenotype in the family (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>A). The variant is positioned on the third nucleotide preceding the splice donor site within exon 9 (out of 12 exons) of the <italic>DLGAP2</italic> gene. It is predicted to alter gene splicing by different prediction tools (e.g., SpliceAI [<xref ref-type="bibr" rid="CR44">44</xref>]). Since the <italic>DLGAP2</italic> gene is minimally expressed in whole blood, a minigene splicing assay was performed to assess the effect of the c.A2702T variant on gene splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). The minigene assay results showed that the variant led to the activation of a cryptic splice site and aberrant splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). Sequencing of the RT-PCR product of the mutant construct showed a 4-bp deletion (GAAA del) (Chr8:1,626,792â1,626,795), resulting in a frameshift and premature termination after 59 codons (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12).</p>
      </sec>
      <sec id="Sec33">
        <title>Family 2</title>
        <p id="Par54">We applied EvORanker to the exome data of a patient diagnosed with a multisystem disease including failure to thrive, recurring abdominal pain, chronic diarrhea, skeletal muscle wasting, elevated liver enzymes, and high levels of creatine kinase (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). The patient is of consanguineous parentage and is the sole affected individual in the family (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). Using HPO terms corresponding to the patientâs phenotype (HP:0001508, HP:0002910, HP:0002574, HP:0002028, HP:0003236, HP:0003202), EvORanker prioritized <italic>LPCAT3</italic> as the top patient candidate gene (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>B). <italic>LPCAT3</italic> demonstrated strong coevolution signals with genes related to the patientâs phenotype (<italic>PYGL</italic>, <italic>DLD</italic>, <italic>TXNRD2</italic>, <italic>COG8</italic>, <italic>SUCLG1</italic>, <italic>MVK</italic>, <italic>SMAD4</italic>, <italic>CPT1A</italic>) in the plant (<italic>Viridiplantae</italic> and <italic>Eudicotyledons</italic>), <italic>Mammalia</italic>, and <italic>Fungi</italic> kingdoms (Fig. <xref rid="Fig11" ref-type="fig">11</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figs. S13, S14 and S15). The genes that showed the strongest coevolution with <italic>LPCAT3</italic> were significantly enriched within the <italic>phenotype-related genes</italic> (<italic>p</italic>-valueâ=â7.93âÃâ10<sup>â15</sup>) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). Conversely, the genes that interacted with <italic>LPCAT3</italic> through STRING did not exhibit significant enrichment within the <italic>phenotype-related genes</italic> (<italic>p</italic>-valueâ=â0.53) (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). Despite this, <italic>LPCAT3</italic> still had the most significant <italic>p</italic>-value among all candidates based on the combined EvORanker score (Fisher combined <italic>p</italic>-valueâ=â1.42âÃâ10<sup>â13</sup>). <italic>LPCAT3</italic> was ranked third by ExomeWalker [<xref ref-type="bibr" rid="CR8">8</xref>], excluded by PHIVE [<xref ref-type="bibr" rid="CR3">3</xref>] and ranked 8th by Phenolyzer [<xref ref-type="bibr" rid="CR59">59</xref>]. The proband (II-4) was homozygous for a truncating variant in exon 9 of the <italic>LPCAT3</italic> gene (NM_005768:c.G939A, p.W313X) (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A). This variant was not found in the gnomAD population frequency database [<xref ref-type="bibr" rid="CR42">42</xref>] nor in our in-house database. The <italic>LPCAT3</italic> variant was the only variant among the <italic>patient candidate genes</italic> that co-segregated with the phenotype in the family (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>A).<fig id="Fig11"><label>Fig.Â 11</label><caption><p>EvORanker identifies <italic>LPCAT3</italic> as a novel gene underlying a multisystem disorder. <bold>A</bold> Pedigree of a consanguineous family. The affected son has failure to thrive, chronic diarrhea with recurrent abdominal pain, muscle atrophy, elevated liver enzymes, and high creatine kinase levels. Shown is the segregation of the <italic>LPCAT3</italic> NM_005768:c.G939A, p.Trp313Ter variant. N, normal allele; V, variant allele. <bold>B</bold> EvORanker results: <italic>LPCAT3</italic> is ranked as the top candidate relative to other candidate genes. The <italic>x</italic>-axis indicates the proband (patient II-4), and the <italic>y</italic>-axis indicates the combined -log10 <italic>p</italic>-value obtained from running the K-S test using the co-evolved and STRING-interacting genes with each patient gene. Red dots indicate significant <italic>p</italic>-values, and dark blue dots indicate non-significant <italic>p</italic>-values. <italic>LPCAT3</italic> was the only gene that co-segregated with the phenotype in family 2. <bold>C</bold> One-sided, two-sample KolmogorovâSmirnov model. The <italic>x</italic>-axis indicates the semantic similarity score obtained by the OntologySimilarity tool in relation to the patientâs (II-4, family 2) phenotypes (HP:0001508, HP:0002910, HP:0002574, HP:0002028, HP:0003236, HP:0003202). The <italic>y</italic>-axis indicates the cumulative distribution. The orange line corresponds to the empirical distribution of all genes listed in the HPO database, ranked according to semantic similarity. The red line indicates the empirical distribution of the genes coevolved with <italic>LPCAT3</italic>, and the blue line indicates the empirical distribution of the genes interacting with <italic>LPCAT3</italic> based on STRING. The red dashed line indicates the D statistic representing the maximum vertical distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes coevolved with <italic>LPCAT3</italic>. The blue dashed line indicates the D statistic measured by the distance between the empirical cumulative distribution functions of the HPO-ranked genes and the genes interacting with <italic>LPCAT3</italic> based on STRING. Only coevolution-based analysis yielded significant <italic>p</italic>-values corresponding to the D statistic. <bold>D</bold> Coevolution and STRING-based subnetwork showing the patientâs phenotype-related genes coevolving with the <italic>LPCAT3</italic> gene. The yellow node in the network indicates <italic>LPCAT3</italic> and the light grey nodes represent the phenotype-related genes. The black edges represent STRING interactions, and the colored edges represent the clade where two genes co-evolve. We demonstrate that our clade-wise NPP approach uncovered correlations between <italic>LPCAT3</italic> and <italic>phenotype-related genes</italic> that were not captured by STRING</p></caption><graphic xlink:href="13073_2023_1276_Fig11_HTML" id="MO4"/></fig></p>
        <p id="Par55">Complete knockout of <italic>LPCAT3</italic> in mice results in premature death. However, tissue-specific knockouts in the liver and intestines have been documented, with the latter causing impaired growth and abnormal enterocyte morphology along with enterocyte lipid accumulation (Rong et al., 2015). Liver-specific knockouts in mice display a decrease in plasma triglycerides and an occurrence of hepatosteatosis (Rong et al., 2015). The patient from family 2 demonstrated anomalies in both the intestine and liver. Duodenal biopsies showed nodular lesions in the duodenal bulb and the descending portion of the duodenum with atrophic mucosa suggestive of severe enteropathy. Fragments of duodenal mucosa showed partial villous blunting with a mild increase of lamina propria lymphoplasmacytic cell infiltrate. Liver enzymes revealed a reduced ratio of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, suggesting fatty liver disease, along with reduced plasma triglycerides (34Â mg/dL) and HDL levels (27.1Â mg/dL). These findings suggest <italic>LPCAT3</italic> as a potential causative gene for the disease in the proband of this family.</p>
      </sec>
    </sec>
    <sec id="Sec34">
      <title>EvORanker web tool</title>
      <p id="Par56">The EvORanker web tool (<ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>) is an easy-to-use and user-friendly decision support tool built for geneticists and researchers in the NGS field (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S16). The user submits a set of HPO terms describing the patientâs medical condition and the patientâs candidate genes, preferably genes that survived variant filtering. The algorithm then performs the aforementioned analyses and returns the outputs in two stages:<list list-type="order"><list-item><p id="Par57">Step 1: If the queried gene is already listed in the HPO database, a semantic similarity score (ranging from 0 to 1) reflecting the similarity of the geneâs associated HPO terms to the userâs input HPO terms is calculated using the OntologySimilarity package [<xref ref-type="bibr" rid="CR51">51</xref>] and is indicated in a table output in the âStep 1: Semantic Similarity-based Prioritizationâ tab.</p></list-item><list-item><p id="Par58">Step 2: In the case where none of the queried genes are listed in the HPO dataset or where none had a high or sufficient semantic similarity score (i.e., a non-diagnostic case), the user can navigate to co-evolution and STRING-based gene prioritization. The output is a table containing each queried gene and the corresponding EvORanker <italic>p</italic>-value. The EvORanker <italic>p</italic>-value is the result of Fisherâs combined test obtained by integration of multi-clade phylogenetic profiling and STRING-based analysis as described above.</p></list-item></list></p>
      <p id="Par59">EvORanker also provides useful visualizations of the results, including a bar plot of the ranked genes by EvORanker, and a co-evolution and STRING subnetwork generated upon click of any queried gene in the âStep 2â results table. The network highlights the HPO-related genes co-evolving with the query gene in addition to edges representing STRING interactions. Additionally, the user can retrieve more detailed co-evolutionary information including the clade where every two genes co-evolve, the co-evolutionary rank of the HPO-related genes with each query gene, and can inspect gene enrichment results of the coevolving genes and STRING-interacting genes with each query gene. The web interface is available at the following link: <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>. Recognizing the need to analyze a larger number of genes than recommended for the web tool due to memory constraints, we have established a GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>) [<xref ref-type="bibr" rid="CR65">65</xref>]. This repository allows users to access the tool and input an expanded number of genes, accommodating their requirements.</p>
    </sec>
  </sec>
  <sec id="Sec35">
    <title>Discussion</title>
    <p id="Par60">Clinical elucidation of genetic variants in connection to a patientâs phenotype is a time-consuming and costly element in the genomic diagnosis of rare genetic diseases. To address this issue, several computational algorithms have been developed over the years to prioritize candidate genes based on the patientâs phenotype using different sources of information, such as protein-protein interactions, data mining, and gene expression [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>â<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>â<xref ref-type="bibr" rid="CR14">14</xref>]. Nevertheless, although PP was successfully used to identify novel disease genes [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR66">66</xref>], we are not aware of any tool that systematically utilizes clade-based phylogenetic profiling to prioritize patient candidate genes. Herein, we described EvORanker, an algorithm that employs multi-scale phylogenetic profiling and gene interaction data from the STRING database [<xref ref-type="bibr" rid="CR33">33</xref>] to analyze âunsolvedâ WES/WGS cases in search of novel genetic causes of disease. This algorithm integrates unbiased comparative genomic analysis with publicly available gene data, including function and interactions.</p>
    <p id="Par61">Multi-scale phylogenetic profiling is particularly valuable for identifying disease associations for poorly annotated genes. The ability to conduct analysis of every gene independently of existing knowledge expands the scope of disease-gene discovery. This is particularly important in light of the ârich get richerâ phenomenon, where genes that have already been studied receive disproportionate attention, while poorly annotated genes are often overlooked. Among the 6260 tested knockout genes that exhibit a phenotype in mice and have an ortholog in humans, EvORanker was able to link 41% of these genes to the disease phenotype observed in mice (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: S9). This highlights the potential of EvORanker to discover new disease genes and expand our understanding of disease mechanisms.</p>
    <p id="Par62">Furthermore, our study demonstrates the power of our multi-clade concept in capturing co-evolution, as shown by our ability to more effectively identify the âtrueâ disease-causing genes across multiple clades, beyond just Eukaryota or Animalia clades (Figs. <xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S5). This is aligned with the notion that multi-clade phylogenetic profiling-based methods more effectively capture co-evolution [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Importantly, our clade-wise NPP approach revealed correlations between genes that could not be anticipated using other omics (Fig. <xref rid="Fig11" ref-type="fig">11</xref>C, D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). The integration of NPP with STRING leads to increased efficiency of EvORanker (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>), especially for newly annotated genes, and highlights the complementarity of these two datasets. In future studies, we may contemplate incorporating additional datasets into the algorithm, such as mouse and zebrafish knockout data, and other sources for protein-protein interaction networks, by utilizing similar concepts.</p>
    <p id="Par63">We benchmarked our tool using both real patient exome data, in addition to simulated data. The utilization of actual patient data enhances the translational potential of our findings and underscores the clinical relevance of our tool. EvORanker ranked the âtrueâ gene within the top 5 in 95% of the patient-exome dataset. On the other hand, failed to rank the âtrueâ gene within the top 5 for recessive diseases and within the top 10 for dominant diseases in 6/109 exomes. Further investigation revealed that in 3 of those cases (<italic>TBL1XR1</italic>, <italic>NHLRC2</italic>, <italic>ADGRG1</italic>), the HPO terms used as input into the algorithm were both insufficient and non-specific (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). This highlights the importance of precise selection of HPO terms to achieve accurate results. Notably, our results remained consistent across both the real-patient and simulation datasets, further validating the practical utility and effectiveness of our tool in real-world applications.</p>
    <p id="Par64">We applied EvORanker on two unresolved exomes in which previous clinical whole exome sequencing (WES) did not identify a known genetic cause. In the first case (family 1), the <italic>DLGAP2</italic> gene was ranked as the top candidate for a proband with a neurodevelopmental disorder (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>B). <italic>DLGAP2</italic> plays a role in the molecular organization of neuronal synapses and neuronal cell signaling [<xref ref-type="bibr" rid="CR67">67</xref>]. The pathogenicity of the NM_001346810:c.A2702T, p.Glu901Val variant observed in <italic>DLGAP2</italic> was validated by demonstrating its effect on splicing (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S12). Homozygous knockout mice for <italic>DLGAP2</italic> exhibit novelty-induced hyperactivity, increased aggression, impaired reverse learning, decreased dendritic spine density, and synaptopathy [<xref ref-type="bibr" rid="CR68">68</xref>] providing further support for the association of <italic>DLGAP2</italic> with the patientâs phenotype. Furthermore, <italic>DLGAP2</italic> was hypothesized to be a strong candidate for neurodevelopmental and behavioral phenotypes observed in patients harboring 8p23.2-pter microdeletions including <italic>DLGAP2</italic> and four other genes [<xref ref-type="bibr" rid="CR69">69</xref>]. Notably, our analysis using NPP revealed a group of <italic>DLGAP2</italic>-associated genes not detected by STRING (Fig.Â <xref rid="Fig10" ref-type="fig">10</xref>D), providing new avenues for investigating the role of <italic>DLGAP2</italic> in the nervous system.</p>
    <p id="Par65">In the second âunsolvedâ exome, only NPP ranked the <italic>LPCAT3</italic> gene as the top candidate (family 2, Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>C, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S13). This ranking of <italic>LPCAT3</italic> was achieved by the detection of novel functional associations with <italic>phenotype-related genes</italic> based on co-evolution (<italic>PYGL</italic>, <italic>DLD</italic>, <italic>TXNRD2</italic>, <italic>COG8</italic>, <italic>SUCLG1</italic>, <italic>MVK</italic>, <italic>SMAD4</italic>, <italic>CPT1A</italic>) (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>D). These <italic>phenotype-related genes</italic> showed significant coevolution with <italic>LPCAT3</italic> in the clades of <italic>Viridiplantae</italic>, <italic>Eudicotyledons</italic>, <italic>Mammalia</italic>, and <italic>Fungi</italic> (Fig.Â <xref rid="Fig11" ref-type="fig">11</xref>D, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figs. S11 and S14), pointing towards novel associations not captured by STRING [<xref ref-type="bibr" rid="CR33">33</xref>]. These findings are supported by phenotypic similarities between the patient and liver and intestinal knockout mice [<xref ref-type="bibr" rid="CR70">70</xref>], including failure to thrive, enteropathy, and low levels of triglycerides and high-density lipoprotein. <italic>LPCAT3</italic> nullizygous mice exhibit postnatal death [<xref ref-type="bibr" rid="CR70">70</xref>], making it difficult to study the global effects of <italic>LPCAT3</italic> knockdown. Although a recent report linked <italic>LPCAT3</italic> overexpression to skeletal muscle myopathy [<xref ref-type="bibr" rid="CR71">71</xref>], further research is needed to understand the role and mechanism of <italic>LPCAT3</italic> in this condition. Taken together, these results underscore the potential of clade-based NPP to predict functional associations with phenotype-relevant genes. Further validation in additional patients with variants in these genes is warranted to confirm their roles as novel disease-associated genes. Subsequent functional validation studies are crucial to better understand the mechanisms of disease pathogenesis.</p>
    <p id="Par66">EvORanker is entirely gene-based, making it adaptable to various sequencing experiments and accessible for users with minimal computational knowledge. In addition to providing a ranked gene list, EvORanker offers the ability to explore evolutionary and STRING-based gene networks across multiple clades. A recommended strategy for users is to first examine the ranking of genes based on the OntologySimilarity semantic similarity score [<xref ref-type="bibr" rid="CR51">51</xref>], in the event that one of the candidate genes is already listed in the HPO database. If not, the user can then evaluate the ranking of genes based on the EvORanker score, where a novel association between the gene and input phenotypes may be discovered. The EvORanker server is freely available at <ext-link ext-link-type="uri" xlink:href="https://ccanavati.shinyapps.io/EvORanker/">https://ccanavati.shinyapps.io/EvORanker/</ext-link>, which will be updated on a regular basis. We also created a GitHub repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>) [<xref ref-type="bibr" rid="CR65">65</xref>] which allows users to access the tool and input an expanded number of genes.</p>
  </sec>
  <sec id="Sec36">
    <title>Conclusions</title>
    <p id="Par67">In summary, our work introduces EvORanker as a powerful tool in the genomic diagnostic landscape. By integrating multi-scale phylogenetic profiling and STRING-based gene interaction data, EvORanker offers a unique and effective approach to prioritize candidate genes in âunsolvedâ cases identified through whole-exome and whole-genome sequencing. Our validation using real patient exome data and simulation data demonstrates EvORankerâs robust capability to consistently prioritize the âtrueâ gene, showcasing its reliability and translational potential in research applications.</p>
    <p id="Par68">The effectiveness of EvORanker in identifying candidate disease genes, as demonstrated by the identification of <italic>DLGAP2</italic> and <italic>LPCAT3</italic> in previously unresolved cases, highlights its potential to contribute to our understanding of disease mechanisms. Moreover, its adaptability, user-friendly interface, and accessibility without extensive computational expertise make EvORanker a valuable asset for researchers. As we navigate the intricate landscape of rare genetic diseases, EvORanker stands as a promising tool, offering not only a ranked gene list but also insights into STRING-based and evolutionary gene networks across multiple clades. We believe that the adoption of EvORanker will contribute significantly to advancing genomic diagnostics in the pursuit of unraveling the genetic mysteries underlying rare diseases.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <sec id="Sec37">
      <title>Supplementary Information</title>
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="13073_2023_1276_MOESM1_ESM.xlsx">
            <caption>
              <p><bold>Additional file 1: Table S1.</bold> Clinical and Genetic Characteristics of the 109-Patient Exome Dataset. <bold>Table S2.</bold> ClinVar-Simulated Genetic Variants and Associated Phenotypes. <bold>Table S3.</bold> Newly added disease-gene entries in the Human Phenotype Ontology (HPO) database.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="13073_2023_1276_MOESM2_ESM.docx">
            <caption>
              <p><bold>Additional file 2: Figure S1.</bold> Parameter combinations and EvORanker performance. <bold>Figure S2.</bold> The 16 clades used in the phylogenetic profiling-based algorithm. <bold>Figure S3.</bold> Cutoff values and EvORanker performance. <bold>Figure S4.</bold> Distribution of the number of<italic> patient candidate genes</italic> that passed the variant filtering criteria in autosomal and x-linked recessive (red) and dominant (dark blue) cases in the (A) patient exome dataset and the (B) simulated dataset (shuffled three times). <bold>Figure S5.</bold> Contribution of each of the 16 clades to the overall performance of the EvORanker. <bold>Figure S6.</bold> Radar plot showing the ranking of the âtrueâ disease-causing gene (top 1, top 10, or NULL) using EvORanker (red), NPP (golden), and STRING (dark blue). <bold>Figure S7.</bold> Evaluating EvORanker Performance across three independent spike shuffles. <bold>Figure S8.</bold> Performance of NPP versus STRING using the 109-patient exome dataset across the years. <bold>Figure S9.</bold> Comparison of EvORanker and Phenolyzer in identifying true disease gene candidates. <bold>Figure S10.</bold> Radar plot showing the ranking of the âtrueâ disease-causing gene (top 1, top 10, or NULL) using EvORanker (red), PHIVE (golden), and ExomeWalker (blue). <bold>Figure S11.</bold> Distributions of the <italic>HPO-ranked genes</italic>, the co-evolved genes, and STRING-interacting genes with <italic>DLGAP2</italic>. <bold>Figure S12.</bold> Effect of <italic>DLGAP2</italic> p.E901V on splicing. <bold>Figure S13.</bold> Density distributions of the <italic>HPO-ranked genes</italic>, the co-evolved genes, and STRING-interacting genes with <italic>LPCAT3</italic>. <bold>Figure S14.</bold> Clades differentially predict the functional interaction between the <italic>phenotype-related genes</italic> and <italic>LPCAT3</italic>. <bold>Figure S15.</bold> The Phylogenetic profiles of <italic>LPCAT3</italic> and patient HPO-related genes across 1,028 eukaryotes. <bold>Figure S16.</bold> Homepage of the EvoRanker web interface.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisherâs Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Dana Sherill-Rofe and Lara Kamal contributed equally to this work.</p>
    </fn>
    <fn>
      <p>Ephrat Levy-Lahad, Moien Kanaan andÂ Yuval Tabach contributed equally to this work.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>We would like to acknowledge The Carole and Andrew Harper Diversity Program for their support in this research.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authorsâ contributions</title>
    <p>Conceptualization: CC, DSR, YT, MK, PR, and ELL. Algorithm development: CC, IB, DSR, ES, BT, and YT. Web-tool development: CC. Bioinformatics and data analysis: CC and FZ. Exome sequencing and subsequent data analysis for the benchmarking dataset comprising 109 cases, as well as the two âunsolvedâ cases, along with collaboration and communication with clinicians: CC, LK, GR, MK, HK, and MK. In vitro splicing assay: LK, KBA, and IAA. Supervision: YT, ELL, MK, and PR. Manuscript: CC wrote the manuscript with help from YT, DSR, and ELL. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This study was supported by the Israel Science Foundation (grant no. 3797/21) to Yuval Tabach, Ephrat Levy-Lahad, and Paul Renbaum; The Koum Foundation to Ephrat Levy-Lahad and Paul Renbaum; The National Institutes of Health/NIDCD (R01DC011835) to Karen B. Avraham and Moien Kanaan; The Ministry of Innovation, Science and Technology (grant no. 3-17417) to Yuval Tabach.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>All the algorithm-related data files on which the conclusions of the paper rely on are publicly available on GitHub at the following link: <ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link> [<xref ref-type="bibr" rid="CR65">65</xref>].</p>
    <p>The dataset comprising the exome sequencing data of 109 patients at Istishari Arab Hospital in Ramallah, Palestine, is available through Professor Moien Kanaan. It was employed for benchmarking purposes in the current study. However, due to licensing constraints, these data are not publicly accessible. Researchers interested in accessing the dataset may do so upon making a reasonable request. To initiate the request, individuals are required to contact Professor Moien Kanaan directly via email (moien.kanaan@iah.ps). Please note that the process of obtaining access involves a meeting with professor Moien Kanaan, during which the interested party will be required to provide details on how the data will be utilized, secured, and maintained to ensure the privacy and confidentiality of the patients. This may include a discussion on data security measures, protocols for restricting access to authorized personnel, and assurances that the data will not be made available to third parties. The timeline for granting access will be determined on a case-by-case basis, taking into consideration the nature of the request and the required ethical and legal approvals.</p>
    <p>The VCF files for the 300 genomes utilized in the simulation analysis were obtained from the 1000 Genome Project [<xref ref-type="bibr" rid="CR39">39</xref>], accessible at (<ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>) [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par69">The studies involving human participants received ethical approval from the Institutional Review Board (IRB) of the Shaare Zedek Medical Center, Jerusalem, Israel (IRB no. 20/10). All procedures were conducted in accordance with the principles outlined in the Declaration of Helsinki. Prior to their inclusion in the study, written informed consent was obtained from all participants or their parents. Additionally, participants or their parents granted permission to access their medical records. The study was conducted with due consideration of ethical guidelines, ensuring the confidentiality and voluntary participation of all individuals involved.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par70">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par71">The authors declare that they have no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bamshad</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Nickerson</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Chong</surname>
            <given-names>JX</given-names>
          </name>
        </person-group>
        <article-title>Mendelian gene discovery: fast and furious with no end in sight</article-title>
        <source>Am J Hum Genet</source>
        <year>2019</year>
        <volume>105</volume>
        <fpage>448</fpage>
        <lpage>455</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2019.07.011</pub-id>
        <?supplied-pmid 31491408?>
        <pub-id pub-id-type="pmid">31491408</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <mixed-citation publication-type="other">Online Mendelian Inheritance in Man, OMIMÂ®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). 2023. <ext-link ext-link-type="uri" xlink:href="https://omim.org/">https://omim.org/</ext-link>. Accessed 18 Sept 2023.</mixed-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Oellrich</surname>
            <given-names>A</given-names>
          </name>
          <collab>Project SMG</collab>
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Mungall</surname>
            <given-names>CJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Improved exome prioritization of disease genes through cross-species phenotype comparison</article-title>
        <source>Genome Res</source>
        <year>2014</year>
        <volume>24</volume>
        <fpage>340</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.160325.113</pub-id>
        <?supplied-pmid 24162188?>
        <pub-id pub-id-type="pmid">24162188</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Davydov</surname>
            <given-names>EV</given-names>
          </name>
          <name>
            <surname>Goode</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Sirota</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cooper</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Sidow</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Batzoglou</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Identifying a high fraction of the human genome to be under selective constraint using GERP++</article-title>
        <source>PLoS Comput Biol</source>
        <year>2010</year>
        <volume>6</volume>
        <fpage>e1001025</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1001025</pub-id>
        <?supplied-pmid 21152010?>
        <pub-id pub-id-type="pmid">21152010</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Adzhubei</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Jordan</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Sunyaev</surname>
            <given-names>SR</given-names>
          </name>
        </person-group>
        <article-title>Predicting functional effect of human missense mutations using PolyPhen-2</article-title>
        <source>Curr Protoc Hum Genet</source>
        <year>2013</year>
        <volume>Chapter 7</volume>
        <fpage>Unit7.20</fpage>
        <?supplied-pmid 23315928?>
        <pub-id pub-id-type="pmid">23315928</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ioannidis</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Rothstein</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Pejaver</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Middha</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McDonnell</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Baheti</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>REVEL: an ensemble method for predicting the pathogenicity of rare missense variants</article-title>
        <source>Am J Hum Genet</source>
        <year>2016</year>
        <volume>99</volume>
        <fpage>877</fpage>
        <lpage>885</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.08.016</pub-id>
        <?supplied-pmid 27666373?>
        <pub-id pub-id-type="pmid">27666373</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Labes</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wagner</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Lotem</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lahad</surname>
            <given-names>EL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Machine-learning of complex evolutionary signals improves classification of SNVs</article-title>
        <source>NAR Genomics Bioinform</source>
        <year>2022</year>
        <volume>4</volume>
        <fpage>lqac025</fpage>
        <pub-id pub-id-type="doi">10.1093/nargab/lqac025</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Smedley</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Czeschik</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Amberger</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bocchini</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hamosh</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Walking the interactome for candidate prioritization in exome sequencing studies of Mendelian diseases</article-title>
        <source>Bioinformatics Oxf Engl</source>
        <year>2014</year>
        <volume>30</volume>
        <fpage>3215</fpage>
        <lpage>3222</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu508</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zemojtel</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mackenroth</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>JÃ¤ger</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hecht</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Krawitz</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome</article-title>
        <source>Sci Transl Med</source>
        <year>2014</year>
        <volume>6</volume>
        <fpage>252ra123</fpage>
        <pub-id pub-id-type="doi">10.1126/scitranslmed.3009262</pub-id>
        <?supplied-pmid 25186178?>
        <pub-id pub-id-type="pmid">25186178</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tranchevent</surname>
            <given-names>L-C</given-names>
          </name>
          <name>
            <surname>Ardeshirdavani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>ElShal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Alcaide</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Aerts</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Auboeuf</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Candidate gene prioritization with Endeavour</article-title>
        <source>Nucleic Acids Res</source>
        <year>2016</year>
        <volume>44</volume>
        <fpage>W117</fpage>
        <lpage>121</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkw365</pub-id>
        <?supplied-pmid 27131783?>
        <pub-id pub-id-type="pmid">27131783</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <mixed-citation publication-type="other">Zolotareva O, Kleine M. A Survey of gene prioritization tools for Mendelian and complex human diseases. J Integr Bioinform. 2019;16:/j/jib.2019.16.issue-4/jib-2018-0069/jib-2018-0069.xml.</mixed-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Birgmeier</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Haeussler</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Deisseroth</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Steinberg</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Jagadeesh</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Ratner</surname>
            <given-names>AJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>AMELIE speeds Mendelian diagnosis by matching patient phenotype and genotype to primary literature</article-title>
        <source>Sci Transl Med</source>
        <year>2020</year>
        <volume>12</volume>
        <fpage>eaau9113</fpage>
        <pub-id pub-id-type="doi">10.1126/scitranslmed.aau9113</pub-id>
        <?supplied-pmid 32434849?>
        <pub-id pub-id-type="pmid">32434849</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Torkamani</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Artificial intelligence in clinical and genomic diagnostics</article-title>
        <source>Genome Med</source>
        <year>2019</year>
        <volume>11</volume>
        <fpage>70</fpage>
        <pub-id pub-id-type="doi">10.1186/s13073-019-0689-8</pub-id>
        <?supplied-pmid 31744524?>
        <pub-id pub-id-type="pmid">31744524</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>De La Vega</surname>
            <given-names>FM</given-names>
          </name>
          <name>
            <surname>Chowdhury</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Frise</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>McCarthy</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hernandez</surname>
            <given-names>EJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases</article-title>
        <source>Genome Med</source>
        <year>2021</year>
        <volume>13</volume>
        <fpage>153</fpage>
        <pub-id pub-id-type="doi">10.1186/s13073-021-00965-0</pub-id>
        <?supplied-pmid 34645491?>
        <pub-id pub-id-type="pmid">34645491</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pellegrini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Marcotte</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Eisenberg</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Yeates</surname>
            <given-names>TO</given-names>
          </name>
        </person-group>
        <article-title>Assigning protein functions by comparative genome analysis: protein phylogenetic profiles</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>1999</year>
        <volume>96</volume>
        <fpage>4285</fpage>
        <lpage>4288</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.96.8.4285</pub-id>
        <?supplied-pmid 10200254?>
        <pub-id pub-id-type="pmid">10200254</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Enault</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Suhre</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Poirot</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Abergel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Claverie</surname>
            <given-names>J-M</given-names>
          </name>
        </person-group>
        <article-title>Phydbac2: improved inference of gene function using interactive phylogenomic profiling and chromosomal location analysis</article-title>
        <source>Nucleic Acids Res</source>
        <year>2004</year>
        <volume>32</volume>
        <fpage>W336</fpage>
        <lpage>339</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkh365</pub-id>
        <?supplied-pmid 15215406?>
        <pub-id pub-id-type="pmid">15215406</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Subramaniam</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Locally defined protein phylogenetic profiles reveal previously missed protein interactions and functional relationships</article-title>
        <source>Proteins</source>
        <year>2006</year>
        <volume>62</volume>
        <fpage>1115</fpage>
        <lpage>1124</lpage>
        <pub-id pub-id-type="doi">10.1002/prot.20830</pub-id>
        <?supplied-pmid 16385560?>
        <pub-id pub-id-type="pmid">16385560</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eisen</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic analysis and gene functional predictions: phylogenomics in action</article-title>
        <source>Theor Popul Biol</source>
        <year>2002</year>
        <volume>61</volume>
        <fpage>481</fpage>
        <lpage>487</lpage>
        <pub-id pub-id-type="doi">10.1006/tpbi.2002.1594</pub-id>
        <?supplied-pmid 12167367?>
        <pub-id pub-id-type="pmid">12167367</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Protein function predictions based on the phylogenetic profile method</article-title>
        <source>Crit Rev Biotechnol</source>
        <year>2008</year>
        <volume>28</volume>
        <fpage>233</fpage>
        <lpage>238</lpage>
        <pub-id pub-id-type="doi">10.1080/07388550802512633</pub-id>
        <?supplied-pmid 19051102?>
        <pub-id pub-id-type="pmid">19051102</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dey</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic profiling for probing the modular architecture of the human genome</article-title>
        <source>Cell Syst</source>
        <year>2015</year>
        <volume>1</volume>
        <fpage>106</fpage>
        <lpage>115</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cels.2015.08.006</pub-id>
        <?supplied-pmid 27135799?>
        <pub-id pub-id-type="pmid">27135799</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Billi</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Hayes</surname>
            <given-names>GD</given-names>
          </name>
          <name>
            <surname>Newman</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Zuk</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Gabel</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of small RNA pathway genes using patterns of phylogenetic conservation and divergence</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>493</volume>
        <fpage>694</fpage>
        <lpage>698</lpage>
        <pub-id pub-id-type="doi">10.1038/nature11779</pub-id>
        <?supplied-pmid 23364702?>
        <pub-id pub-id-type="pmid">23364702</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Golan</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>HernÃ¡ndez-HernÃ¡ndez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Messer</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Fukuda</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kouznetsova</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Human disease locus discovery and mapping to molecular pathways through phylogenetic profiling</article-title>
        <source>Mol Syst Biol</source>
        <year>2013</year>
        <volume>9</volume>
        <fpage>692</fpage>
        <pub-id pub-id-type="doi">10.1038/msb.2013.50</pub-id>
        <?supplied-pmid 24084807?>
        <pub-id pub-id-type="pmid">24084807</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dey</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Jaimovich</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Seki</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Systematic discovery of human gene function and principles of modular organization through phylogenetic profiling</article-title>
        <source>Cell Rep</source>
        <year>2015</year>
        <volume>10</volume>
        <fpage>993</fpage>
        <lpage>1006</lpage>
        <pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.025</pub-id>
        <?supplied-pmid 25683721?>
        <pub-id pub-id-type="pmid">25683721</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tsaban</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sherill-Rofe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Schueler-Furman</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CladeOScope: functional interactions through the prism of clade-wise co-evolution</article-title>
        <source>NAR Genomics Bioinform</source>
        <year>2021</year>
        <volume>3</volume>
        <fpage>lqab024</fpage>
        <pub-id pub-id-type="doi">10.1093/nargab/lqab024</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Omar</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Guterman-Ram</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Berger</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Levaot</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Schlafen2 mutation in mice causes an osteopetrotic phenotype due to a decrease in the number of osteoclast progenitors</article-title>
        <source>Sci Rep</source>
        <year>2018</year>
        <volume>8</volume>
        <fpage>13005</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-018-31428-z</pub-id>
        <?supplied-pmid 30158544?>
        <pub-id pub-id-type="pmid">30158544</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Arkadir</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lossos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Abu Snineh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Schueler-Furman</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Nitschke</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MYORG is associated with recessive primary familial brain calcification</article-title>
        <source>Ann Clin Transl Neurol</source>
        <year>2019</year>
        <volume>6</volume>
        <fpage>106</fpage>
        <lpage>113</lpage>
        <pub-id pub-id-type="doi">10.1002/acn3.684</pub-id>
        <?supplied-pmid 30656188?>
        <pub-id pub-id-type="pmid">30656188</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Date</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Marcotte</surname>
            <given-names>EM</given-names>
          </name>
        </person-group>
        <article-title>Discovery of uncharacterized cellular systems by genome-wide analysis of functional linkages</article-title>
        <source>Nat Biotechnol</source>
        <year>2003</year>
        <volume>21</volume>
        <fpage>1055</fpage>
        <lpage>1062</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt861</pub-id>
        <?supplied-pmid 12923548?>
        <pub-id pub-id-type="pmid">12923548</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Allen-Vercoe</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Beiko</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Phylogenetic clustering of genes reveals shared evolutionary trajectories and putative gene functions</article-title>
        <source>Genome Biol Evol</source>
        <year>2018</year>
        <volume>10</volume>
        <fpage>2255</fpage>
        <lpage>2265</lpage>
        <pub-id pub-id-type="doi">10.1093/gbe/evy178</pub-id>
        <?supplied-pmid 30137329?>
        <pub-id pub-id-type="pmid">30137329</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sherill-Rofe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Rahat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Findlay</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mellul</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Guberman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Braun</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes</article-title>
        <source>Genome Res</source>
        <year>2019</year>
        <volume>29</volume>
        <fpage>439</fpage>
        <lpage>448</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.241414.118</pub-id>
        <?supplied-pmid 30718334?>
        <pub-id pub-id-type="pmid">30718334</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stupp</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Zitnik</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zuk</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Tabach</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Co-evolution based machine-learning for predicting functional interactions between human genes</article-title>
        <source>Nat Commun</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>6454</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-021-26792-w</pub-id>
        <?supplied-pmid 34753957?>
        <pub-id pub-id-type="pmid">34753957</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Unterman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Bloch</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Cazacu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kazimirsky</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ben-Zeev</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Berman</surname>
            <given-names>BP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome</article-title>
        <source>eLife</source>
        <year>2021</year>
        <volume>10</volume>
        <fpage>e67085</fpage>
        <pub-id pub-id-type="doi">10.7554/eLife.67085</pub-id>
        <?supplied-pmid 34355696?>
        <pub-id pub-id-type="pmid">34355696</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Braun</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sharon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Unterman</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shtern</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Benenson</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ACE2 co-evolutionary pattern suggests targets for pharmaceutical intervention in the COVID-19 pandemic</article-title>
        <source>iScience</source>
        <year>2020</year>
        <volume>23</volume>
        <fpage>101384</fpage>
        <pub-id pub-id-type="doi">10.1016/j.isci.2020.101384</pub-id>
        <?supplied-pmid 32738617?>
        <pub-id pub-id-type="pmid">32738617</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gable</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Lyon</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Junge</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wyder</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Huerta-Cepas</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>STRING v11: proteinâprotein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title>
        <source>Nucleic Acids Res</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>D607</fpage>
        <lpage>D613</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id>
        <?supplied-pmid 30476243?>
        <pub-id pub-id-type="pmid">30476243</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yue</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Breschi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Vierstra</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Ryba</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A comparative encyclopedia of DNA elements in the mouse genome</article-title>
        <source>Nature</source>
        <year>2014</year>
        <volume>515</volume>
        <fpage>355</fpage>
        <lpage>364</lpage>
        <pub-id pub-id-type="doi">10.1038/nature13992</pub-id>
        <?supplied-pmid 25409824?>
        <pub-id pub-id-type="pmid">25409824</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Canavati</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Afawi</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Pendziwiat</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Abu Rayyan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kamal</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Inclusion of hemimegalencephaly into the phenotypic spectrum of NPRL3 pathogenic variants in familial focal epilepsy with variable foci</article-title>
        <source>Epilepsia</source>
        <year>2019</year>
        <volume>60</volume>
        <fpage>e67</fpage>
        <lpage>73</lpage>
        <pub-id pub-id-type="doi">10.1111/epi.15665</pub-id>
        <?supplied-pmid 31111464?>
        <pub-id pub-id-type="pmid">31111464</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kamal</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Pierce</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Canavati</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rayyan</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Jaraysa</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lobel</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities</article-title>
        <source>Cold Spring Harb Mol Case Stud</source>
        <year>2020</year>
        <volume>6</volume>
        <fpage>a005652</fpage>
        <pub-id pub-id-type="doi">10.1101/mcs.a005652</pub-id>
        <?supplied-pmid 33028645?>
        <pub-id pub-id-type="pmid">33028645</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Elson</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stein</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rabie</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Barnea-Zohar</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Winograd-Katz</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Reuven</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Sorting Nexin 10 as a key regulator of membrane trafficking in bone-resorbing osteoclasts: lessons learned from osteopetrosis</article-title>
        <source>Front Cell Dev Biol</source>
        <year>2021</year>
        <volume>9</volume>
        <fpage>671210</fpage>
        <pub-id pub-id-type="doi">10.3389/fcell.2021.671210</pub-id>
        <?supplied-pmid 34095139?>
        <pub-id pub-id-type="pmid">34095139</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Landrum</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Benson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Chao</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chitipiralla</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ClinVar: improving access to variant interpretations and supporting evidence</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1062</fpage>
        <lpage>D1067</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1153</pub-id>
        <?supplied-pmid 29165669?>
        <pub-id pub-id-type="pmid">29165669</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <mixed-citation publication-type="other">The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68â74.</mixed-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <mixed-citation publication-type="other">1000 Genomes Project. Data Release 20100804. <ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/</ext-link>. Accessed 23 Aug 2023.</mixed-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hakonarson</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>
        <source>Nucleic Acids Res</source>
        <year>2010</year>
        <volume>38</volume>
        <fpage>e164</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq603</pub-id>
        <?supplied-pmid 20601685?>
        <pub-id pub-id-type="pmid">20601685</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <mixed-citation publication-type="other">Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genome-wide mutational constraint map quantified from variation in 76,156 human genomes. Genetics. 2022. Available from: <ext-link ext-link-type="uri" xlink:href="http://biorxiv.org/lookup/doi/10.1101/2022.03.20.485034">http://biorxiv.org/lookup/doi/10.1101/2022.03.20.485034</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jian</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Boerwinkle</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>In silico prediction of splice-altering single nucleotide variants in the human genome</article-title>
        <source>Nucleic Acids Res</source>
        <year>2014</year>
        <volume>42</volume>
        <fpage>13534</fpage>
        <lpage>13544</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku1206</pub-id>
        <?supplied-pmid 25416802?>
        <pub-id pub-id-type="pmid">25416802</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jaganathan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Panagiotopoulou</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>McRae</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Darbandi</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Knowles</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>YI</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Predicting splicing from primary sequence with deep learning</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>176</volume>
        <fpage>535</fpage>
        <lpage>548.e24</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2018.12.015</pub-id>
        <?supplied-pmid 30661751?>
        <pub-id pub-id-type="pmid">30661751</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ng</surname>
            <given-names>PC</given-names>
          </name>
          <name>
            <surname>Henikoff</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>SIFT: predicting amino acid changes that affect protein function</article-title>
        <source>Nucleic Acids Res</source>
        <year>2003</year>
        <volume>31</volume>
        <fpage>3812</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkg509</pub-id>
        <?supplied-pmid 12824425?>
        <pub-id pub-id-type="pmid">12824425</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>KÃ¶hler</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gargano</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Matentzoglu</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Carmody</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Lewis-Smith</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Vasilevsky</surname>
            <given-names>NA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The human phenotype ontology in 2021</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D1207</fpage>
        <lpage>D1217</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1043</pub-id>
        <?supplied-pmid 33264411?>
        <pub-id pub-id-type="pmid">33264411</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <mixed-citation publication-type="other">Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1303.3997">http://arxiv.org/abs/1303.3997</ext-link>. Cited 2022 Sep 15.</mixed-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McKenna</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hanna</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Banks</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sivachenko</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cibulskis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kernytsky</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>
        <source>Genome Res</source>
        <year>2010</year>
        <volume>20</volume>
        <fpage>1297</fpage>
        <lpage>1303</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id>
        <?supplied-pmid 20644199?>
        <pub-id pub-id-type="pmid">20644199</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>FADO</given-names>
          </name>
          <name>
            <surname>de Andrade</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Palmero</surname>
            <given-names>EI</given-names>
          </name>
        </person-group>
        <article-title>Insights on variant analysis in silico tools for pathogenicity prediction</article-title>
        <source>Front Genet</source>
        <year>2022</year>
        <volume>13</volume>
        <fpage>1010327</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2022.1010327</pub-id>
        <?supplied-pmid 36568376?>
        <pub-id pub-id-type="pmid">36568376</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fromer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Purcell</surname>
            <given-names>SM</given-names>
          </name>
        </person-group>
        <article-title>Using XHMM software to detect copy number variation in whole-exome sequencing data</article-title>
        <source>Curr Protoc Hum Genet Editor Board Jonathan Haines Al</source>
        <year>2014</year>
        <volume>81</volume>
        <fpage>7.23.1</fpage>
        <lpage>7.23.21</lpage>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Greene</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Turro</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>ontologyX: a suite of R packages for working with ontological data</article-title>
        <source>Bioinformatics</source>
        <year>2017</year>
        <volume>33</volume>
        <fpage>1104</fpage>
        <lpage>1106</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btw763</pub-id>
        <?supplied-pmid 28062448?>
        <pub-id pub-id-type="pmid">28062448</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>SchrÃ¶er</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Trenkler</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Exact and randomization distributions of Kolmogorov-Smirnov tests two or three samples</article-title>
        <source>Comput Stat Data Anal</source>
        <year>1995</year>
        <volume>20</volume>
        <fpage>185</fpage>
        <lpage>202</lpage>
        <pub-id pub-id-type="doi">10.1016/0167-9473(94)00040-P</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>R Core Team</collab>
        </person-group>
        <source>R: a language and environment for statistical computing</source>
        <year>2022</year>
        <publisher-loc>Vienna</publisher-loc>
        <publisher-name>R Foundation for Statistical Computing</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Fisher</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <source>Statistical methods for research workers</source>
        <year>1925</year>
        <publisher-loc>Edinburgh</publisher-loc>
        <publisher-name>Oliver and Boyd</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mosteller</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Fisher</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Questions and answers</article-title>
        <source>Am Stat</source>
        <year>1948</year>
        <volume>2</volume>
        <fpage>30</fpage>
        <lpage>31</lpage>
        <pub-id pub-id-type="doi">10.1080/00031305.1948.10483415</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>SchrÃ¶der</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Culhane</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Quackenbush</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Haibe-Kains</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>survcomp: an R/Bioconductor package for performance assessment and comparison of survival models</article-title>
        <source>Bioinformatics</source>
        <year>2011</year>
        <volume>27</volume>
        <fpage>3206</fpage>
        <lpage>3208</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btr511</pub-id>
        <?supplied-pmid 21903630?>
        <pub-id pub-id-type="pmid">21903630</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Blake</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Baldarelli</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kadin</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Bult</surname>
            <given-names>CJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mouse Genome Database (MGD): knowledgebase for mouse-human comparative biology</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D981</fpage>
        <lpage>D987</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1083</pub-id>
        <?supplied-pmid 33231642?>
        <pub-id pub-id-type="pmid">33231642</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <mixed-citation publication-type="other">OBO Phenotype Ontology. HPO to MP best matches. 2023. <ext-link ext-link-type="uri" xlink:href="https://github.com/obophenotype/upheno/blob/master/mappings/hp-to-mp-bestmatches.tsv">https://github.com/obophenotype/upheno/blob/master/mappings/hp-to-mp-bestmatches.tsv</ext-link>. Accessed 15 Feb 2023.</mixed-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Phenolyzer: phenotype-based prioritization of candidate genes for human diseases</article-title>
        <source>Nat Methods</source>
        <year>2015</year>
        <volume>12</volume>
        <fpage>841</fpage>
        <lpage>843</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth.3484</pub-id>
        <?supplied-pmid 26192085?>
        <pub-id pub-id-type="pmid">26192085</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Booth</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Azaiez</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kahrizi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Frees</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Exonic mutations and exon skipping: lessons learned from DFNA5</article-title>
        <source>Hum Mutat</source>
        <year>2018</year>
        <volume>39</volume>
        <fpage>433</fpage>
        <lpage>440</lpage>
        <pub-id pub-id-type="doi">10.1002/humu.23384</pub-id>
        <?supplied-pmid 29266521?>
        <pub-id pub-id-type="pmid">29266521</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hirsch</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tangshewinsirikul</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Booth</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Azaiez</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Yefet</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Quint</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A synonymous variant in MYO15A enriched in the Ashkenazi Jewish population causes autosomal recessive hearing loss due to abnormal splicing</article-title>
        <source>Eur J Hum Genet</source>
        <year>2021</year>
        <volume>29</volume>
        <fpage>988</fpage>
        <lpage>997</lpage>
        <pub-id pub-id-type="doi">10.1038/s41431-020-00790-w</pub-id>
        <?supplied-pmid 33398081?>
        <pub-id pub-id-type="pmid">33398081</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <mixed-citation publication-type="other">Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, Allen J, et al. shiny: web application framework for R. R package version 1.8.0.9000. 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://github.com/rstudio/shiny">https://github.com/rstudio/shiny</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://shiny.posit.co/">https://shiny.posit.co/</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shannon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Markiel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ozier</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Baliga</surname>
            <given-names>NS</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Ramage</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>
        <source>Genome Res</source>
        <year>2003</year>
        <volume>13</volume>
        <fpage>2498</fpage>
        <lpage>2504</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
        <?supplied-pmid 14597658?>
        <pub-id pub-id-type="pmid">14597658</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Franceschini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Szklarczyk</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Frankild</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kuhn</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Simonovic</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Roth</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>STRING v9.1: protein-protein interaction networks, with increased coverage and integration</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>D808</fpage>
        <lpage>15</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks1094</pub-id>
        <?supplied-pmid 23203871?>
        <pub-id pub-id-type="pmid">23203871</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <mixed-citation publication-type="other">Canavati C. EvoRanker: a phylogenetic profiling-based algorithm for prioritizing candidate genes. 2023. Available from: <ext-link ext-link-type="uri" xlink:href="https://github.com/ccanavati/EvoRanker">https://github.com/ccanavati/EvoRanker</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Findlay</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Heath</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>VM</given-names>
          </name>
          <name>
            <surname>Malina</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Morin</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Coulombe</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice</article-title>
        <source>EMBO J</source>
        <year>2018</year>
        <volume>37</volume>
        <fpage>e100158</fpage>
        <pub-id pub-id-type="doi">10.15252/embj.2018100158</pub-id>
        <?supplied-pmid 30154076?>
        <pub-id pub-id-type="pmid">30154076</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rasmussen</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Rasmussen</surname>
            <given-names>HB</given-names>
          </name>
          <name>
            <surname>Silahtaroglu</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>The DLGAP family: neuronal expression, function and role in brain disorders</article-title>
        <source>Mol Brain</source>
        <year>2017</year>
        <volume>10</volume>
        <fpage>43</fpage>
        <pub-id pub-id-type="doi">10.1186/s13041-017-0324-9</pub-id>
        <?supplied-pmid 28870203?>
        <pub-id pub-id-type="pmid">28870203</pub-id>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Norris</surname>
            <given-names>RH</given-names>
          </name>
          <name>
            <surname>Gordon</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Nithianantharajah</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Neurodevelopmental synaptopathies: Insights from behaviour in rodent models of synapse gene mutations</article-title>
        <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
        <year>2018</year>
        <volume>84</volume>
        <fpage>424</fpage>
        <lpage>439</lpage>
        <pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.12.001</pub-id>
        <?supplied-pmid 29217145?>
        <pub-id pub-id-type="pmid">29217145</pub-id>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Catusi</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Garzo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Capra</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Briuglia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Baldo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Canevini</surname>
            <given-names>MP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>8p23.2-pter microdeletions: seven new cases narrowing the candidate region and review of the literature</article-title>
        <source>Genes</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>652</fpage>
        <pub-id pub-id-type="doi">10.3390/genes12050652</pub-id>
        <?supplied-pmid 33925474?>
        <pub-id pub-id-type="pmid">33925474</pub-id>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <mixed-citation publication-type="other">Rong X, Wang B, Dunham MM, Hedde PN, Wong JS, Gratton E, et al. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. eLife. 2015;4:e06557.</mixed-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ferrara</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Verkerke</surname>
            <given-names>ARP</given-names>
          </name>
          <name>
            <surname>Maschek</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Shahtout</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Siripoksup</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Eshima</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Low lysophosphatidylcholine induces skeletal muscle myopathy that is aggravated by high-fat diet feeding</article-title>
        <source>FASEB J Off Publ Fed Am Soc Exp Biol</source>
        <year>2021</year>
        <volume>35</volume>
        <fpage>e21867</fpage>
      </element-citation>
    </ref>
  </ref-list>
</back>
